Selection from HEOR Bibliography
| Search criteria | ||||
| Diabetes |
||||
| Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study | ||||
| Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group | ||||
| "1 Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel 2 Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany 3 German Centre for Diabetes Research (DZD), München-Neuherberg, Germany 4 Department of Health Service Administration, China Medical University, Taichung, Taiwan 5 Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan 6 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 7 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 8 Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan 9 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 10 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 11 Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK 12 Institute of Applied Health Research, University of Birmingham, Birmingham, UK 13 Midlands Health Data Research UK, Birmingham, UK 14 DEMAND Hub, University of Birmingham, Birmingham, UK 15 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden 16 Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland 17 IQVIA Solutions Denmark A/S, Copenhagen, Denmark 18 IQVIA, Espoo, Finland 19 IQVIA, Tartu, Estonia 20 Boehringer Ingelheim International GmbH, Ingelheim, Germany 21 Boehringer Ingelheim International GmbH, US 22 Lilly Deutschland GmbH, Bad Homburg, Germany 23 Steno Diabetes Center Copenhagen, Herlev, Denmark 24 Department of Public Health, University of Copenhagen, Copenhagen, Denmark 25 Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway 26 Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway 27 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA 28 Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain" | ||||
| "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636 Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October" |
||||
| , Article | ||||
| , Denmark, Finland, Germany, Norway, Spain, Sweden, UK | ||||
| Abstract: https://doi.org/10.1016/j.diabet.2022.101418 (https://www.sciencedirect.com/science/article/pii/S1262363622000994) | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study | 2023 | English | , Clinical setting: hospital, Clinical setting: Primary care | |
| Empagliflozin is Associated with Lower Risk of Cardiovascular Events and All-Cause Mortality in Routine Care in East Asia: Results from the EMPRISE Study | ||||
| Dae Jung Kim (1), Wayne H-H Sheu (2), Wook-Jin Chung (3), Daisuke Yabe (4-7), Kyoung Hwa Ha (1), Masaomi Nangaku (8), Elise Chia-Hui Tan (9), Koichi Node (10), Atsutaka Yasui (11), Weiyu Lei (12), Sunwoo Lee (13), Laura Saarelainen (14), Anouk Deruaz-Luyet (15), Moe H. Kyaw (16) and Yutaka Seino (4,17), EMPRISE East Asia Study Group | ||||
| "1 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 2 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 3 Department of Cardiovascular Medicine, Gachon University Gil Medical Center, Incheon, South Korea 4 Kansai Electric Power Medical Research Institute, Kobe, Japan 5 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 6 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 7 Division of Metabolism and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan 8 Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan 9 National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan, and Institute of Hospital and Healthcare Administration, National Yang-Ming University, Taipei, Taiwan 10 Department of Cardiovascular Medicine, Saga University, Saga, Japan 11 Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan 12 Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan 13 Boehringer Ingelheim Korea Ltd, Seoul, Korea 14 IQVIA, Espoo, Finland 15 Boehringer Ingelheim International GmbH, Ingelheim, Germany 16 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA 17 Kansai Electric Power Hospital, Osaka, Japan " | ||||
| "JDI journal Virtual Conference: ACC, May 2021" |
||||
| , Article | ||||
| , Japan, Korea, Taiwan | ||||
| Abstract: https://doi.org/10.1111/jdi.13959 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study | 2023 | English | , Clinical setting: hospital, Clinical setting: Primary care, Retrospective cohort analysis | |
| Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: a real-world data analysis | ||||
| Hirokazu Takahashi 1 2, Keiko Asakawa 3, Yoshinori Kosakai 3, Takumi Lee 3, Mitsuhiro Rokuda 3 (rwesheorj A) | ||||
| 1) Liver Center, Saga University Hospital, Saga, Japan 2) Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan 3) Astellas Pharma Inc., Tokyo, Japan | ||||
| Diabetes Obesity and Metabolism |
||||
| , Article, Online article | ||||
| , Japan | ||||
| Abstract: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15399 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2023 | English | , Database Study, Retrospective cohort analysis | |
| Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study | ||||
| "Kerstin M G Brand, Laura Saarelainen, Jaak Sonajalg, Emmanuelle Boutmy, Caroline Foch, Marja Vääräsmäki, Laure Morin-Papunen, Judith Schlachter, CLUE Study Group, Katja M Hakkarainen, Pasi Korhonen CLUE Study Group: Minna Vehkala, Robyn Thorén, Henrik Svanström " | ||||
| "Leading author: Kerstin Brand: Merck KGaA, Darmstadt, Germany IQVIA author affiliations: Global Database Studies, IQVIA, Espoo, Finland; Global Database Studies, IQVIA, Tartu, Estonia; Global Database Studies, IQVIA, Solna, Sweden; Global Database Studies, IQVIA" | ||||
| BMJ Open Diab Res Care 2022;10:e002363. doi:10.1136/bmjdrc-2021-002363 |
||||
| , Article | ||||
| , Finland | ||||
| Abstract: https://drc.bmj.com/content/10/1/e002363.full | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Obesity | 2022 | English | , Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective cohort analysis | |
| Metformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study | ||||
| Kerstin MG Brand1, Robyn Thoren2, Jaak Sõnajalg3, Emmanuelle Boutmy1, http://orcid.org/0000-0002-0254-5560Caroline Foch1, Judith Schlachter1, Katja M Hakkarainen2, Laura Saarelainen4 | ||||
| Merck KGaA, Darmstadt, Germany Global Database Studies, IQVIA, Solna, Sweden Global Database Studies, IQVIA, Tartu, Estonia Global Database Studies, IQVIA, Espoo, Finland | ||||
| BMJ Open Diab Res Care 2022;10:e003056. doi:10.1136/bmjdrc-2022-003056 |
||||
| , Article | ||||
| , Finland | ||||
| Abstract: https://drc.bmj.com/content/10/6/e003056 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2022 | English | , Observational study, Population Based Study | |
| High‑Expenditure Disease in the EU‑28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes? | ||||
| Wolfgang Greiner, Keyur Patel, Christina-Jane Crossman-Barnes, Troels Vingtoft Rye-Andersen, Christian Hvid, Tom Vandebrouck | ||||
| Department for Health Economics, Bielefeld University, Bielefeld, Germany; IQVIA Ltd, HEOR, London, UK; Novo Nordisk Region Europe Pharmaceuticals A/S, Copenhagen, Denmark; Novo Nordisk Region Europe Pharmaceuticals A/S, Brussels, Belgium | ||||
| PharmacoEconomics-Open. 2021 Jan; doi.org/10.1007/s41669-020-00253-4 |
||||
| , Article | ||||
| , Europe | ||||
| Abstract: https://link.springer.com/epdf/10.1007/s41669-020-00253-4?sharing_token=k4IP2sUMn4HrAsHs0WBqlPe4RwlQNchNByi7wbcMAY4Tirkz8MqaNXdxznG7LjXgeeOE1lL_TUFtfOXdhNB_IQ05wAS6SyWtTgC3QV4GkZ1V3rKbHAI_lwyKV2fZ5OfrjVrTPTsYaJr4E7ZctQaMI_Yhmg_dNtoFcG1705dWSU4%3D | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics, Oncology | 2021 | English | , Burden of illness, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Literature Review, Quality of life, Retrospective database analysis, Review | |
| The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease | ||||
| Lars Holger Ehlers 1, Mark Lamotte 2, Sofia Monteiro 3, Susanne Sandgaard 4, Pia Holmgaard 4, Evan C Frary 4, Niels Ejskjaer 5 6 7 | ||||
| 1Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 2IQVIA Real World Solutions, Zaventem, Belgium. 3IQVIA Real World Solutions, London, UK. 4Boehringer Ingelheim Danmark A/S, København Ø, Hovedstaden, Denmark. 5Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. n.ejskjaer@rn.dk. 6Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark. n.ejskjaer@rn.dk. 7Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark. n.ejskjaer@rn.dk. | ||||
| Diabetes Therapy https://doi.org/10.1007/s13300-021-01040-y IQVIA HEOR Zaventem Brussels PMID: 33856655 PMCID: PMC8099952 DOI: 10.1007/s13300-021-01040-y |
||||
| , Denmark | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/33856655/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2021 | English | , Clinical setting: Primary care, Cost effectiveness | |
| Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China | ||||
| Ahmed Salem 1, Peng Men 2 3, Mafalda Ramos 4, Yan-Jun Zhang 5, Anastasia Ustyugova 6, Mark Lamotte 7 | ||||
| 1IQVIA, Real World Solutions, Zaventem 1930, Belgium. 2Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China. 3Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China. 4IQVIA, Global HEOR, Porto Salvo 2740-266, Portugal. 5Boehringer Ingelheim, Health Economics & Outcomes Research, Government Affairs & Market Access, Shanghai 200040, China. 6Boehringer Ingelheim, CardioMetabolism Respiratory, Ingelheim am Rhein 55216, Germany. 7IQVIA, Global HEOR, Zaventem 1930, Belgium. | ||||
| Journal of Comparative Effectiveness Research 2021 https://doi.org/10.2217/cer-2020-0284. PMID: 33576249 DOI: 10.2217/cer-2020-0284 |
||||
| , Article | ||||
| , China | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/33576249/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2021 | English | , Clinical setting: Primary care, Cost effectiveness | |
| Type 2 diabetes and cancer: an umbrella review of observational and Mendelian randomisation studies | ||||
| Jonathan Pearson-Stuttard 1, Nikos Papadimitriou 2 3, Georgios Markozannes 2, Sofia Cividini 4, Artemisia Kakourou 2, Dipender Gill 5, Evangelos C Rizos 6 7, Grace Monori 5, Heather A Ward 5, Maria Kyrgiou 8 9, Marc J Gunter 3, Konstantinos K Tsilidis 2 5 | ||||
| 1Department of Epidemiology and Biostatistics, MRC-PHE Center for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom. j.pearson-stuttard@imperial.ac.uk. 2Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. 3Nutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon, France. 4Department of Health Data Science, University of Liverpool, Liverpool, United Kingdom. 5Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom. 6Department of Internal Medicine, University Hospital of Ioannina, Ioannina, Greece. 7School of Medicine, European University of Cyprus, Nicosia, Cyprus. 8Department of Gut, Metabolism and Reproduction, and Surgery and Cancer, IRDB, Imperial College London, London, United Kingdom. 9West London Gynecological Cancer Center, Imperial NHS Trust, London, United Kingdom. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom. IQVIA. | ||||
| PMID: 33737302 DOI: 10.1158/1055-9965.EPI-20-1245 |
||||
| , Article | ||||
| Abstract: https://cebp.aacrjournals.org/content/cebp/early/2021/03/18/1055-9965.EPI-20-1245.full.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2021 | English | , Epidemiological study, Literature Review, Meta analysis | |
| Effectiveness and safety of empagliflozin in routine care in Europe and East Asia: results from the empagliflozin comparative effectiveness and safety (EMPRISE) study | ||||
| A. Karasik1 , S. Lanzinger2 , E. Chia-Hui Tan3 , D. Yabe4 , D. Jung Kim5 , W. H-H Sheu6 , C. MelzerCohen1 , R.W. Holl2 , K. Ha5 , T. Nyström7 , L. Niskanen8 , M. Linnemann Jensen9 , M.H. Kyaw10, J. Núñez11, EMPRISE EU and East Asia Study Group; | ||||
| Maccabi Research & Innovation Center, Tel Aviv University, Tel Aviv, Israel, 2 Inst. for Epidemiology & Medical Biometry, Uni. of Ulm, Ulm, Germany, 3National Research Inst. of Chinese Medicine, Taipei, Taiwan, 4Dept. of Diabetes and Endocrinology, Gifu University Graduate School of Medicine, Gifu, Japan, 5Dept. of Endocrinology & Metabolism, Ajou Uni. School of Medicine, Suwon, Republic of Korea, 6Taipei Veterans General Hospital, Taipei, Taiwan, 7Dept. of Clinical Science & Education, Södersjukhuset, Karolinska Institutet, Solna, Sweden, 8Department of Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 9 IQVIA, Copenhagen, Denmark, 10Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, USA, 11Dept. of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain | ||||
| https://doi.org/10.2337/DB21-127-LB Virtual EASD 2021, 57 Annual Meeting, 27 September - 10 October 2021 |
||||
| , Abstract | ||||
| , Finland, Germany, Israel, Japan, South Korea, Spain, Sweden, Taiwan | ||||
| Abstract: https://easddistribute.m-anage.com/from.storage?image=gOIMdpw6-DbPpKIQZ5HFcJGqJ2quHgbqFewkkUQkLblXdwzJ9kfmAYikI6R6NFu_GLAQJwEZKsC1PXU8ndyryA2 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2021 | English | , Database Study, Methodology, Population Based Study | |
| Cardiovascular Effectiveness of Empagliflozin Compared to DPP-4i in Routine Care in East Asia: Results from the EMPRISE study | ||||
| Dae Jung Kim, Wayne H.-H. Sheu, Wook-Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Elise Chia-Hui Tan, Yusuke Taneda, Vanessa Lei, Laura Saarelainen, Anouk Deruaz-Luyet, Moe H. Kyaw, Yutaka Seino, EMPRISE East Asia Study Group, Boehringer Ingelheim International GmbH, Ingelheim, Germany, StatFinn - EPID Research an IQVIA Company, Espoo, Finland | ||||
| 1 Ajou University, Suwon, South Korea; 2 Taichung Veterans General Hospital, Taichung, Taiwan; 3 Gachon University Gil Medical Center, Incheon, South Korea; 4 Kansai Electric Power Medical Research Institute, Kobe, Japan; 5 Gifu University Graduate School of Medicine, Gifu, Japan; 6 National Research Institute of Chinese Medicine, Taipei, Taiwan; 7 Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan; 8 Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan; 9 IQVIA, Espoo, Finland; 10 Boehringer Ingelheim International GmbH, Ingelheim, Germany; 11 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 12 Kansai Electric Power Hospital, Osaka, Japan | ||||
| J Am Coll Cardiol. 2021 May, 77 (18_Supplement_1) 542. https://doi.org/10.1016/S0735-1097(21)01901-X |
||||
| , Abstract, Presentation | ||||
| , Japan, South Korea, Taiwan | ||||
| Abstract: https://www.jacc.org/doi/epdf/10.1016/S0735-1097%2821%2901901-X | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2021 | English | , Database Study, Methodology, Observational study | |
| Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk ofcardiovascular and renal disease among type 2 diabetes patients in routinecare in europe and israel: EMPRISE study results | ||||
| T Nystroem1;AKarasik2; J Nunez3; S Lanzinger4; C Melzer-Cohen2; R W Holl4;P Casajust5; E Toresson Grip6; M Carrasco7; J Foersch8; K Karlsdotter9;M Tuovinen10; R Klement11;MHKyaw12; L Niskanen | ||||
| Karolinska Institutet,Department of Clinical Science and Education, Södersjukhuset, Solna, Sweden;2Tel Aviv University, Maccabi Research and Innovation Center, Tel Aviv, Israel;3University of Valencia, Department of Cardiology, Hospital Clínico Universitariode Valencia, INCLIVA, CIBER Cardiovascular, Valencia, Spain;4University of Ulm,Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany;5Trial FormSupport, Real-World Evidence, Barcelona, Spain;6Swedish Institute for HealthEconomics Quantify Research, Stockholm, Sweden;7Boehringer Ingelheim EspañaS.A., Barcelona, Spain;8Boehringer Ingelheim Pharma GmbH & Co. Kg, HP CountryMedical Affairs, Ingelheim Am Rhein, Germany;9Boehringer Ingelheim AB, Stock-holm, Sweden;10Boehringer Ingelheim KY, Secondment Boehringer Ingelheim UKHEOR Team, Helsinki, Finland;11IQVIA, Global Database Studies, Tartu, Estonia;12Boehringer Ingelheim Pharmaceutical Inc., Connecticut, United States of America;13University of Eastern Finland, Kuopio, Finland; | ||||
| European Journal of Heart Failure (2021)23(Suppl. S2) 2–322doi:10.1002/ejhf.2297 |
||||
| , Abstract, Article | ||||
| , Finland, Germany, Israel, Spain, Sweden | ||||
| Abstract: https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.2297 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2021 | English | , Database Study, Meta analysis, Methodology, Population Based Study | |
| Evaluating the ability of economic models of diabetes to simulate new cardiovascular outcomes trials: a report on the Ninth Mount Hood Diabetes Challenge | ||||
| Si L, Willis MS, Asseburg C, Tew M, Clarke PM, Lamotte M, Ramos M, Hui S, Shi L, Zhang P, McEwan P, Ye W, Herman WH, Isaman DJ, Kuo S, Schramm W, Sailer F, Brennan A, Pollard D, Smolen HJ, Leal J, Gray A, Patel R, Feenstra T, Palmer AJ | ||||
| IQVIA, Zaventem, Belgium and IQVIA, Lisbon, Portugal | ||||
| Value in Health |
||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2020 | English | , Cost effectiveness | |
| Contrasting three type 2 diabetes cardiovascular risk equations for east asia with ukpds82 using the IQVIA core diabetes model | ||||
| Ramos M1, Monteiro S2, Olivieri AV3, Lamotte M1 | ||||
| 1 IQVIA, Zaventem, Belgium 2 IQVIA, London, UK 3 IQVIA, Basel, Switzerland | ||||
| ISPOR US 2020 Orlando, Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB56 |
||||
| , Article | ||||
| , Asia Pacific | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2020 | English | , Population Based Study | |
| Impact of using different types of hba1c progression in the IQVIA core diabetes model | ||||
| Ramos M1, Monteiro S2, Lamotte M1 | ||||
| 1 IQVIA, Zaventem, Belgium 2 IQVIA, London, UK | ||||
| ISPOR US 2020 Orlando Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB52 |
||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2020 | English | , Population Based Study | |
| Does including acute pancreatitis as a complication have an impact on cost-effectiveness analyses using the IQVIA core diabetes model? | ||||
| Monteiro S1, Ramos M2, Lamotte M2 | ||||
| 1 IQVIA, London, UK 2 IQVIA, Zaventem, Belgium | ||||
| ISPOR US 2020 Orlando Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB52 |
||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2020 | English | , Population Based Study | |
| Cost of Macrovascular Complications in People With Diabetes From a Public Healthcare Perspective: A Retrospective Database Study in Brazil | ||||
| Guilherme Silva Julian 1, Daniel Campos 1, Julie Broe Honore 2, Flávia Sauer Tobaruella 3, Jung Hyun Yoon 3, Nino Hallén 2 | ||||
| 1 IQVIA Brasil, São Paulo, Brazil. 2 Novo Nordisk A/S, Søborg, Denmark. 3 Novo Nordisk Farmacêutica Do Brasil Ltda, São Paulo, Brazil. | ||||
| PMID: 32372710 DOI: 10.1080/13696998.2020.1764966 |
||||
| , Article | ||||
| , Brazil | ||||
| Abstract: https://www.tandfonline.com/doi/full/10.1080/13696998.2020.1764966 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2020 | English | , Observational study, Retrospective database analysis | |
| Cross-sectional survey in patients with type 1 and type 2 diabetes to understand mealtime insulin unmet needs in Japan: The MINUTES-J study | ||||
| Hitoshi Ishii 1, Suzuki Shuichi 2, Paul Williams 3, Sven Demiya 4, Toshihiko Aranishi 2, Tamas Treuer 5 (rwesheorj 4) | ||||
| 1) Department of Diabetology, Nara Medical University, Nara, Japan 2) Eli Lilly Japan, K.K., Kobe, Japan 3) RWE Patient-Centered Endpoints Center of Excellence, IQVIA, Paris, France 4) IQVIA Solutions K.K., Tokyo Japan 5) Eli Lilly and Company, Budapest, Hungary | ||||
| Diabetes Research and Clinical Practice |
||||
| , Article | ||||
| , Japan | ||||
| Abstract: https://www.sciencedirect.com/science/article/pii/S0168822719314494?via%3Dihub | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2020 | English | , Patient questionnaire | |
| An Assessment of Physician Reasons for Prescribing Insulin Lispro 200 units/ml in Germany | ||||
| Jieling Chen1, Magaly Perez-Nieves1, Carolina Piras De Oliveira1, Erik Spaepen2, Beatrice Osumili3, Jiat Ling Poon1, Nanette Schloot2, Nuria Lara4, Laura Garcia Alvarez4, Montserrat Roset4 | ||||
| 1 Eli Lilly and Company, Indianapolis, US 2 Eli Lilly and Company, HaaPACS GmbH, Schriesheim, Germany 3 Eli Lilly and Company, Surrey, UK 4 IQVIA, Real World Solutions, Barcelona, Spain | ||||
| Postgraduate Medicine |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: https://www.endocrine-abstracts.org/ea/0063/ea0063p207 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2020 | English | , Compliance | |
| Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study | ||||
| Yutaka Seino*, Dae Jung Kim, Daisuke Yabe, Elise Chia-Hui Tan, Wook-Jin Chung, Kyoung Hwa Ha, Masaomi Nangaku, Koichi Node, Riho Klement**, Atsutaka Yasui, Wei-Yu, Sunwoo Lee, Moe H Kyaw, Anouk Deruaz-Luyet, Kimberly G Brodovicz,Wayne H-H Sheu, on behalf of the EMPRISE East Asia study group | ||||
| * Kansai Electric Power Medical Research Institute, Kobe, Japan and Kansai Electric Power Hospital, Osaka, Japan **EPID Research an IQVIA company, Tartu, Estonia | ||||
| Endocrinology, Diabetes and Metabolism 2020;00:e00183 |
||||
| , Article | ||||
| , Japan, South Korea, Taiwan | ||||
| Abstract: https://onlinelibrary.wiley.com/doi/full/10.1002/edm2.183 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2020 | English | , Epidemiological study, Retrospective database analysis | |
| An Assessment of Physician Reasons for Prescribing Insulin Lispro 200 units/ml in Germany | ||||
| Jieling Chen1, Magaly Perez-Nieves1, Carolina Piras De Oliveira1, Erik Spaepen2, Beatrice Osumili3, Jiat Ling Poon1, Nanette Schloot2, Nuria Lara4, Laura Garcia Alvarez4, Montserrat Roset4 | ||||
| 1 Eli Lilly and Company, Indianapolis, US 2 Eli Lilly and Company, HaaPACS GmbH, Schriesheim, Germany 3 Eli Lilly and Company, Surrey, UK 4 IQVIA, Real World Solutions, Barcelona, Spain | ||||
| Postgraduate Medicine |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: https://www.endocrine-abstracts.org/ea/0063/ea0063p207 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2020 | English | , Compliance | |
| A Retrospective Observational Cohort study to Assess the Prevalence of Diabetic Kidney Disease Among Type 2 Diabetes Patients in Ontario, Canada | ||||
| Wally Rapattoni, David Zante, Ali Tehrani, Varun Myageri, Shane Golden, Brad Millson, Sheldon W. Tobe, Jennifer B. Rose | ||||
| Ali Tehrai, Varun Myageri, shane Golden, Brad Millson | ||||
| ERA - EDRA Virtual Congress June 6-9 2020 |
||||
| , Poster | ||||
| , Canada | ||||
| Abstract: https://academic.oup.com/ndt/article/35/Supplement_3/gfaa142.P0775/5853053 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Public Health | 2020 | English | , Clinical setting: hospital, Clinical setting: Primary care, Cost analysis, direct-to-patient research, Observational study, Retrospective cohort analysis | |
| Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes | ||||
| Mafalda Ramos 1, Anastasia Ustyugova 2, Nikco Hau 3, Mark Lamotte 4 | ||||
| 1IQVIA Global HEOR, Porto Salvo 2740-266, Portugal. 2Boehringer Ingelheim International GmbH, TA CardioMetabolism Respiratory, Binger Str 173, Ingelheim am Rhein 55216, Germany. 3Boehringer Ingelheim Ltd, UK Market Access, Bracknell RG128YS, UK (at the time of the study). 4IQVIA, Global HEOR, Zaventem 1930, Belgium. | ||||
| Journal of Comparative Effectiveness Research 2020. https://doi.org/10.2217/cer-2020-0071 PMID: 32573253 DOI: 10.2217/cer-2020-0071 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/32573253/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
| Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK | ||||
| Mafalda Ramos 1, Michael H Cummings 2, Anastasia Ustyugova 3, Syed I Raza 4, Shamika U de Silva 4, Mark Lamotte 5 | ||||
| 1Global HEOR/Real World Solutions, IQVIA, 2740-266, Porto Salvo, Portugal. 2Academic Department of Diabetes and Endocrinology, Queen Alexandra Hospital, Portsmouth, PO6 3LY, Hampshire, UK. 3Boehringer Ingelheim International GmbH, 55216, Ingelheim Am Rhein, Germany. 4Boehringer Ingelheim Ltd., Bracknell, RG12 8YS, Berkshire, UK. 5Global HEOR/Real World Solutions, IQVIA, 1930, Zaventem, Belgium. Mark.lamotte@iqvia.com. | ||||
| Diabetes Therapy 2020; 11(9), 2041-2055; https://doi.org/10.1007/s13300-020-00883-1. PMID: 32700188 PMCID: PMC7434815 DOI: 10.1007/s13300-020-00883-1 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/32700188/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
| DOES INCLUDING ACUTE PANCREATITIS AS A COMPLICATION HAVE AN IMPACT ON COST-EFFECTIVENESS ANALYSES USING THE IQVIA CORE DIABETES MODEL? | ||||
| Monteiro S, Ramos M, Lamotte M | ||||
| IQVIA HEOR Zaventem Brussels | ||||
| ISPOR US 2020 Orlando. Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB44. |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
| IMPACT OF USING DIFFERENT TYPES OF HBA1C PROGRESSION IN THE IQVIA CORE DIABETES MODEL. | ||||
| Ramos M, Monteiro S, Lamotte M | ||||
| IQVIA HEOR Zaventem Brussels | ||||
| ISPOR US 2020 Orlando Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB52. |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
| Three Asian Type 2 Diabetes cardiovascular risk equations simulation using the IQVIA Core Diabetes Model | ||||
| Ryo Mitsuo 1, Sven Demiya 1, Adeeb Tawseef 1, Raf De Moor 1, M Ramos, M Lamotte (rwesheorj 1) | ||||
| IQVIA HEOR Zaventem Brussels | ||||
| Japan Diabetes Society 2020 Annual Meeting |
||||
| , Poster | ||||
| , Asia Pacific, Japan | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
| CONTRASTING THREE TYPE 2 DIABETES CARDIOVASCULAR RISK EQUATIONS FOR EAST ASIA WITH UKPDS82 USING THE IQVIA CORE DIABETES MODEL. | ||||
| Ramos M, Monteiro S, Olivieri AV, Lamotte M. | ||||
| IQVIA HEOR Zaventem Brussels | ||||
| ISPOR US 2020 Orlando. Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB56 |
||||
| , Poster | ||||
| , Asia Pacific | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
| Does Including EGFR Along to HBA1C As a Driver of Treatment Switch Changes Outcomes in Cost-Effectiveness Analyses in Type 2 Diabetes? | ||||
| Ramos M, Monteiro S, Lamotte M | ||||
| IQVIA HEOR Zaventem Brussels | ||||
| ISPOR Europe 2020 Virtual conference Milano Nov 16-19 Abstract ID# 108179. |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
| The Cost-Effectiveness of Empagliflozin in Type 2 Diabetes in Denmark, Incorporating Cardiovascular Outcomes | ||||
| Ehlers LH, Lamotte M, Monteiro S, Sandgaard S, Holmgaard P, Frary EC, Staehr P, Ejskjaer N. | ||||
| IQVIA HEOR Zaventem Brussels | ||||
| ISPOR Europe 2020 Virtual conference Milano Nov 16-19 Abstract ID# 107114 |
||||
| , Poster | ||||
| , Denmark | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
| Cost-Effectiveness of the FreeStyle Libre System versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Treatment not Reaching Glycemic Goals in Sweden. | ||||
| Jendle J, Eeg-Olofsson K, Svensson AM, Franzen S, Lamotte M, Levrat-Guillen F. | ||||
| IQVIA HEOR Zaventem Brussels | ||||
| American Diabetes Association’s (ADA’s) 81st Scientific Sessions. Poster presentation number 135-LB |
||||
| , Poster | ||||
| , Sweden | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
| USO DE DATOS DE PRACTICA REAL PARA ANALIZAR LOS TRATAMIENTOS PRESCRITOS EN LA DIABETES TIPO 2 EN ESPA?A | ||||
| Maria Targhetta*, Jean Paul Tang*, Hector Gutierrez*, Nuria Perulero*, Daniel Callejo*, Miriam Solozabal* | ||||
| IQVIA Spain | ||||
| XXXIX Jornadas de Economa de la Salud. Albacete, 12 al 14 de junio de 2019 |
||||
| , Oral presentation | ||||
| , Spain | ||||
| Abstract: http://www.aes.es/jornadas/pdfs/Jornadas_AES_2019-Libro_abstracts.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2019 | Spanish | , Clinical setting: Primary care, Population Based Study, Retrospective database analysis | |
| GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data. | ||||
| Divino V, Boye KS, Lebrec J, DeKoven M, Norrbacka K | ||||
| IQVIA, Eli Lilly | ||||
| Journal. Diabetes Ther. 2019 Jun;10(3):1067-1088. |
||||
| , Article | ||||
| , Belgium, Canada, France, Germany, Italy, Netherlands | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31028689 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2019 | English | , Retrospective database analysis | |
| European Multi-Country Drug Utilization Study of Dulaglutide | ||||
| Ayad K. Ali1, Karen E. Wells2, Mathieu Ros3, Massoud Toussi3 | ||||
| 1Eli Lilly and Company, Indianapolis, IN, USA 2IQVIA, Oakland, MI, USA 3IQVIA, Courbevoie, France | ||||
| ICPE, Philadelphia, USA, 24-28 August 2019 |
||||
| , Abstract | ||||
| , France, Germany, Spain, Sweden, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Drug safety | 2019 | English | , Epidemiological study, Observational study, Retrospective cohort analysis, Retrospective database analysis | |
| A population-based analysis of anti-diabetic medications in four Canadian provinces: secular trends and prescribing patterns | ||||
| Secrest MH, Azoulay L, Dahl M, Clemens KK, Durand M, Hu N, Targownik L, Turin TC, Dormuth CR, and Filion KB | ||||
| IQVIA, Cambridge, MA | ||||
| Pharmacoepidemiology & Drug Safety (in press) |
||||
| , Article, In press/to be published | ||||
| , Canada | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Drug Utlization Study | 2019 | English | , Epidemiological study, Observational study, Retrospective cohort analysis, Retrospective database analysis | |
| CLUE: Consequences for life of children with in utero exposure to metformin in Finland | ||||
| Kerstin Brand, Judith Schlachter, Emmanuelle Boutmy, Caroline Foch, Pasi Korhonen, Katja Hakkarainen, Jaak Sonajalg, Minna Vehkala, Laura Saarelainen | ||||
| Merck KGaA: Kerstin Brand, Judith Schlachter, Emmanuelle Boutmy, Caroline Foch IQVIA (SF-EPID): Pasi Korhonen, Katja Hakkarainen, Jaak Sonajalg, Minna Vehkala, Laura Saarelainen | ||||
| The International Diabetes Federation (IDF) Congress 2019 |
||||
| , Oral presentation | ||||
| , Finland, Nordic | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2019 | English | , Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Public Health, Retrospective cohort analysis, Retrospective database analysis | |
| EMPAGLIFLOZIN VS SITAGLITPIN, SAXAGLIPTIN AND LIRAGLUTIDE IN SPAIN. A BUDGET IMPACT MODEL BASED ON THE CORE DIABETES MODEL AND CARDIOVASCULAR OUTCOMES TRIALS | ||||
| Carrasco Perez M, Ustyugova A, Rubio M, Callejo-Velasco D, Gasche D, Gonzalez-Rojas Guix N | ||||
| Boehringer Ingelheim and IQVIA | ||||
| ISPOR Europe, Copenhagen, Denmark, 2-6 November 2019 |
||||
| , Poster | ||||
| , Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2019 | English | , Budget impact, Clinical setting: Primary care | |
| An assessment of physician reasons for prescribing insulin lispro 200 units/ml in a prefilled pen in Germany | ||||
| Jieling Chen1, Magaly Perez-Nieves1, Carolina Piras De Oliveira1, Erik Spaepen2, Beatrice Osumili3, Jiat Ling Poon1, Nanette Schloot2, Nuria Lara4, Laura Garcia Alvarez4, Montserrat Roset4 & Dirk Lennartz5 | ||||
| 1Lilly and Company, Indianapolis, USA; 2Eli Lilly and Company Deutschland GmbH, Bad Homburg, Germany; 3Eli Lilly and Company, Surrey, United Kingdom; 4IQVIA, Real-World Evidence Solutions, Barcelona, Spain; 5IQVIA, Real-World Evidence Solutions, Munich, Germany. | ||||
| Endocrine Abstracts (2019) 63 P207 | DOI: 10.1530/endoabs.63.P207 |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: https://www.endocrine-abstracts.org/ea/0063/ea0063P207 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2019 | English | , Compliance, Survey research | |
| Projected long-term clinical benefit and cost-effectiveness of empagliflozin compared to glimepiride in patients with type 2 diabetes in China | ||||
| Lamotte M1, Salem A2, Mettam S2, Ustyugova A2, Zhang YJ3, Ramos M1 | ||||
| 1 IQVIA, Zaventem, Belgium 2 Boehringer Ingelheim International, GmbH, Germany 3 Boehringer Ingelheim, Beijing, China | ||||
| ADA, San Francisco, US, 07-11 June 2019 |
||||
| , Poster | ||||
| , China | ||||
| Abstract: https://doi.org/10.2337/db19-1292-P | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2019 | English | , Cost effectiveness, Population Based Study | |
| Contrasting Framingham Risk Equations in Type 2 Diabetes Using the IQVIA Core Diabetes Model | ||||
| Monteiro S1, Ramos M2, Altrabsheh E1, Gurjar K3, Olivieri A4, Lamotte M2 | ||||
| 1 IQVIA, London, UK 2 IQVIA, Zaventem, Belgium 3 IQVIA, Gurgaon, India 4 IQVIA, Basel, Switzerland | ||||
| ISPOR, New Orleans, 18-22 May 2019 |
||||
| , Poster | ||||
| , UK | ||||
| Abstract: https://doi.org/10.1016/j.jval.2019.04.585 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2019 | English | , Cost effectiveness, Population Based Study | |
| Contrasting three type 2 diabetes cardiovascular risk equations for East Asia with UKPDS82 using the IQIVA core diabetes model | ||||
| Olivieri A1, Ramos M2, Monteiro S3, Altrabsheh E3, Gurjar K4, Lamotte M2 | ||||
| 1 IQVIA, Basel, Switzerland 2 IQVIA, Zaventem, Belgium 3 IQVIA, London, UK 4 IQVIA, Gurgaon, India | ||||
| ISPOR, New Orleans, 18-22 May 2019 |
||||
| , Poster | ||||
| , China | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2019 | English | , Cost effectiveness, Population Based Study | |
| Body mass index associated utility approaches in the IQVIA core diabetes model | ||||
| Ramos M1, Olivieri A2, Monteiro S3, Altrabsheh E3, Gurjar K4, Lamotte M1 | ||||
| 1 IQVIA, Zaventem, Belgium 2 IQVIA, Basel, Switzerland 3 IQVIA, London, UK 4 IQVIA, Gurgaon, India | ||||
| ISPOR, New Orleans, 18-22 May 2019 |
||||
| , Poster | ||||
| , UK | ||||
| Abstract: https://doi.org/10.1016/j.jval.2019.04.573 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2019 | English | , Cost effectiveness, Population Based Study | |
| Comparability of results using two alternative versions of the IQVIA CORE Diabetes Model | ||||
| Gurjar K1, Ramos M2, Monteiro S3, Altrabsheh E3, Olivieri A4, Lamotte M2 | ||||
| 1 IQVIA, Gurgaon, India 2 IQVIA, Zaventem, Belgium 3 IQVIA, London, UK 4 IQVIA, Basel, Switzerland | ||||
| ISPOR, New Orleans, 18-22 May 2019 |
||||
| , Poster | ||||
| , UK | ||||
| Abstract: https://doi.org/10.1016/j.jval.2019.04.580 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2019 | English | , Cost effectiveness, Population Based Study | |
| Association Between Cardiovascular Disease Risk Factors and Hypoglycaemic events in Type 2 Diabetes Using the IQVIA Core Diabetes Model | ||||
| Altrabsheh E1, Monteiro S1, Ramos M2, Gurjar K3, Olivieri A4, Lamotte M2 | ||||
| 1 IQVIA, London, UK 2 IQVIA, Zaventem, Belgium 3 IQVIA, Gurgaon, India 4 IQVIA, Basel, Switzerland | ||||
| ISPOR, New Orleans, 18-22 May 2019 |
||||
| , Poster | ||||
| , UK | ||||
| Abstract: https://doi.org/10.1016/j.jval.2019.04.613 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2019 | English | , Cost effectiveness, Population Based Study | |
| Health economic effects of the updated foot ulcer submodel | ||||
| Monteiro S1, Ramos M2, Lamotte M2 | ||||
| 1 IQVIA, London, UK 2 IQVIA, Zaventem, Belgium | ||||
| ISPOR, Copenhagen, Denmark, 4-6 November 2019 |
||||
| , Poster | ||||
| , UK | ||||
| Abstract: https://doi.org/10.1016/j.jval.2019.09.899 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2019 | English | , Cost effectiveness | |
| The clinical and economic impact of adding an adherence module to the IQVIAcore diabetes model | ||||
| Ramos M1, Monteiro S2, Altrabsheh E2, Lamotte M1 | ||||
| 1 IQVIA, Zaventem, Belgium 2 IQVIA, London, UK | ||||
| ISPOR, Copenhagen, Denmark, 4-6 November 2019 |
||||
| , Poster | ||||
| , Germany | ||||
| Abstract: https://doi.org/10.1016/j.jval.2019.09.943 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2019 | English | , Cost effectiveness, Survey research | |
| Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis | ||||
| Lau E1, Salem A2, Chan JCN1, So WY1, Kong A1, Lamotte M2, Luk A1 | ||||
| 1 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, SAR China 2 IQVIA, Zaventem, Belgium | ||||
| Cost Eff Resour Alloc. 2019 Jul 2;17:13. |
||||
| , Article | ||||
| , Hong Kong | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31303866 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2019 | English | , Cost effectiveness | |
| The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood | ||||
| Kent S1, Becker F1, Feenstra T2,3, Tran-Duy A4, Schlackow I1, Tew M4, Zhang P5, Ye W6, Lizheng S7, Herman W6, McEwan P8, Schramm W9, Gray A1, Leal J1, Lamotte M10, Willis M11, Palmer AJ4,12, Clarke P13,14 | ||||
| 1 Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK 2 National Institute for Public Health and the Environment (RIVM), Centre for Nutrition, Prevention and Health Services Research, Bilthoven, The Netherlands 3 University of Groningen, Faculty of Science and Engineering, Groningen Research Institute of Pharmacy, Groningen, The Netherlands 4 Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia 5 Division of Diabetes Translation, Centres for Disease Control and Prevention, Atlanta, US 6 School of Public Health, University of Michigan, Ann Arbor, US 7 Department of Health Management and Policy, School of Public Health and Tropical Medicine, Tulane University, New Orleans, US 8 Centre for Health Economics, Swansea University, Swansea, UK 9 GECKO Institute, Heilbronn University, Heilbronn, Germany 10 IQVIA, Zaventem, Belgium 11 The Swedish Institute for Health Economics, Lund, Sweden 12 Menzies Institute for Medical Research, The University of Tasmania, Hobart, Australia 13 Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK 14 Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia | ||||
| Pharmacoeconomics. 2019 Nov;37(11):1305-1312. |
||||
| , Article | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31347104 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2019 | English | , Retrospective database analysis | |
| Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach | ||||
| Foos V1, Wang K2, McEwan P3, Zhang Y2, Xin P2, Jiang X2, Qu S4, Xiong T4, De Moor R1, Ramos M1, Lamotte M1, Ji L5 | ||||
| 1 IQVIA, Zaventem, Belgium 2 Lilly Suzhou Pharmaceutical Co, Ltd, Shanghai, China 3 Centre for Health Economics, Swansea University, Wales, England, UK 4 RWE Solutions & HEOR, QuintilesIMS, Shanghai, China 5 Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China | ||||
| Value Health Reg Issues. 2019 May;18:36-46. |
||||
| , Article | ||||
| , China | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/30419449 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2019 | English | , Cost effectiveness | |
| Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease | ||||
| Ramos M1, Foos V1, Ustyugova A2, Hau N3, Gandhi P4, Lamotte M1 | ||||
| 1 IQVIA, Zaventem, Belgium 2 Boehringer Ingelheim International GmbH, Ingelheim, Germany 3 Boehringer Ingelheim Ltd, Bracknell, UK 4 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, US | ||||
| Diabetes Ther. 2019 Dec;10(6):2153-2167 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31602601 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2019 | English | , Cost effectiveness | |
| Advancing glycemic management in people with diabetes | ||||
| Aitken M1, Villa P1, Lamotte M1, Tewary V1, Ramos M1 | ||||
| 1 IQVIA, Zaventem, Belgium | ||||
| with paper on the IQVIA institute web page |
||||
| , Article | ||||
| Abstract: https://www.iqvia.com/insights/the-iqvia-institute/reports/advancing-glycemic-management-in-people-with-diabetes | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2019 | English | , Cost effectiveness | |
| Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data | ||||
| Kathleen Lang, Hiep Nguyen, Huan Huang, Elise Bauer, Philip Levin | ||||
| Huan Huang, IQVIA | ||||
| Current Medical Research and Opinion |
||||
| , Article | ||||
| , USA | ||||
| Abstract: https://www.tandfonline.com/doi/full/10.1080/03007995.2018.1437027 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Population Based Study, Retrospective database analysis | |
| The relationship of predicted benefits in life expectancy and quality adjusted life expectancy for improved glucose control in type 2 diabetes simulation modeling. | ||||
| Ramos M, Foos V, McEwan P, Lamotte M | ||||
| IQVIA, Zaventem, Belgium | ||||
| ISPOR 20th Annual European Congress, 2017, November 4-8, Glasgow, Scotland |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2018 | English | , Cost effectiveness | |
| Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease | ||||
| Huan Huang, Sharash Shetty, Elise Bauer, Kathleen Lang | ||||
| Huan Huang, IQVIA | ||||
| Current Medical Research and Opinion |
||||
| , Article | ||||
| , USA | ||||
| Abstract: http://www.tandfonline.com/eprint/PqtzuUz9tjZ3mSt7AaIz/full | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Population Based Study, Retrospective database analysis | |
| Child growth and development outcomes following in-utero exposure to metformin versus insulin for treatment of gestational diabetes. | ||||
| Landi SN, Radke S, Engel SM, Sturmer T, Boggess K, Howe A, Jonsson Funk M | ||||
| Pharmacoepidemiol Drug Saf 2018: 27 (2):351-351. |
||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | ||
| A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Antidiabetic Therapies Added to Metformin in Patients with Type 2 Diabetes (T2D). | ||||
| Huang H, Bell K, Gani R, Tugwell C, Eudicone J, Krukas‐Hampel MR | ||||
| Huan Huang is at IQVIA | ||||
| Am J Manag Care |
||||
| , Article | ||||
| , USA | ||||
| Abstract: https://www.ajmc.com/journals/supplement/2018/real-world-evidence-type2-diabetes-sglt2-inhibitors/retrospective-realworld-study-dapagliflozin-vs-oral-antidiabetic | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Population Based Study | |
| "Risk of chronic kidney disease in young adults with impaired glucose tolerance/ impaired fasting glucose: a retrospective cohort study using electronic primary care records" | ||||
| Ferozkhan Jadhakhan, Tom Marshall, Ronan Ryan and Paramjit Gill. | ||||
| University of Birmingham | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Retrospective database analysis | |
| EXPLAINING THE DISPARITIES OF MARKET ACCESS FOR GLIFLOZINS IN FRANCE, SPAIN, GERMANY AND THE UNITED-KINGDOM | ||||
| Bodaghi Charles, Benque Emma, Troubat Arnaud | ||||
| IQVIA France - RWI | ||||
| ISPOR 2018 |
||||
| , Poster | ||||
| , France, Germany, Spain, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Clinical setting: Home care, Pricing & Reimbursement | |
| Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. | ||||
| Palmer AJ1, Si L1, Tew M2, Hua X2, Willis MS3, Asseburg C3, McEwan P4, Leal J5, Gray A5, Foos V6, Lamotte M6, Feenstra T7, 8, O’Connor PC 9, Brandle M 10, Smolen HJ11, Gahn JC11, Valentine WJ12, Pollock RF12, Breeze P13, Brennan A13, Pollard D13, Ye W14, Herman WH15, Isaman DJ14, Kuo S16, Laiteerapong N17, Tran-Duy A2, Clarke PM2 | ||||
| 1 University of Tasmania, Hobart, Tasmania, Australia 2 University of Melbourne, Melbourne, Victoria, Australia 3 The Swedish Institute for Health Economics, Lund, Sweden 4 Health Economics and Outcomes Research Ltd., Cardiff, UK 5 University of Oxford, Oxford, UK 6 IQVIA, Zaventem, Belgium 7 National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands 8 Groningen University, Groningen, The Netherlands 9 HealthPartners Institute and HealthPartners Center for Chronic Care Innovation, Minneapolis, MN, USA 10 Kantonsspital St. Gallen, St. Gallen, Switzerland 11 Medical Decision Modeling Inc., Indianapolis, IN, USA 12 Ossian Health Economics and Communications, Basel, Switzerland 13 University of Sheffield, Sheffield, UK 14 University of Michigan, Ann Arbor, MI, USA 15 University of Michigan, Ann Arbor, MI, USA 16 University of Michigan, Ann Arbor, MI, USA 17 University of Chicago, Chicago, IL, USA | ||||
| Value in Health, 2018, 21(6): 724-731 |
||||
| , Article | ||||
| , International | ||||
| Abstract: https://doi.org/10.1016/j.jval.2018.02.002 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2018 | English | , Cost effectiveness | |
| Review and Validation of Cardiovascular Risk Prediction Models in East Asian Populations. | ||||
| Foos V, McEwan P, Lamotte M | ||||
| IQVIA, Zaventem, Belgium | ||||
| Value in Health, Volume 21, Supplement 1, May 2018, Page S220 |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2018 | English | , Cost effectiveness | |
| Changes in Patient Characteristics, Glucose Lowering Treatment, Glycemic Control and Complications in Type 2 Diabetes in General Practices (Disease Analyzer, Germany: 2008-2016) | ||||
| Rathmann W, Scheerer M, Rohwedder K, Busch S, Kostev K | ||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | ||
| Increased Depression Symptom Score in Newly Diagnosed Type 2 Diabetes Patients | ||||
| Rathmann W, Engelhard J, ANderson D, Kostev K, Zou M, Busch S, Kuss O, Hahn M | ||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Mental health | 2018 | English | ||
| Frequency of Blood Pressure and Estimated Glomerular Filtration Rate Testing in Type 2 Diabetes Mellitus: A Retrospective Study with 43,509 Patients | ||||
| Kostev K, Lucas A, Jacob L | ||||
| EXP CLIN ENDOCRINOL DIABETES. 2018 MAR 12. |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Metabolic Disorders , Vascular disease | 2018 | English | , Retrospective cohort analysis | |
| Assessing the Benefits of Co-pay Card Usage Among Diabetic Patients in Canada | ||||
| Jing Guo 1, Christian Silva 1, Chris Stewart 1, Andrew Leung 1, Behlool Khan 2, Johanna Mancini 2 | ||||
| 1 Department of Mechanical and Industrial Engineering, University of Toronto 2 IQVIA | ||||
| , Poster | ||||
| , Canada | ||||
| Abstract: http://imsbrogancapabilities.com/pdf/rwe/frontiers-2018-final-poster-for-presentation.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Retrospective cohort analysis | |
| Persistence with Insulin Glargine 300 lU/mL compared to other Basal Insulins: A Canadian Retrospective Cohort Study | ||||
| Kobina Quansah 1, Luc Sauriol 2, Atif Kukaswadia 1, Samantha Bremner 3, Bradley Millson 3 | ||||
| 1 IQVIA, Mississauga, ON, Canada, 2 Sanofi, Laval, QC, Canada, 3 IQVIA, Kanata, ON, Canada | ||||
| ADA 2018, June 22-26, 2018, Orlando, FL |
||||
| , Poster | ||||
| , Canada | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Retrospective cohort analysis | |
| Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes | ||||
| Mocarski M, Yeaw J, Divino V, DeKoven M, Guerrero G, Langer J, Thorsted BL | ||||
| Novo Nordisk, IQVIA | ||||
| J Manag Care Spec Pharm |
||||
| , Article | ||||
| , USA | ||||
| Abstract: https://www.jmcp.org/doi/10.18553/jmcp.2017.17218 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Utility analysis | |
| Real-World Use of Dulaglutide in Europe: A Multi-Country Drug Utilization Study | ||||
| Ali AK, Toussi M, Phillips S, Roste M | ||||
| Ali AK: Eli Lilly and Company; Toussi M: IQVIA; Phillips S: IQVIA; Roste M: IQVIA | ||||
| 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management |
||||
| , Abstract | ||||
| , France, Germany, Spain, Sweden | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Drug Utlization Study, Drug Utlization Study | 2018 | English | , Database Study, Epidemiological study | |
| Identification of Incident Pancreatic Cancer in Administrative Health Data: A Validation Study by the Canadian Network for Observational Drug Effect Studies | ||||
| Wu JW, Axzoulay L, Huang A, Paterson M, Wu F, Secrest MH, Filion K | ||||
| Wu JW: Analysis Group; Secrest MH: IQVIA | ||||
| 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management |
||||
| , Abstract | ||||
| , Canada | ||||
| Condition | Year | Language | Analysis type | |
| , Database Validity and methodology, Diabetes, Oncology | 2018 | English | , Database Study, Retrospective cohort analysis, Retrospective database analysis | |
| The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population. | ||||
| Blonde L, Burudpakdee C, Divino V, Bookhart B, Cai J, Pfeifer M, Coleman CI. | ||||
| Ochsner Medical Center, Hartford Hospital Evidence-Based Practice Center, Janssen Scientific Affairs, Janssen Medical Affairs, IQVIA | ||||
| Curr Med Res Opin. |
||||
| , Article | ||||
| , USA | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/29671627 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Retrospective database analysis | |
| TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES | ||||
| Norrbacka K, Divino V, Boye K, Lebrec J, Dekoven M | ||||
| Eli Lilly, IQVIA | ||||
| ISPOR Europe 2018 |
||||
| , Poster | ||||
| , Belgium, Canada, France, Germany, Italy, Netherlands | ||||
| Abstract: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/84796?pdfid=57383 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Retrospective database analysis | |
| Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study. | ||||
| Federici, M.O., McQuillan, J., Biricolti, G., Losi, S. | ||||
| Eli Lilly Italy; IQVIA London | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Epidemiological study | |
| Different patterns of second?line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study | ||||
| Persson F, Bodegard J, Lahtela JT, Nyström T, Jørgensen ME, Jensen ML, Gulseth HL, Thuresson M, Hoti F, Nathanson D, Norhammar A, Birkeland KI, Eriksson JG, Eriksson JW | ||||
| StatFinn & EPID Research, Espoo, Finland | ||||
| Endocrinol Diabetes Metab. |
||||
| , Article | ||||
| , Denmark, Finland, Nordic, Norway, Sweden | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354817/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Population Based Study, Retrospective database analysis | |
| Comparison of cost-effectiveness acceptability curves (CEAC) in modeled analyses with and without established heterogeneity of patient characteristics. | ||||
| Foos V, McEwan P, Lamotte M | ||||
| 22nd ISPOR Annual International Meeting, 2017, May 20-24, Boston, MA, USA |
||||
| , Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Cost effectiveness | |
| Estimating glomerular filtration rate in primary care electronic medical record databases in Europe | ||||
| Jouaville SL1, Bizouard G1, Boutmy E1, Keja J2 | ||||
| 1QuintilesIMS, Boulogne Billancourt, France, 2QuintilesIMS, Rotterdam, Netherlands | ||||
| 22nd ISPOR Annual International Meeting, Boston, 2017 |
||||
| , Abstract | ||||
| , Germany, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Methodology, Nephrology | 2017 | English | , Clinical setting: Primary care, Retrospective database analysis | |
| Assessing the economic burden of type 2 diabetes in China reflecting the current standard of the disease management and for improved management scenarios using a modeling approach. | ||||
| Foos V1, Lamotte M1, McEwan P4, Jiang X3, Zhang YL3, Qu S2, De Moor R1, Ramos R1, Xiong T2, Wang K3 | ||||
| 1 IMS Health, Brussels, Belgium 2 IMS Health, Shanghai, China 3 Eli Lilly, Shanghai, China 4 Swansea University, Wales | ||||
| 22nd ISPOR Annual International Meeting, 2017, May 20-24, Boston, MA, USA |
||||
| , Abstract | ||||
| , China | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Cost effectiveness | |
| Approaches to standardizing cardiovascular risk equation endpoints in order to facilitate their inclusion within a type 2 diabetes model. | ||||
| McEwan P, Foos V, Lamotte M | ||||
| 22nd ISPOR Annual International Meeting, 2017, May 20-24, Boston, MA, USA |
||||
| , Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Cost effectiveness | |
| Etude DISCOVER France - étude enrichie visant à décrire la prise en charge des patients diabétiques de type 2 | ||||
| Harmand S.1, Maillard C.1, Thomas F.2 | ||||
| 1. QuintilesIMS, La Défense, France. 2. Astra Zeneca, La Défense, France | ||||
| ADELF-SFSP congress (l'Association des épidémiologistes de langue française - Société française de santé publique) June 2017 in France |
||||
| , Abstract, Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | French | , Clinical setting: Primary care, Longitudinal study, Observational study, Patient questionnaire, Quality of life, Real World Data | |
| Long-term patterns of adherence to medication therapy among patients with type 2 diabetes mellitus in Denmark: The importance of initiation | ||||
| Jensen ML1,2, Jørgensen ME1, Hansen EH2, Aagaard L3, Carstensen B1. | ||||
| 1 Steno Diabetes Center Copenhagen, Gentofte, Denmark. QuintilesIMS 2 Faculty of Health and Medical Sciences, Department of Pharmacy, Section for Social and Clinical Pharmacy, Universitetsparken 2, University of Copenhagen,Denmark. 3 Faculty of Health, University of Southern Denmark, Odense, Denmark. | ||||
| PLoS One. 2017; 12(6): e0179546. |
||||
| , Article | ||||
| , Denmark, Nordic | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493299/ | ||||
| Condition | Year | Language | Analysis type | |
| , Clinical practice, Diabetes | 2017 | English | , clinical setting: Secondary care, Compliance, Epidemiological study, Retrospective cohort analysis | |
| The impact of biosimilar launch on molecule price and pharmaceutical expense: the case of the insulin glargine in Italy | ||||
| Tucci C1, Cioni L1, Mantuano M1, Tettamanti A1 | ||||
| 1 QuintilesIMS, Milan, Italy | ||||
| ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland |
||||
| , Poster | ||||
| , Italy | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health policy, Pricing and reimbursement, Regulatory | 2017 | English | , Literature Review, Pricing & Reimbursement, Public Health | |
| Regional Differences in Insulin Therapy Regimens in 5 European Countries | ||||
| Rathmann W, Czech M, Franek E, Kostev K | ||||
| Int J Clin Pharmacol Ther. 2017 May;55(5):403-408. |
||||
| , Article | ||||
| , France, Germany, Hungary, Poland, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | ||
| Risk of non-fatal stroke in type 2 diabetes mellitus patients: a retrospective comparison between disease management programs and standard care | ||||
| Wiefarn S, Heumann C, Rettelbach A, Karel K | ||||
| J Diabetes Sci Technol. 2017 Jul;11(4):808-813. |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Stroke and other CNS | 2017 | English | ||
| Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy In Type 2 Diabetes: A Primary Care Database Study | ||||
| Kostev K, Pscherer S, Rist R, Busch S, Scheerer MF | ||||
| J Diabetes Sci Technol. 2017 May;11(3):590-596. |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | ||
| Calculated Daily Insulin Dosages Overestimate Prescribed Insulin Doses in Type 2 Diabetes: A Primary Care Database Study. | ||||
| Kostev K, Rathmann W | ||||
| J Diabetes Sci Technol. 2017 May;11(3):597-601. |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Database Study | |
| Treatment Persistence of Basal Insulins in Poland and Germany | ||||
| Rathmann W, Czech M, Franek E, Kostev K | ||||
| Int J Clin Pharmacol Ther. 2017 Feb;55(2):119-125. |
||||
| , Article | ||||
| , Germany, Poland | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | ||
| Psoriasis risk in patients with type 2 diabetes in German primary care practices | ||||
| Jacob L, Kostev K | ||||
| Prim Care Diabetes. 2017 Feb;11(1):52-56 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Dermatology, Diabetes | 2017 | English | ||
| Treatment outcomes and tolerability following initiation of GLP-1 Receptor Agonists among Type 2 diabetes patients in Primary Care Practices in Germany | ||||
| Qiao Q, Johnsson K, Grandy S, Kostev K | ||||
| J Diabetes Sci Technol. 2017 Mar;11(2):272-277. |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | ||
| Prescription patterns and the cost of antihyperglycemic drugs in patients with type 2 diabetes mellitus in Germany | ||||
| Jacob L, von Vultee C, Kostev K | ||||
| J Diabetes Sci Technol. 2017 Jan;11(1):123-127. |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | ||
| Impact of disease management program on HbA1c values in diabetes type 2 patients in Germany | ||||
| Kostev K , Rockel T, Jacob J | ||||
| J Diabetes Sci Technol. 2017 Jan;11(1):117-122. |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | ||
| Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: Reply to Dr. Driessen and colleagues [letter]. | ||||
| Kostev K, Dombrwoski S | ||||
| Epidemiology, QuintilesIMS, Darmstädter Landstraße 108, 60598, Frankfurt am Main, Germany. kkostev@de.imshealth.com. Epidemiology, QuintilesIMS, Darmstädter Landstraße 108, 60598, Frankfurt am Main, Germany. | ||||
| Osteoporos Int. 2017 Jul 13. doi: 10.1007/s00198-017-4139-4. [Epub ahead of print] |
||||
| , Abstract, Letter | ||||
| , Germany | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28707089 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | ||
| Persistence with oral antihyperglycemic drugs in type 2 diabetes mellitus patients with dementia in Germany | ||||
| Jacob L, Adam-Schnepf L, Kostev K | ||||
| Faculty of Medicine, University of Paris 5, Paris, France. Department of Neurology, Epilepsy Center, University of Erlangen, Germany. Epidemiology QuintilesIMS, Frankfurt, Germany. Electronic address: kkostev@de.imshealth.com. | ||||
| J Diabetes Sci Technol. 2017 Jun 1:1932296817719090 |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28648971 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Neurological disorders | 2017 | English | , Retrospective database analysis | |
| Prescription patterns and disease control in type 2 diabetes mellitus patients in nursing home and home care settings: a retrospective analysis in Germany | ||||
| Kostev K, Rockel T, Jacob L | ||||
| QuintilesIMS, Frankfurt, Germany. Faculty of Medicine, University of Paris 5, Paris, France. | ||||
| J Diabetes Sci Technol. 2017 J Diabetes Sci Technol. 2018 Jan;12(1):136-139 |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28539088 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective cohort analysis | |
| Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany – a retrospective analysis of real-world data | ||||
| Dombrowski S, Kostev K, Jacob L | ||||
| Osteoporos Int. 2017 Apr 29. doi: 10.1007/s00198-017-4051-y. [Epub ahead of print] |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Real World Data, Retrospective cohort analysis | |
| Seasonality of insulin use in German outpatients with diabetes: a retrospective analysis | ||||
| Kostev K, Gläser S, Jacob L | ||||
| J Diabetes Sci Technol. 2017 Apr 1:1932296817703994. doi: 10.1177/1932296817703994. [Epub ahead of print] |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective cohort analysis | |
| Association of Dipeptidyl Peptidase 4 Inhibitors with Risk of Metastases in Patients with Type 2 Diabetes and Breast, Prostate or Digestive System Cancer | ||||
| Rathmann W, Kostev K | ||||
| J Diabetes Complications. 2017 Jan 26. pii: S1056-8727(16)31034-0. doi: 10.1016/j.jdiacomp.2017.01.012. [Epub ahead of print] |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Oncology | 2017 | English | ||
| IMPLICATIONS OF THE GERMAN HTA-PROCESS ON MARKET-UPTAKE OF ORAL TREATMENTS FOR TYPE-2-DIABETES (T2DM) SINCE 2007 | ||||
| Dr. Roger-Axel Greiner; Tina Fischer; Benno Antoni; Dr. Ariane Batscheider | ||||
| ISPOR 20th Annual European Congress |
||||
| , Abstract | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Market impact, Retrospective database analysis | |
| The relationship of predicted benefits in life expectancy and quality adjusted life expectancy for improved glucose control in type 2 diabetes simulation modeling. | ||||
| Ramos M1, McEwan P2, Lamotte M1, Foos V1 | ||||
| 1 QuintilesIMS, Zaventem, Belgium, 2 Health Economics and Outcomes Research Ltd, Cardiff, United Kingdom | ||||
| International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress, Nov 4 - 8, 2017, Glasgow, Scotland, United Kingdom |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Methodology | 2017 | English | , Cost effectiveness | |
| Exploration of run-time requirements in probabilistic sensitivity analysis utilizing a patient level based type 2 diabetes simulation model. | ||||
| Foos V1, Lamotte M1, Sathananthan A2, Altrabsheh E2, McEwan P3 | ||||
| 1 QuintilesIMS, Zaventem, Belgium, 2 QuintilesIMS, London, United Kingdom, 3 Health Economics and Outcomes Research Ltd, Cardiff, United Kingdom | ||||
| International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress, 2017, Nov 4 - 8, Glasgow, Scotland |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2017 | English | , Cost effectiveness | |
| L’observance médicamenteuse des patients diabétiques de type 2 en île-de-france : état des lieux et priorités d’actions [Drug adherence in patients with type 2 diabetes in Île-de-France: state of play and priorities for action]. | ||||
| Bardoulat I1, Chauvin F1, De Saunière A2, Le Jeunne P1, Perrot D1, Collet C2 | ||||
| 1 QuintilesIMS, La Défense, France 2 ARS Île-de-France, Paris, France | ||||
| 9ème Colloque données de santé en vie réelle / AFCROs (Cité Universitaire, Paris, 13 juin 2017) |
||||
| , Oral presentation | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Medication compliance | 2017 | French | , Clinical setting: Primary care, clinical setting: Secondary care, Compliance, Retrospective database analysis | |
| L’observance médicamenteuse des patients diabétiques de type II en Île-de-France : Résultats de l’étude et priorités d’actions | ||||
| Catherine Collet(1) – Anne de Saunière (1) – Dominique Perrot (2) – Isabelle Bardoulat (2) | ||||
| (1) ARS Ile de France, Paris, France – (2) Quintiles IMS, Paris, France | ||||
| Congrés annuel de la Société Francophone du Diabète du 28 au 31 mars 2017, Lille, France |
||||
| , Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Medication compliance | 2017 | French | , Clinical setting: Primary care, clinical setting: Secondary care, Compliance, Retrospective database analysis | |
| L’observance médicamenteuse des patients diabétiques de type II en Île-de-France : Résultats de l’étude et priorités d’actions [Drug adherence in patients with type II diabetes in the Île-de-France region: study results and priorities for action]. | ||||
| Collet C1, De Saunière A1, Perrot D2, Bardoulat I2 | ||||
| 1 ARS Ile de France, Paris, France 2 Quintiles IMS, Paris, France | ||||
| Congrés annuel de la Société Francophone du Diabète du 28 au 31 mars 2017, Lille, France |
||||
| , Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Medication compliance | 2017 | French | , Clinical setting: Primary care, clinical setting: Secondary care, Compliance, Retrospective database analysis | |
| Análisis de coste-efectividad de empagliflozina en pacientes con diabetes mellitus tipo 2 y enfermedad cardiovascular establecida en España [Analysis of cost-effectiveness of empagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease established in Spain]. | ||||
| Barrull C1, Massafrets M2, Planellas L1, Perulero N1 | ||||
| 1 RWI, QuintilesIMS, Barcelona 2 Market Access Department, Boehringer Ingelheim, Barcelona | ||||
| XXXVII Jornadas de Economía de la Salud2017, 6 - 8 de septiembre, Barcelona, España |
||||
| , Poster | ||||
| , Spain | ||||
| Abstract: http://www.aes.es/jornadas/en/ | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes, Health economics, Pricing and reimbursement | 2017 | Spanish | , Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Cost effectiveness, Cost utility, Literature Review, Patient questionnaire, Randomised controlled trial | |
| GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries. | ||||
| Divino V., DeKoven M., Khan FA., Boye KS., Sapin H., Norrbacka K. | ||||
| Lilly. IMS authors: Divino V, DeKoven M | ||||
| Diabetes Ther. |
||||
| , Article | ||||
| , Belgium, France, Germany, Netherlands, Sweden | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28070733 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective database analysis | |
| Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States. | ||||
| Cai J., Divino V., Burudpakdee C. | ||||
| Janssen. IMS authors: Divino V, Burudpakdee C | ||||
| Curr Med Res Opin. |
||||
| , Article | ||||
| , USA | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28418262 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective database analysis | |
| Real-World Basal Insulin Intensification Patterns in the United States | ||||
| Mocarski M., Yeaw J., Divino V., DeKoven M., Guerrero G., Langer J., Thorsted B. | ||||
| Novo Nordisk. IMS authors: Yeaw J, Divino V, DeKoven M | ||||
| AMCP Managed Care & Specialty Pharmacy Annual Meeting 2017 |
||||
| , Poster | ||||
| , USA | ||||
| Abstract: http://www.jmcp.org/mwg-internal/de5fs23hu73ds/progress?id=4SaagFc0EJa9TDRbm9m3nOTNIHytJhnoIrRBnUTh5TE,&dl | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective database analysis | |
| Dosing Concordance with Prescribing Information (PI) of Dipeptidyl-Peptidase-IV Inhibitors (DPP4-is) When Renal Function | ||||
| Huang H, Shetty S, Weijia W, Bauer E, Pascual JR, White C | ||||
| QuintilesIMS | ||||
| Annual Congress of Endocrine Disorders and Therapies 2017 |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Epidemiological study, Population Based Study, Retrospective database analysis | |
| A Retrospective Real-World Study of Dapagliflozin vs. Other Oral Antidiabetic Therapies Added to Metformin in Patients with Type 2 Diabetes (T2D) | ||||
| Huan Huang, Kelly Bell, Ray Gani, Cathy Tugwell, James Eudicone, Michelle R. Krukas-Hampel | ||||
| QuintilesIMS | ||||
| American Diabetes Association 2017 |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Epidemiological study, Retrospective database analysis | |
| A Retrospective Real-World Study of Dapagliflozin versus Other Oral Antidiabetic (OAD) Therapies Added to Metformin in Patients with Type 2 Diabetes (T2D) and hypertension | ||||
| Huan Huang, Kelly Bell, Ray Gani, Cathy Tugwell, James Eudicone, Michelle R. Krukas-Hampel | ||||
| QuintilesIMS | ||||
| ISPOR 2017 |
||||
| , Poster | ||||
| , USA | ||||
| Abstract: https://www.ispor.org/research_pdfs/55/pdffiles/PDB14.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Epidemiological study, Retrospective database analysis | |
| "Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a largescale multinational family of cohort studies of five outcomes" | ||||
| "Vincent Lo Re, Dena M Carbonari, M Elle Saine, Craig W Newcomb, Jason A Roy, Qing Liu, Qufei Wu, Serena Cardillo, Kevin Haynes, Stephen E Kimmel, Peter P Reese, David J Margolis, Andrea J Apter, K Rajender Reddy, Sean Hennessy, Harshvinder Bhullar, Arlene M Gallagher, Daina B Esposito, Brian L Strom." | ||||
| University of Pennsylvania | ||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective database analysis | |
| Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs | ||||
| Saine ME, Gizaw M, Carbonari DM, Newcomb CW, Roy JA, Cardillo S, Esposito DB, Bhullar H, Gallagher AM, Strom BL & Lo Re V 3rd | ||||
| Perelman School of Medicine, University of Pennsylvania | ||||
| Pharmacoepidemiology and Drug Safety |
||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Database Validity and methodology, Diabetes | 2017 | English | , Retrospective database analysis | |
| Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a largescale multinational family of cohort studies of five outcomes | ||||
| Lo Re V, Carbonari DM, Saine ME, Newcomb CW, Roy JA, Liu Q, Wu Q, Cardillo S, Haynes K, Kimmel SE, Reese PP, Margolis DJ, Apter AJ, Reddy KR, Hennessy S, Bhullar H, Gallagher AM, Esposito DB & Strom BL | ||||
| University of Pennsylvania | ||||
| BMJ Open Diabetes Research & Care |
||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective database analysis | |
| Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom | ||||
| Feher M, Vega-Hernandez G, Mocevic E, Buysse B, Myland M, Power GS, Nystrup Husemoen LL, Kim J & Witte DR | ||||
| Chelsea and Westminster Hospital | ||||
| Diabetes Therapy |
||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Drug Utlization Study | 2017 | English | , Retrospective database analysis | |
| "Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom." | ||||
| "Michael Feher . Gabriela Vega-Hernandez . Emina Mocevic .Brian Buysse . Melissa Myland . Geraldine S. Power . Lise L. Nystrup Husemoen . Joseph Kim . Daniel R. Witte." | ||||
| IQVIA/Novo Nordisk | ||||
| Diabetes Therapy |
||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective database analysis | |
| Determinants of the relationship between improved glucose control and modelled health outcomes in type 2 diabetes simulation models. | ||||
| Foos V1, Lamotte M1, Altrabsheh E2, Sathananthan A2, McEwan P3 | ||||
| 1 QuintilesIMS, Zaventem, Belgium, 2 QuintilesIMS, London, United Kingdom, 3 Health Economics and Outcomes Research Ltd, Cardiff, United Kingdom | ||||
| International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress, 2017, November 4 - 8, Glasgow, Scotland |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2017 | English | , Cost effectiveness | |
| Real-world basal insulin intensification patterns in the United States | ||||
| Thorsted B, Divino V, DeKoven M, Guerrero G,Langer J, Yeaw J, | ||||
| Novo Nordisk. IMS authors: Yeaw J, Divino V, DeKoven M | ||||
| 53rd EASD Annual Meeting |
||||
| , Poster | ||||
| , USA | ||||
| Abstract: https://www.easd.org/virtualmeeting/home.html#!resources/real-world-basal-insulin-intensification-patterns-in-the-united-states-cc3f25a7-276f-451c-9618-05a417f5fce9 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective database analysis | |
| SCHÉMAS THÉRAPEUTIQUES ET POSOLOGIQUES CHEZ DES PATIENTS AVEC UN DIABÈTE DE TYPE 2 (DT2) INITIANT UN TRAITEMENT PAR AGONISTE DU RÉCEPTEUR DU GLUCAGON-LIKE PEPTIDE 1 (AR GLP-1) EN EUROPE | ||||
| Norrbacka K, Divino V, Dekoven M, Boye KS | ||||
| Eli Lilly, IQVIA | ||||
| Societé Francophone du Diabete 2017 |
||||
| , Poster | ||||
| , Belgium, Canada, France, Germany, Italy, Netherlands | ||||
| Abstract: https://www.sfdiabete.org/sites/www.sfdiabete.org/files/files/evenements/17sfd_final_v12.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective database analysis | |
| Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom. | ||||
| Feher, M., Vega-Hernandez, G., Mocevic, E., Buysse, B., Myland, M., Power, GS | ||||
| Chelsea and Westminster Hospital; IQVIA London | ||||
| , Article | ||||
| , England | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Epidemiological study | |
| Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study | ||||
| Strongman H, Korhonen P, Williams R, Bahmanyar S, Hoti F, Christopher S, Majak M, Kool-Houweling L, Linder M, Dolin P, Heintjes EM | ||||
| EPID Research, Espoo, Finland | ||||
| BMJ Open Diab Res Care (2017);5: p. e000364-e000364 |
||||
| , Article | ||||
| , Finland, Netherlands, Sweden, UK | ||||
| Abstract: https://drc.bmj.com/content/5/1/e000364 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Epidemiological study, Retrospective database analysis | |
| Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults | ||||
| Strandberg AY, Khanfir H, Mäkimattila S, Saukkonen T, Strandberg TE, Hoti F | ||||
| University of Helsinki, Clinicum, Helsinki, Finland, Aava Medical Centre, Kerava, Finland | ||||
| Ann Med. (2017) 49(4):357-364 |
||||
| , Article | ||||
| , Finland | ||||
| Abstract: https://www.tandfonline.com/doi/abs/10.1080/07853890.2016.1278302?journalCode=iann20 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective database analysis | |
| Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK | ||||
| Vega-Hernandez G1, Wojcik R2, Schlueter M2 | ||||
| 1 Novo Nordisk Ltd, London, UK. 2 QuintilesIMS, London, UK | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective database analysis | |
| Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden | ||||
| Lind M1,2, Matsson PO3, Linder R4, Svenningsson I5, Jørgensen L6, Ploug UJ7, Gydesen H7, Dorkhan M8, Larsen S8, Johansson G9. | ||||
| 1Department of Medicine, NU-Hospital Group, Trollhättan/Uddevalla, Sweden. lind.marcus@telia.com. 2Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden. lind.marcus@telia.com. 3Domnarvet VC, Borlänge, Sweden. 4Pygargus, Stockholm, Sweden. 5Research and Development Unit, Primary Health Care, Närhälsan, Vänersborg, Sweden. 6IMS Health, Stockholm, Sweden. 7Novo Nordisk A/S, Søborg, Denmark. 8Novo Nordisk Scandinavia AB, Malmö, Sweden. 9Department of Caring Sciences and Family Medicine, Uppsala University, Uppsala, Sweden. | ||||
| Diabetes Ther |
||||
| , Article | ||||
| , Nordic, Sweden | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900983/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Retrospective cohort analysis | |
| Implications of introducing patient heterogeneity in cost effectiveness modeling. | ||||
| Foos V1, McEwan P2, Lamotte M3 | ||||
| 1 IMS Health, Zaventem, Belgium 2 Health Economics and Outcomes Research Ltd, Cardiff, United Kingdom 3 IMS Health, Vilvoorde, Belgium | ||||
| 19th ISPOR Annual European Congress, 2016, October 29- November 2, Vienna, Austria |
||||
| , Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Methodology | |
| Replacing input probability distributions with mean values can bias simulation output: an illustration using the Core Diabetes Model. | ||||
| McEwan P1, Foos V2, Lamotte M3 | ||||
| 1 Health Economics and Outcomes Research Ltd, Cardiff, United Kingdom 2 IMS Health, Zaventem, Belgium, 3 IMS Health, Vilvoorde, Belgium | ||||
| 19th ISPOR Annual European Congress, 2016, October 29- November 2, Vienna, Austria |
||||
| , Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Methodology | |
| Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study. | ||||
| Lefebvre P1, Pilon D1, Robitaille MN1, Lafeuille MH1, Chow W2, Pfeifer M2, Duh MS3. | ||||
| 1a Groupe d'analyse, Ltée , Montréal , Québec , Canada ; 2b Janssen Scientific Affairs, LLC , Raritan , NJ , USA ; 3c Analysis Group, Inc. , Boston , MA , USA. | ||||
| Curr Med Res Opin. 2016 Jun;32(6):1151-9 |
||||
| , Article | ||||
| , USA | ||||
| Abstract: http://www.tandfonline.com/doi/full/10.1080/03007995.2016.1183604 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Retrospective database analysis | |
| Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes | ||||
| Anyanwagu U, Mamza J, Mehta R, Donnelly R, Idris I | ||||
| Division of Medical Sciences & Graduate Entry Medicine, School of Medicine; Research Design Services (East Midlands), School of Medicine | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes, Miscellaneous | 2016 | English | , Retrospective database analysis | |
| Type 2 diabetes, high blood pressure and acute pancreatitis | ||||
| Bexelius TS, Ljung R, Garcia Rodriguez LA | ||||
| Upper Gastrointestinal Research, Department of Molecular Medicine and Surgery, and Department of Medical Epidemiology and Biostatistics, Karolinska Institute | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes, Miscellaneous | 2016 | English | , Retrospective database analysis | |
| Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database | ||||
| Mamza J, Mehta R, Donnelly R, Idris I | ||||
| Division of Medical Sciences & Graduate Entry Medicine, School of Medicine; Trent Research Design Services, University of Nottingham | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Retrospective database analysis | |
| Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study | ||||
| Mamza J, Mehta R, Donnelly R, Idris I | ||||
| Division of Medical Sciences & Graduate Entry Medicine , University of Nottingham; Research Design Services (East Midlands), School of Medicine | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Retrospective database analysis | |
| Intra-cluster and inter-period correlation coefficients for cross-sectional cluster randomised controlled trials for type-2 diabetes in UK primary care | ||||
| Martin J, Girling A, Nirantharakumar K, Ryan R, Marshall T, Hemming K | ||||
| Institute of Applied Health Research, University of Birmingham | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Retrospective database analysis | |
| Risk factors for diabetic retinopathy in people with Type 2 diabetes: A case-control study in a UK primary care setting | ||||
| Martín-Merino E, Fortuny J, Rivero-Ferrer E, Lind M, Garcia-Rodriguez LA | ||||
| Centro Español de Investigación Farmacoepidemiológica; DS&E –GlobalClinicalEpidemiology,NovartisFarmaceuticaS.A.,Barcelona; Institute ofMedicine,UniversityofGothenburg,Gothenburg; Department ofMedicine,NU-HospitalOrganization,Uddevalla | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Retrospective database analysis | |
| Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project | ||||
| Roberto G, Leal I, Sattar N, Loomis AK, Avillach P, Egger P, van Wijngaarden R, Ansell D, Reisberg S, Tammesoo ML, Alavere H, Pasqua A, Pedersen L, Cunningham J, Tramontan L, Mayer MA, Herings R, Coloma P, Lapi F, Sturkenboom M, van der Lei J, Schuemie MJ, Rijnbeek P, Gini R | ||||
| Development, Groton, Connecticut, United States of America; Department of Biomedical Informatics, Harvard Medical School & Children’s Hospital Informatics Program, Boston Children’s Hospital, Boston, Massachusetts, United States of America; GlaxoSmithKline, Worldwide Epidemiology GSK, Stockley Park West, Uxbridge, United Kingdom,; PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands; The Health Improvement Network, Cegedim Strategic Data Medical Research Ltd, London, United Kingdom; Quretec, Software Technology and Applications Competence Center, University of Tartu, Tartu, Estonia; Estonian Genome Center, University of Tartu, Tartu, Estonia; Tartu University Hospital, Tartu, Estonia; Health Search, Italian College of General Practitioners and Primary Care, Firenze, Italy; Department of Clinical Epidemiology, Aarhus University Hosptial, Aarhus, Denmark; University of Manchester, Manchester, United Kingdom; Arsenàl.IT Consortium, Veneto's Research Centre for eHealth Innovation, Treviso, Italy,; Hospital del Mar Medical Research Institute (IMIM) and Universitat Pompeu Fabra, Barcelona, Spain; Janssen Research & Development, Epidemiology, Titusville, New Jersey, United States of America,; Observational Health Data Sciences and Informatics, New York, New York, United States of America | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Retrospective database analysis | |
| Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study | ||||
| Sharma M, Nazareth I, Petersen I | ||||
| Department of Primary Care and Population Health, University College London; Department of Clinical Epidemiology, Aarhus University | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Retrospective database analysis | |
| Treatment Outcomes Following Initiation of Dapagliflozin or Basal Supported Oral Therapy Among Type 2 Diabetes Patients In Primary Care Practices In Germany | ||||
| Ehlken B, Kostev K | ||||
| ISPOR 19TH ANNUAL EUROPEAN CONGRESS, VIENNA |
||||
| , Conference | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | ||
| Cost of Antihyperglycemic Therapy In Type 2 Diabetes Patients Depending on HBA1C And Bmi Values | ||||
| Sorg A, Dombrowski S, Kostev K | ||||
| ISPOR 19TH ANNUAL EUROPEAN CONGRESS |
||||
| , Conference | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | ||
| Prevalence of medically treated children with ADHD and type 1 diabetes in Germany – Analysis of two representative databases | ||||
| Kapellen TM, Reimann R, Kiess W, Kostev K | ||||
| J Pediatr Endocrinol Metab. 2016 Nov 1;29(11):1293-1297 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Neurological disorders, Pediatrics | 2016 | English | , Epidemiological study | |
| Changes in HbA1c, Body Weight, and Systolic Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Therapy: A Primary Care Database Study | ||||
| Scheerer M, Rist R, Proske O, Meng A, Kostev K | ||||
| Diabetes Metab Syndr Obes. 2016 Oct 31;9:337-345. |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes, Metabolic Disorders | 2016 | English | , Database Study | |
| Change in HbA1c after Initiating Second-Line Therapy in Type 2 Diabetes: A Primary Care Database Study. | ||||
| Rathmann W, Bongaerts B, Kostev K | ||||
| Diabetes Obes Metab. 2016 Aug;18(8):840-3 |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Database Study | |
| Impact of Metformin on Metastases in Patients with Breast Cancer and Type 2 Diabetes | ||||
| Jacob L, Kostev K, Rathmann W, Kalder M | ||||
| J Diabetes Complications. 2016 Aug;30(6):1056-9 |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Oncology | 2016 | English | ||
| Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany | ||||
| Qiao Q, Grandy S, Hiller J, Kostev K | ||||
| PLoS One. 2016 Mar 28;11(3):e0152281 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | ||
| Adherence to GLP-1 Receptor Agonist Therapy Administered by Once-Daily or Once-Weekly Injection in Type 2 Diabetes Patients in Germany | ||||
| Qiao Q, Grandy S, Ouwens M, Kostev K | ||||
| Diabetes Metab Syndr Obes. 2016 Jun 28;9:201-5 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Metabolic Disorders | 2016 | English | ||
| Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records. | ||||
| Kolaczynski WM, Hankins M, Ong SH, Richter H, Clemens A, Toussi M. | ||||
| Diabetes Ther. 2016 Sep;7(3):483-96. doi: 10.1007/s13300-016-0177-8. |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes, Metabolic Disorders | 2016 | English | , Retrospective database analysis | |
| REAL-WORLD TREATMENT PATTERNS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS NEWLY INITIATED WITH ANTIHYPERGLYCEMIC MEDICATIONS IN THE UNITED STATES | ||||
| Cai J., Burudpakdee C., Divino V. | ||||
| Janssen. IMS authors: Burudpakdee C, Divino V | ||||
| ISPOR 21st Annual International Meeting |
||||
| , Oral presentation | ||||
| , USA | ||||
| Abstract: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/62486?pdfid=44270 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Retrospective database analysis | |
| Treatment and dosing patterns among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Europe. | ||||
| Kirsi Norrbacka; Victoria Divino; Mitch DeKoven; Kristina Secnik Boye | ||||
| Lilly. IMS authors: Divino V, DeKoven M | ||||
| European Association for the Study of Diabetes 52nd annual meeting |
||||
| , Poster | ||||
| , Belgium, France, Germany, Netherlands, Sweden | ||||
| Abstract: https://www.easd.org/virtualmeeting/home.html#!resources/treatment-and-dosing-patterns-among-patients-with-type-2-diabetes-initiating-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-in-europe-5ef3fe71-7e5d-4bdd-8b32-b4187d2a9aac | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Retrospective database analysis | |
| Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project | ||||
| Roberto G, Leal I, Sattar N, Loomis AK, Avillach P, Egger P, van Wijngaarden R, Ansell D, Reisberg S, Tammesoo ML, Alavere H, Pasqua A, Pedersen L, Cunningham J, Tramontan L, Mayer MA, Herings R, Coloma P, Lapi F, Sturkenboom M, van der Lei J, Schuemie MJ, Rijnbeek P & Gini R | ||||
| Regional Agency for Healthcare Services of Tuscany, Epidemiology unit | ||||
| PLoS One |
||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Retrospective database analysis | |
| Adjusting for the Effect of Switching Basal Insulin Treatment on the Risk of First Severe Hypoglycaemia | ||||
| Khanfir H, Korhonen P, Mäkimattila S, Hoti F | ||||
| EPID Research, Espoo, Finland | ||||
| Pharmacoepidemiology and Drug Safety (2016); 25(S3): 3-679 |
||||
| , Abstract | ||||
| , Finland | ||||
| Abstract: https://onlinelibrary.wiley.com/doi/full/10.1002/pds.4070 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Population Based Study, Retrospective database analysis | |
| Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries | ||||
| Korhonen P, Heintjes E M, Williams R, Hoti F, Christopher S, Majak M, Kool-Houweling L, Strongman H, Linder M, Dolin P, Bahmanyar S | ||||
| EPID Research Ltd, Espoo, Finland | ||||
| BMJ (2016);354:i3903 |
||||
| , Article | ||||
| , Finland, Netherlands, Sweden, UK | ||||
| Abstract: https://researchonline.lshtm.ac.uk/4646203/1/Pioglitazone%20use%20and%20risk_GOLD%20VoR.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Population Based Study, Retrospective cohort analysis | |
| All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine | ||||
| Strandberg AY, Hoti FJ, Strandberg TE, Christopher S, Haukka J, Korhonen P | ||||
| University of Helsinki, Clinicum, Helsinki, Finland, Aava Medical Centre, Kerava, Finland | ||||
| PLoS ONE (2016);11(3): e0151910 |
||||
| , Article | ||||
| , Finland | ||||
| Abstract: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0151910 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Epidemiological study, Population Based Study, Retrospective database analysis | |
| Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies. | ||||
| McDonell AL1, Kiiskinen U2, Zammit DC3, Kotchie RW1, Thuresson PO3, Nicolay C4, Haslam T1, Bruinsma M5, Janszen-Van Oosterhout AJ6, Otto T4 | ||||
| 1IMS Health, London, UK; 2Eli Lilly and Company, Helsinki, Finland; 3IMS Health, Basel, Switzerland; 4Eli Lilly and Company, Bad Homburg, Germany; 5IMS Health, Rotterdam, the Netherlands; 6Eli Lilly Nederland, Houten, the Netherlands | ||||
| ClinicoEconomics and Outcomes Research, 2015; 7:95-103 |
||||
| , Article | ||||
| , Germany, Netherlands, UK | ||||
| Abstract: http://www.dovepress.com/estimating-the-real-world-daily-usage-and-cost-for-exenatide-twice-dai-peer-reviewed-article-CEOR | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| Cost-effectiveness of switching from biphasic human insulin (BHI) to biphasic insulin aspart 30 (BIAsp-30) in type 2 diabetes patients with suboptimal glycaemic control in Singapore | ||||
| Goh SY1, Tan SC2, Lim LC3, Chua B4, Hunt B5 | ||||
| 1 Department of Endocrinology, Singapore General Hospital, Singapore 2 Health Economics & Outcomes Research, IMS Health Asia Pacific, Singapore 3 Department of Medicine, Alexandra Hospital, Singapore 4 Department of Vascular Surgery, Singapore General Hospital, Singapore 5 Ossian Health Economics and Communications, Switzerland | ||||
| Journal of Diabetology, February 2015; 1:2 |
||||
| , Online article | ||||
| , Singapore | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Cost effectiveness | |
| If we followed NICE guidelines and treated people with diabetes earlier, patients and the NHS would benefit from a reduction in complications, mortality and direct healthcare costs | ||||
| Baxter M1, Hex N2, Samyshkin Y3, Hudson R1, Mahon J2, Alexiou D3, Bartlett C2 | ||||
| 1 Sanofi, Guildford, UK, 2 York Health Economics Consortium, York, UK, 3 IMS Health, London, UK | ||||
| Diabetes UK Professional Conference 2015 11-13 March 2015, ExCeL London |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Cost analysis | |
| Incidence of Microvascular Outcomes among Type 2 Diabetes Patients Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Cohort Study Using German Electronic Medical Records | ||||
| Hankins M1, Ong SH, Richter H, Kolaczynski WM, Clemens A, Vora J, Machnicki G, Toussi M | ||||
| 1 IMS Health, London, UK 2 Novartis 3 IMS Health, Paris, France | ||||
| American Diabetes Association’s 75th Scientific Sessions, June 5-9, 2015, Boston, Massachusetts |
||||
| , Oral presentation | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective cohort analysis | |
| The association between smoking cessation and glycaemic control in patients with type 2 diabetes: a THIN database cohort study | ||||
| Lycett D, Nichols L, Ryan R, Farley A, Roalfe A, Mohammed MA, Szatkowski L, Coleman T, Morris R, Farmer A & Aveyard P | ||||
| 1Coventry University, Faculty of Health and Life Sciences, Coventry, UK. 2School of Health and Population Sciences, University of Birmingham, Birmingham, UK. 3University of Bradford, Bradford, UK. 4School of Medicine, University of Nottingham, Division of Epidemiology and Public Health, Clinical Sciences Building, Nottingham City Hospital, Nottingham, UK. 5School of Medicine, University of Nottingham, Division of Primary Care, Medical School, Queen's Medical Centre, Nottingham, UK. 6School of Social and Community Medicine, University of Bristol, Canynge Hall, Bristol, UK. 7University of Oxford, Nuffield Department of Primary Care Health Sciences, New Radcliffe House Radcliffe Observatory Quarter, Oxford, UK | ||||
| Lancet Diabetes Endocrinol 3(6):423-30 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.thelancet.com/journals/landia/article/PIIS2213-8587(15)00082-0/abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| The effect of past antibiotic exposure on diabetes risk | ||||
| Boursi B1,2,3, Mamtani R1, Haynes K1 & Yang YX1 | ||||
| 1Perelman School of Medicine at the University of Pennsylvania,Philadelphia, USA.2 The Integrated Cancer Prevention Center,Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. 3 Tel-Aviv University, Tel-Aviv, Israel | ||||
| Eur J Endocrinol. 2015 Jun;172(6):639-48. doi: 10.1530/EJE-14-1163. Epub 2015 Mar 24 |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25805893 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| Bisphosphonates and glucose homeostasis: a population-based, retrospective cohort study | ||||
| Toulis KA1, Nirantharakumar K2,3, Ryan R2, Marshall T2 & Hemming K2 | ||||
| 1 Department of Endocrinology, General Military Hospital, Thessaloniki, Greece; 2 Departments of Public Health, Epidemiology, and Biostatistics and Primary Care Clinical Sciences,University of Birmingham, Birmingham , United Kingdom; 3 University Hospitals Birmingham National Health Service Foundation Trust, Birmingham, United Kingdom. | ||||
| J Clin Endocrinol Metab. 2015 May;100(5):1933-40. doi: 10.1210/jc.2014-3481. Epub 2015 Feb 19. |
||||
| , Abstract | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25695881 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs | ||||
| Saine ME, Carbonari DM, Newcomb CW, et al. | ||||
| Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania | ||||
| BMC Pharmacology and Toxicology 2015, 16:8 doi:10.1186/s40360-015-0007-z |
||||
| , Article | ||||
| , UK, USA | ||||
| Abstract: http://www.biomedcentral.com/2050-6511/16/8 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| DISCOVERing treatment of type 2 diabetes in real world settings using electronic medical record databases | ||||
| Charbonnel B1, Gomes MB2, Khunti K3, Nicolucci A4, Pocock S5, Shestakova MV6, Shimomura I6, Fenici P7, García-Álvarez L8, Hammar N9, Hashigami K10, Hiller J8, Medina J11, Surmont FA12, Ji L13 | ||||
| 1University of Nantes, Nantes, France; 2Rio de Janeiro State University, Rio de Janeiro, Brazil; 3University of Leicester, Leicester, UK; 4Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy; 5London School of Hygiene and Tropical Medicine, London, UK; 6Endocrinology Research Center, Moscow, Russian Federation; 7Osaka University, Osaka, Japan; 8AstraZeneca, Cambridge, UK; 9IMS Health, London, UK; 10AstraZeneca, Mölndal, Sweden; 11AstraZeneca, Tokyo, Japan; 12AstraZeneca, Madrid, Spain; 13AstraZeneca, Shanghai, China; 14Diabetes Center, Peking University People’s Hospital, Beijing, China | ||||
| EASD - 51st Annual Meeting of the European Association for the Study of Diabetes, 14–18 September 2015, Stockholm, Sweden |
||||
| , Poster | ||||
| , Canada, France, Germany, UK | ||||
| Abstract: http://www.easdvirtualmeeting.org/resources/discovering-treatment-of-type-2-diabetes-in-real-world-settings-using-electronic-medical-record-databases--3 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Real World Data, Retrospective database analysis | |
| Cost-effectiveness of dulaglutide 1.5mg once weekly for the treatment of patients with type two diabetes mellitus in Sweden | ||||
| Raibouaa A1, Borgeke H2, Alexiou D3, Lowin J3, Norrbacka K4 | ||||
| 1Eli Lilly and Company Limited, Windlesham, Surrey, UK, 2Eli Lilly Sweden AB, Solna, Sweden, 3IMS Health, London, UK, 4Eli Lilly and Company, Helsinki, Finland | ||||
| ISPOR, 18th Annual European Congress,7-11 November 2015 |
||||
| , Abstract | ||||
| , Italy, Nordic | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Cost effectiveness | |
| Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK | ||||
| Valentine WJ, Curtis BH, Pollock RF, Van Brunt K, Paczkowski R, Brändle M, Boye KS & Kendall DM | ||||
| Ossian Health Economics and Communications, Basel, Switzerland | ||||
| Diabetes Res Clin Pract. 2015 Jul;109(1):95-103. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25989713 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| Diabetes, Lower-Extremity Amputation, and Death | ||||
| Hoffstad O, Mitra N, Walsh J & Margolis DJ | ||||
| Department of Biostatistics and Epidemiology, University of Pennsylvania | ||||
| Diabetes care; vol: 38 no. 10 1852-1857 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://care.diabetesjournals.org/content/38/10/1852.short?rss=1 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| Type 1 Diabetes Is Associated With an Increased Risk of Fracture Across the Life Span: A Population-Based Cohort Study Using The Health Improvement Network (THIN) | ||||
| Weber DR, Haynes K, Leonard MB, Willi SM & Denburg MR | ||||
| Perelman School of Medicine at the University of Pennsylvania | ||||
| Diabetes Care [ahead of print] |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26216874 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| The association between smoking cessation and glycaemic control in patients with type 2 diabetes: a THIN database cohort study | ||||
| Lycett D, Nichols L, Ryan R, Farley A, Roalfe A, Mohammed MA, Szatkowski L, Coleman T, Morris R, Farmer A & Aveyard P | ||||
| School of Health and Population Sciences, University of Birmingham | ||||
| Lancet Diabetes Endocrinol 3(6):423-30 |
||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study | ||||
| Mamza J, Mehta R, Donnelly R & Idris I | ||||
| Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham | ||||
| Diabetes Ther. 6(2):213-26 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26014844 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| Incidence of Microvascular Outcomes among Type 2 Diabetes Patients Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Cohort Study Using German Electronic Medical Records | ||||
| Matthew Hankins, Siew Hwa Ong, Hartmut Richter, Wlodzimierz M. Kolaczynski, Andreas Clemens, Gerardo Machnicki, Jiten Vora, Massoud Toussi | ||||
| 75th Scientific Sessions of the American Diabetes Association, American Diabetes Association’s 75th Scientific Sessions, June 5-9, 2015, Boston, Massachusetts |
||||
| , Conference | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective cohort analysis | |
| Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study | ||||
| Valensi P1, de Pouvourville G2, Benard N3, Chanut-Vogel C3, Kempf C4, Eymard E5, Moisan C3, Dallongeville J6. | ||||
| 1Department of Endocrinology-Diabetology-Nutrition, Jean-Verdier Hospital, AP-HP, Paris Nord University, CRNH-IdF, CINFO, Bondy, France.2ESSEC, Cergy-Pontoise, France.3MSD France, Courbevoie, France.4CSD, Boulogne, France.5MSD France, Courbevoie, France 6INSERM U744, Institut Pasteur, Lille, France. | ||||
| Diabetes Metab. 2015 Jun;41(3):231-8 |
||||
| , Article | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Prospective study | |
| Durée de maintien d'une bitherapie par Metformine-Sitagliptine chez les diabétiques de type 2 - Etude observationelle ODYSSEE | ||||
| C. Moisan 1,, P. Valensi 2, G. De Pouvourville 3, N. Benard 4, C. Chanut-Vogel 4, J. Dallongeville 5 | ||||
| 1 MSD France, Paris, France, 2 Service d’endocrinologie, diabétologie, nutrition, Hôpital Jean-Verdier, CRNH-IdF, CINFO, Bondy, Paris, France, 3 ESSEC, Paris, France, 4 MSD France, Paris, France, 5 INSERM U744, Institut Pasteur, Paris, France. | ||||
| SFD 2015 |
||||
| , Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| A CROSS-SECTIONAL STUDY ON INSULIN TREATMENTS AND GLYCEMIC CONTROL IN TYPE 2 DIABETES IN FRANCE, ITALY, GERMANY, UK AND SPAIN | ||||
| Phan T1, Boutmy E2, Coulombel N2 | ||||
| 1Novo Nordisk Health Care AG, Zürich, Switzerland, 2IMS Health, Boulogne-Billancourt, France | ||||
| ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
| , Poster | ||||
| , France, Germany, Italy, Spain, UK | ||||
| Abstract: http://www.ispor.org/research_pdfs/51/pdffiles/PDB13.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| CARDIOVASCULAR OUTCOMES OF ANTIDIABETIC THERAPY - RESULTS OF A LITERATURE | ||||
| Greiner R, Eheberg D, Paulus G, Batscheider A | ||||
| IMS Health, Munich, Germany | ||||
| ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2015 | English | ||
| Synthetic Glucocorticoids and Early Variations of Blood Pressure: A Population-Based Cohort Study | ||||
| Fardet L, Nazareth I1, Petersen I | ||||
| Department of Primary Care and Population Health, University College London | ||||
| J Clin Endocrinol Metab. 2015 Jul;100(7):2777-83. doi: 10.1210/jc.2015-1127. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25978108 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Miscellaneous | 2015 | English | , Retrospective database analysis | |
| ASSESSMENT OF A FRENCH ENDOCRINOLOGIST ELECTRONIC MEDICAL RECORD DATABASE FOR USE IN OBSERVATIONAL STUDIES | ||||
| Hellard C, Jouaville SL, Pilet S, Meihoc A | ||||
| Cededim Strategic Data, Boulogne-Billancourt, France | ||||
| ISPOR 20th Annual International Meeting Philadelphia, PA, USA May, 2015 |
||||
| , Poster | ||||
| , France | ||||
| Abstract: http://www.ispor.org/research_study_digest/details.asp | ||||
| Condition | Year | Language | Analysis type | |
| , Database Validity and methodology, Diabetes | 2015 | English | , Retrospective database analysis | |
| Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. | ||||
| Detournay B1, Halimi S2, Robert J1, Deschaseaux C3, Dejager S4. | ||||
| 1Cemka-Eval, Bourg-la Reine, France. 2Department of Diabetology, Endocrinology and Nutrition, Grenoble University Hospital Center, Grenoble, France ; University Joseph Fourier, Grenoble, France. 3Novartis Pharma SAS, Market Access Department, Rueil-Malmaison, France. 4Novartis Pharma SAS, Medical and Scientific Affairs, Rueil Malmaison, France ; Department of Diabetology, Metabolism and Endocrinology, Pitié-Salpétrière Hospital, Paris, France. | ||||
| Vasc Health Risk Manag. 2015 Jul 17;11:417-25. doi: 10.2147/VHRM.S84507. eCollection 2015. |
||||
| , Article | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Pricing and reimbursement | 2015 | English | , Prospective study, Retrospective database analysis | |
| Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study | ||||
| Grundvold I1, Bodegard J2, Nilsson PM3, Svennblad B4, Johansson G5, Östgren CJ6, Sundström J7,8. | ||||
| 1Department of Cardiology, Oslo University Hospital, Ullevaal, PB 4956, Nydalen, 0424, Oslo, Norway. uxirgr@ous-hf.no. 2AstraZeneca Nordic, Södertälje, Sweden. Johan.Bodegard@astrazeneca.com. 3Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden. peter.nilsson@med.lu.se. 4Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. bodil.svennblad@ucr.uu.se. 5Department of Public health and Caring Science, Uppsala University, Uppsala, Sweden. gunnar.johansson@pubcare.uu.se. 6Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. carl.johan.ostgren@liu.se. 7Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. johan.sundstrom@medsci.uu.se. 8Department of Medical Sciences, Uppsala University, Uppsala, Sweden. johan.sundstrom@medsci.uu.se. | ||||
| Cardiovasc Diabetol |
||||
| , Article | ||||
| , Sweden | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299152/ | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2015 | English | , Real World Evidence | |
| Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting | ||||
| Sabale U1, Bodegård J2, Sundström J3, Östgren CJ4, Nilsson P5, Johansson G3, Svennblad B3, Henriksson M2. | ||||
| 1AstraZeneca Nordic-Baltic, Södertälje, Sweden. Electronic address: ugne.sabale@astrazeneca.com. 2AstraZeneca Nordic-Baltic, Södertälje, Sweden. 3Uppsala University, Uppsala, Sweden. 4Linköping University, Linköping, Sweden. 5Lund University, Malmö, Sweden | ||||
| Prim Care Diabetes |
||||
| , Nordic, Sweden | ||||
| Abstract: http://www.primary-care-diabetes.com/article/S1751-9918(15)00002-9/abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Cost of illness, Real World Evidence | |
| Healthcare utilisation and costs following initiation of insulin treatment in type 2 diabetes: a longterm follow-up in clinical practice | ||||
| A. Kalkan1, J. Bodegard1, J. Sundström2, B. Svennblad2, C. Östgren3, P.M. Nilsson4, G. Johansson2, M. Ekman1 | ||||
| 1 AstraZeneca, Södertälje, 2Uppsala University, 3Linköping University, 4Lund University, Malmö, Sweden. | ||||
| European Association for the Study of Diabetes (EASD) Annual Meeting; 2015; Stockholm |
||||
| , Abstract | ||||
| , Sweden | ||||
| Abstract: http://www.easdvirtualmeeting.org/resources/healthcare-utilisation-and-costs-following-initiation-of-insulin-treatment-in-type-2-diabetes-a-long-term-follow-up-in-clinical-practice--2 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Cost of illness, Real World Evidence | |
| Weight change over time and its link to healthcare costs among newly-diagnosed type 2 diabetes patients in Sweden | ||||
| U. Sabale1, J. Bodegard1, J. Sundström2, B. Svennblad2, C. Östgren3, P.M. Nilsson4, G. Johansson2, M.Ekman1 | ||||
| 1AstraZeneca, Södertälje, 2Uppsala University, Uppsala, 3Linköping University, Linköping, 4Lund University, Malmö, Sweden. | ||||
| European Association for the Study of Diabetes (EASD) Annual Meeting; 2015; Stockholm. |
||||
| , Abstract | ||||
| , Nordic, Sweden | ||||
| Abstract: http://staging.easdvirtualmeeting.org/resources/weight-change-over-time-and-its-link-to-healthcare-costs-among-newly-diagnosed-type-2-diabetes-patients-in-sweden--2 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Real World Evidence | |
| Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. | ||||
| Detournay B1, Halimi S2, Robert J1, Deschaseaux C3, Dejager S4. | ||||
| 1Cemka-Eval, Bourg-la Reine, France. 2Department of Diabetology, Endocrinology and Nutrition, Grenoble University Hospital Center, Grenoble, France ; University Joseph Fourier, Grenoble, France. 3Novartis Pharma SAS, Market Access Department, Rueil-Malmaison, France. 4Novartis Pharma SAS, Medical and Scientific Affairs, Rueil Malmaison, France ; Department of Diabetology, Metabolism and Endocrinology, Pitié-Salpétrière Hospital, Paris, France. | ||||
| Vasc Health Risk Manag. 2015 Jul 17;11:417-25 |
||||
| , Article | ||||
| , France | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514348/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| Évaluation d’une base de données issue des dossiers médicaux informatisés d’un panel d’endocrinologues français | ||||
| Christine Hellard, Sophie L. Jouaville, Simon Pilet, Adeline Meilhoc | ||||
| QuintilesIMS, Boulogne-Billancourt, France | ||||
| Rev Epidemiol Sante Publique, 2016 ; 64 (5) : S280-S281 |
||||
| , Abstract | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Database Validity and methodology, Diabetes | 2015 | French | , Retrospective database analysis | |
| Coverage Limits on Blood Glucose Test Strip Reimbursement for Diabetics in Canada: Utilization Impact for Diabetic Patients in the Ontario Public Drug Program (OPDP) | ||||
| Bosnic N1, Goodfield J1, Robertson C1, Zhang Y1 | ||||
| 1 Health Economics and Outcomes Research, IMS Brogan Health, Ontario, Canada | ||||
| ISPOR 20th Annual International Meeting, |
||||
| , Presentation | ||||
| , Canada | ||||
| Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/ispor-bosnic-deck-impact-of-diabetes-test-strip-coverage-limits-in-canada.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States. | ||||
| Foos V1, Varol N, Curtis BH, Boye KS, Grant D, Palmer JL, McEwan P | ||||
| 1 IMS Health , Basel , Switzerland | ||||
| J Med Econ., 2015, 18(6): 420-32 |
||||
| , Article | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Economic evaluation | |
| Symptom report and treatment experience of hypogonadal men with and without type 2 diabetes in a United States health plan. | ||||
| Shortridge EF1, Polzer P2, Donga P3, Wade RL3 | ||||
| 1 Spine and Biologics, Medtronic Inc., Memphis, TN, USA. 2 Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA. 3 Health Economics and Outcomes Research, IMS Health, Plymouth Meeting, PA, USA. | ||||
| Int J Clin Pract. 2015 Jul;69(7):783-90. |
||||
| , Article | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Endocrinology | 2015 | English | , Retrospective database analysis | |
| Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors | ||||
| Cea Soriano L, Johansson S, Stefansson B, Rodríguez LA | ||||
| Spanish Centre for Pharmacoepidemiologic Research (CEIFE); AstraZeneca R&D | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| An algorithm to improve diagnostic accuracy in diabetes in computerised problem orientated medical records (POMR) compared with an established algorithm developed in episode orientated records (EOMR) | ||||
| de Lusignan S, Liaw ST, Dedman D, Khunti K, Sadek K, Jones S | ||||
| University of Surrey, Guildford; University of New South Wales; Clinical Practice Research Datalink, London; University of Leicester, Leicester | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Database Validity and methodology, Diabetes | 2015 | English | , Retrospective database analysis | |
| A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK | ||||
| Idris I, Gordon J, Tilling C, Vora J | ||||
| Division of Medical Sciences & Graduate Entry Medicine, University of Nottingham | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2015 | English | , Retrospective database analysis | |
| New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer | ||||
| Lu Y, García Rodríguez LA, Malgerud L, González-Pérez A, Martín-Pérez M, Lagergren J, Bexelius TS | ||||
| Department of Molecular Medicine and Surgery, Karolinska Institutet; 2Department of Epidemiology and Biostatistics, Imperial College London; 3Centro Espan˜ ol de Investigacio´ n Farmacoepidemiolo´ gica; 4Department of Clinical Sciences, Intervention and Technology (CLINTEC), Karolinska Institutet; 5Division of Cancer Studies, King´ s College London; 6Department of Medical Epidemiology and Biostatistics, Karolinska Institutet | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Miscellaneous, Oncology | 2015 | English | , Retrospective database analysis | |
| Diabetes, Cardiovascular Morbidity, and Risk of Age-Related Macular Degeneration in a Primary Care Population | ||||
| Vassilev ZP, Ruigómez A, Soriano-Gabarró M, García Rodríguez LA | ||||
| Bayer Pharma; Spanish Centre for Pharmacoepidemiologic Research (CEIFE) | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes, Miscellaneous, Ophthalmology | 2015 | English | , Retrospective database analysis | |
| Managing diabetes in primary care: how does the configuration of the workforce affect quality of care? | ||||
| Trevor Murrells, Jane Ball, Jill Maben, Gerry Lee, Graham Cookson, Peter Griffiths | ||||
| King’s College London | ||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Retrospective database analysis | |
| Cost and co-morbidities associated with hypoglycemic inpatients in Belgium. | ||||
| Chevalier P1, Vandebrouck T2, De Keyzer D2, Mertens A3, Lamotte M1 | ||||
| 1. IMS Health HEOR, Vilvoorde, Belgium 2. Novo Nordisk, Brussels, Belgium 3. University Hospitals of Leuven, Leuven, Belgium | ||||
| The Journal of Medical Economics, Volume 19, 2016 - Issue 1 |
||||
| , Article | ||||
| , Belgium | ||||
| Abstract: http://dx.doi.org/10.3111/13696998.2015.1086775 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | ||
| Bladder Cancer Risk in Relation to Exposure to Pioglitazone among Patients with T2DM in the Pan European Multi-Database Bladder Cancer Risk Characterisation Study | ||||
| Korhonen P, Haukka J, Tayler M, Haddad PM, Patel MX, Tiihonen J | ||||
| EPID Research Ltd, Espoo, Finland | ||||
| American Diabetes Association's 75th Scientific Session, Boston, USA, 5-9 June, 2015 |
||||
| , Finland, Netherlands, Sweden, UK | ||||
| Abstract: https://ada.scientificposters.com/epsAbstractADA.cfm?id=1 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | , Population Based Study, Retrospective database analysis | |
| Validating the UKPDS 82 Risk Equations to Contemporary Outcomes Studies In Type 2 Diabetes | ||||
| Grant D1, Foos V2, McEwan P3 | ||||
| 1IMS Health, London, United Kingdom, 2IMS Health, Basel, Switzerland, 3HEOR Consulting, Monmouth, United Kingdom | ||||
| ISPOR, 19th Annual International Meeting, Montreal, Canada - PDB81 |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Epidemiological study | |
| Contrasting Cost Effectiveness Results Derived From the UKPDS 68 And 82 Risk Equations in Type 2 Diabetes | ||||
| McEwan P1, Foos V2, Grant D3 | ||||
| 1HEOR Consulting, Monmouth, United Kingdom, 2IMS Health, Basel, Switzerland, 3IMS Health, London, United Kingdom | ||||
| ISPOR, 19th Annual International Meeting, Montreal, Canada, May 31 - June 4th 2014 - PDB79 |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Cost effectiveness | |
| Illustrating the Relationship between the Number of Hypoglycaemia Events, Event Rate Reduction and the Impact on Estimates of Quality Of Life Improvement in Health Economic Studies | ||||
| Foos V1, McEwan P2, Grant D3 | ||||
| 1IMS Health, Basel, Switzerland, 2HEOR Consulting, Monmouth, United Kingdom, 3IMS Health, London, United Kingdom | ||||
| ISPOR, 19th Annual International Meeting, Montreal, Canada, May 31 - June 4th 2014 - PDB80 |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Quality of life | |
| Assessing Simulation Run Time Requirements to Achieve Stabilized Absolute and Incremental Cost Effectiveness Results in Type 2 Diabetes: A Study Using the IMS Core Diabetes Model | ||||
| Foos V1, Grant D2, McEwan P3 | ||||
| 1IMS Health, Basel, Switzerland, 2IMS Health, London, United Kingdom, 3HEOR Consulting, Monmouth, United Kingdom | ||||
| ISPOR, 19th Annual International Meeting, Montreal, Canada, May 31 - June 4th 2014 - PDB82 |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Cost effectiveness | |
| Macro- and microvascular outcomes in patients with type 2 diabetes treated with rapid-acting insulin analogues or human regular insulin: a retrospective database analysis. | ||||
| Rathmann W1, Schloot NC2, Kostev K3, Reaney M4, Zagar AJ5, Haupt A2 | ||||
| 1 Institute of Biometrics and Epidemiology, German Diabetes Center, Dusseldorf, Germany 2 Lilly Deutschland GmbH, Bad Homburg, Germany 3 IMS Health, Frankfurt, Germany 4 Lilly Research Centre, Windlesham, Surrey, UK 5 Eli Lilly and Company, Indianapolis, US | ||||
| Exp Clin Endocrinol Diabetes., 2014 Feb;122(2):92-9 |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24558019 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Retrospective database analysis | |
| Prevalence and risk factors of neuropathy in newly diagnosed type 2 diabetes in primary care practices: A retrospective database analysis in Germany and UK. | ||||
| Kostev K1, Jockwig A2, Hallwachs A3, Rathmann W4 | ||||
| 1 IMS Health, Frankfurt, Germany 2 Fresenius University of Applied Sciences, Idstein, Germany 3 Praxis for Internal Medicine and Nephrology, Munich, Germany 4 Institute of Biometrics and Epidemiology, German Diabetes Center, Duesseldorf, Germany | ||||
| Prim Care Diabetes., 2014, Feb 13. pii: S1751-9918(14)00012-6. doi: 10.1016/j.pcd.2014.01.011. [Epub ahead of print] |
||||
| , Article | ||||
| , Germany, UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/?term=Prevalence+and+Risk+Factors+of+Neuropathy+in+Newly+Diagnosed+Type+2+Diabetes+in+Primary+Care+Practices%3A+A+Retrospective+Database+Analysis+in+Germany+and+UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Retrospective database analysis | |
| Use of antidiabetic agents in the treatment of gestational dia-betes mellitus in Germany: developments between 2008 and 2012. | ||||
| Heilmaier C1, Thielscher C1, Ziller M2, Altmann V3, Kostev K3 | ||||
| 1 FOM University, Essen, Germany 2 Phillips-University of Marburg, Marburg, Germany 3 IMS Health, Frankfurt, Germany | ||||
| Journal of Obstetrics and Gynaecology Research, 2014, Jun; 40(6): 1592-7 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Retrospective database analysis | |
| Risk factors for discontinuation of insulin pump therapy in pediatric and young adult patients. | ||||
| Kostev K1, Rockel T1, Rosenbauer J2, Rathmann W2 | ||||
| 1 IMS Health, Frankfurt, Germany 2 Institute of Biometrics and Epidemiology, German Diabetes Center, Duesseldorf, Germany | ||||
| Prim Care Diabetes., 2014 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Burden of illness | |
| Health economic evaluation of canagliflozin in the treatment of type 2 diabetes mellitus in Belgium. | ||||
| Lamotte M1, Wyffels V2, Knudsen M3, Troelsgaard A4, Hemels M4 | ||||
| 1 IMS Health, Vilvoorde, Belgium 2 Janssen, Belgium 3 IMS Health, London, UK 4 Janssen A/S, Denmark | ||||
| ISPOR 19th Annual International Meeting, Montreal, QC, Canada, 31 May–4 June, 2014 |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Economic evaluation | |
| Association of diabetes and cancer diagnosis in primary care practices in France | ||||
| Grandfils N, Ricarte C, Solomiac A | ||||
| IMS Health, Paris La Défense, France | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Abstract, Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Oncology | 2014 | English | , Retrospective database analysis | |
| Using an innovative approach to build a prospective Diabetes Cohort Registry Of Patients with type 2 Diabetes in Germany: Diareg (PRM 61) | ||||
| Garcia Alvarez L1, Rathmann W2, Bode-Greuel K3, Engelhard J3, Busch S4, Schröder-Bernhardi D3, Hiller J1 | ||||
| 1IMS Health, London, UK, 2German Diabetes Center, Duesseldorf, Germany, 3IMS Health, Frankfurt am Main, Germany, 4AstraZeneca, Hamburg Area, Germany | ||||
| ISPOR 17th Annual European Conference, Amsterdam 8 - 12 November 2014 |
||||
| , Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Methodology | 2014 | English | , Methodology | |
| Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care | ||||
| Nyeland,ME1, Ploug,UJ1, Richards,A1, Garcia Alvarez L2, Demuth D2, Muthutantri A2, Skovgaard R1, Evans M3 R. Skovgaard,1 M. Evans3 | ||||
| 1 Novo Nordisk A/S, Søborg,Denmark 2 Real-World Evidence Solutions and Health Economics & Outcomes Research, IMS Health, London, UK 3 University Hospital Llandough, Cardiff, Wales, UK | ||||
| Int J Clin Pract doi: 10.1111/ijcp.12575 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://onlinelibrary.wiley.com/doi/10.1111/ijcp.12575/pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Retrospective database analysis | |
| Assessing the relationship between improved life expectancy due to better cardiovascular risk factor management and the likelihood of microvascular complications in type 2 diabetes mellitus | ||||
| McEwan P1, Grant D2, Foos V | ||||
| Health Economics and Outcomes Research Ltd., Cardiff, UK, 2IMS Health, London, UK, 3IMS Health, Basel, Switzerland | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Database Study | |
| Epidemiology and unmet medical need in diabetes mellitus type 2 in Germany – results of a literature search | ||||
| Greiner R, Paulus G, Driedger J, Schröder C, Timtschenko V, Batscheider A, Eheberg D, Vosgerau S | ||||
| IMS Health, Munich, Germany, | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Epidemiological study | |
| Progression of physiological parameters over time in type 1 diabetes mellitus patients in France | ||||
| Beaudet A, Ong RC | ||||
| IMS Health, Basel, Switzerland | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Economic evaluation | |
| Burden of non-adherence to type 1 diabetes mellitus therapeutic guidelines in France | ||||
| Beaudet A, Ong RC | ||||
| IMS Health, Basel, Switzerland | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Burden of illness | |
| Health economic evaluation of canagliflozin in the treatment of type 2 diabetes mellitus in Czech Republic | ||||
| Troelsgaard A1, Pitcher A2, Veselá Š3, Lovato E2, Hemels M1 | ||||
| Janssen A/S, Birkerød, Denmark, 2IMS Health, London, UK, 3Janssen-Cilag Czech Republic, Prague, Czech Republic | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , Czech | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Economic evaluation | |
| Health economic evaluation of canagliflozin in the treatment of type 2 diabetes mellitus in Portugal | ||||
| Troelsgaard A1, Knudsen M2, Maia-Lopes S3, Luz M3, Hemels M1 | ||||
| 1Janssen A/S, Birkerød, Denmark, 2IMS Health, Hellerup, Denmark, 3Janssen-Cilag Farmacêutica, Barcarena, Portugal | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , Portugal | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Economic evaluation | |
| Health economic evaluation of canagliflozin in the treatment of type 2 diabetes mellitus in France | ||||
| Granados D1, Maurel F2, Knudsen M3, Troelsgaard A4, Hemels M4 | ||||
| 1Janssen, Paris, France, 2IMS Health, Paris, France, 3IMS Health, Hellerup, Denmark, 4Janssen A/S, Birkerød, Denmark | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Cost effectiveness, Economic evaluation | |
| Health economic evaluation of canagliflozin in the treatment of type 2 diabetes mellitus in Slovakia | ||||
| Troelsgaard A1, Pitcher A2, Binder R3, Stetka R4, Ondrusova M5, Lovato E2, Hemels M1 | ||||
| Janssen A/S, Birkerød, Denmark, 2IMS Health, London, UK, 3Janssen, Bratislava, Slovak Republic, 4Pharm-In, Ltd, Bratislava, Slovak Republic, 5Pharm-In Ltd, Bratislava, Slovak Republic | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , Slovakia | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Economic evaluation | |
| Health economic evaluation of canagliflozin in the treatment of type 2 diabetes mellitus in Norway | ||||
| Troelsgaard A1, Huetson P2, Kjellberg J3, Hemels M1, Knudsen M4 | ||||
| Janssen A/S, Birkerød, Denmark, 2IMS Health, Stockholm, Sweden, 3Zefferin Farma AB, Stockholm, Sweden, 4IMS Health, Hellerup, Denmark | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , Nordic, Norway | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Economic evaluation | |
| The cost-effectiveness of canagliflozin compared with liraglutide in patients with type 2 diabetes inadequately controlled with metformin and sulfonylurea in France | ||||
| Troelsgaard A1, Pitcher A2, Granados D3, Hemels M1, Lloyd A | ||||
| 1Janssen A/S, Birkerød, Denmark, 2IMS Health, London, UK, 3Janssen, Paris, France | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Economic evaluation | |
| Cost-effectiveness analysis of flash glucose monitoring for type 2 diabetes patients receiving insulin treatment in the UK | ||||
| Li H1, Bilir SP2, Donga P3, Samiian A4, Munakata J2 | ||||
| 1IMS Health, Alexandria, CA, USA, 2IMS Health, San Francisco, CA, USA, 3IMS Health, Plymouth Meeting, PA, USA, 4Abbott Diabetes Care, Alameda, CA, USA | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Cost effectiveness | |
| Quantifying nonlinear effects in stochastic Markov simulation using UKPDS 68 and UKPDS 82 equations in type 2 diabetes modeling analysis with the IMS CORE Diabetes Model (CDM) | ||||
| McEwan P1, Grant D2, Lamotte M3, Foos V4 | ||||
| 11HEOR Consulting, Monmouth, UK 2 IMS Health, London,UK 3 IMS Health, Vilvoorde, Belgium, 4 IMS Health, Basel, Switzerland | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Meta analysis | |
| Impact of single risk factor changes on long term outcomes and cost in a type 2 diabetes modeling study contrasting projections with UKPDS 68 versus UKPDS 82 risk equations | ||||
| Foos V1, McEwan P2, Grant D3 | ||||
| 1 IMS Health, Basel, Switzerland 2 HEOR Consulting, Monmouth, UK 3 IMS Health, London, UK | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Budget impact | |
| All-cause mortality validation of the CORE Diabetes Model against predictions of the Charlson Comorbidity Index | ||||
| Foos V1, McEwan P2, Lamotte M3, Grant D4 | ||||
| 1 IMS Health, Basel, Switzerland 2 HEOR Consulting, Monmouth, UK 3 IMS Health, Vilvoorde, Belgium, IMS Health, London, UK | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Burden of illness | |
| Review of utility values for economic modeling in type 2 diabetes | ||||
| Beaudet A1, Clegg J1, Thuresson PO1, Lloyd A2, McEwan P3 | ||||
| 1 IMS Health, Basel, Switzerland, 2 IMS Health, London, UK 3 4Centre for Health Economics, Swansea University, Swansea, UK. | ||||
| Value Health. 2014 Jun;17(4):462-70 |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Review | |
| If we followed the National Institute of Health and Care Excellence (NICE) guidelines and treated people with diabetes earlier, patients and the National Health Service (NHS) would benefit from a reduction in complications, mortality and direct healthcare costs | ||||
| Baxter M1, Hex N2, Samyshkin Y3, Hudson R1, Mahon J4, Alexiou D3, Bartlett C2 | ||||
| 1 Sanofi, Guildford, UK 2 York Health Economics Consortium (YHEC), UK 3 IMS Health, London, UK 4 Coldingham Economics, Galashiels, UK | ||||
| Diabetes UK Professional Conference 2015 |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Population Based Study | |
| Budget impact analysis of Biphasic Insulin Aspart in the treatment of Type 2 Diabetes Mellitus in Malaysia: A Public Payer Perspective | ||||
| Tan SC1, Matzen P2, Yeo LN2 | ||||
| 1 IMS Asia Pacific, Singapore 2 Novo Nordisk Pharma Malysia, Kuala Lumpur, Malaysia | ||||
| ISPOR 6th Asia-Pacific Conference, Beijing, China, 6-9 September, 2014 |
||||
| , Poster | ||||
| , Malaysia | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Budget impact | |
| Budget Impact analysis of wider adoption of Biphasic Insulin Aspart (Biasp) in the treatment of type 2 Diabetes Mellitus (T2dm): A perspective of patients treated by public providers in Singapore | ||||
| Tan SC1, Matzen P2, Khoo SP2 | ||||
| 1 IMS Asia Pacific, Singapore 2 Novo Nordisk Pharma Malaysia, Kuala Lumpur, Malaysia 3 Novo Nordisk Pharma Singapore, Singapore | ||||
| ISPOR 6th Asia-Pacific Conference, Beijing, China, 6-9 September, 2014 |
||||
| , Poster | ||||
| , Singapore | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Budget impact | |
| Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK | ||||
| Bennett H, McEwan P, Bergenheim K & Gordon J | ||||
| Health Economics and Outcomes Research Ltd | ||||
| Diabetes Ther. 2014 Dec;5(2):567-78. doi: 10.1007/s13300-014-0079-6. Epub 2014 Sep 4 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25185770 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Retrospective database analysis | |
| Changes in HbA1c and frequency of measuring HbA1c and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK. | ||||
| Lind M, Pivodic A, Cea-Soriano L, Nerman O, Pehrsson NG & Garcia-Rodriguez LA | ||||
| University of Gothenburg Institute of Medicine | ||||
| Diabetologia. 2014 Aug;57(8):1586-94. doi: 10.1007/s00125-014-3250-8. Epub 2014 May 9. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24811709 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Retrospective database analysis | |
| Clinical outcomes and cost-effectiveness of continuous positive airway pressure to manage obstructive sleep apnea in patients with type 2 diabetes in the U.K | ||||
| Guest JF, Panca M, Sladkevicius E, Taheri S & Stradling J | ||||
| Catalyst Health Economics Consultants | ||||
| Diabetes Care. 2014 May;37(5):1263-71. doi: 10.2337/dc13-2539. Epub 2014 Apr 4 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24705611 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Mental health | 2014 | English | , Retrospective database analysis | |
| Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin. | ||||
| Flory JH, Small DS, Cassano PA, Brillon DJ, Mushlin AI & Hennessy S | ||||
| Weill Cornell Medical College | ||||
| J Comp Eff Res. 2014 Jan;3(1):29-39. doi: 10.2217/cer.13.87 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24345255 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Retrospective database analysis | |
| Distinguishing incident and prevalent diabetes in an electronic medical record database. | ||||
| Mamtani R, Haynes K, Finkelman BS, Scott FI & Lewis JD | ||||
| Pharmacoepidemiol Drug Saf. 2014 Feb;23(2):111-8. doi: 10.1002/pds.3557. Epub 2013 Dec 19. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24375925 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Epidemiological study | |
| Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas. | ||||
| Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, Haas NB, Vaughn DJ & Lewis JD | ||||
| University of Pennsylvania Abramson Cancer Center | ||||
| Diabetes Care. 2014 Jul;37(7):1910-7. doi: 10.2337/dc13-1489. Epub 2014 Feb 4 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24496803 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Oncology | 2014 | English | , Retrospective database analysis | |
| Incidence of retinal complications in a cohort of newly diagnosed diabetic patients | ||||
| Martín-Merino E, Fortuny J, Rivero-Ferrer Z & García-Rodríguez LA | ||||
| Centro Español de Investigación Farmacoepidemiológica | ||||
| PLoS One. 2014 Jun 25;9(6):e100283. doi: 10.1371/journal.pone.0100283. eCollection 2014 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24963628 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Ophthalmology | 2014 | English | , Retrospective database analysis | |
| Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based, BMI-matched cohort study. | ||||
| Rho YH, Lu N, Peloquin CE, Man A, Zhu Y, Zhang Y & Choi HK | ||||
| Boston University School of Medicine The Clinical Epidemiology Unit | ||||
| 2016;75:91-95 Ann Rheum Dis doi:10.1136/annrheumdis-2014-205827 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://ard.bmj.com/content/early/2014/09/02/annrheumdis-2014-205827.abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Rheumatology | 2014 | English | , Retrospective database analysis | |
| Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK. | ||||
| McEwan P, Bennett H, Ward T & Bergenheim K | ||||
| Swansea University1Swansea Centre for Health Economics | ||||
| Pharmacoeconomics. 2015 Feb;33(2):149-61. doi: 10.1007/s40273-014-0225-z |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25344660 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health policy | 2014 | English | , Retrospective database analysis | |
| Safety results from OCAPI: a European Observational Cohort Study of insulin glulisine-treated children aged 6-12 years with type 1 diabetes. | ||||
| Konstantinova M1, Loizeau V2, Pilorget V3, Cali A3, Danne T4. | ||||
| 1University Paediatric Hospital, Sofia, Bulgaria. 2Lincoln, Boulogne-Billancourt, France. 3Sanofi, Paris, France. 4"Auf der Bult" Children and Youth Hospital, Hannover, Germany. | ||||
| Exp Clin Endocrinol Diabetes. 2014 Oct;122(9):523-7. doi: 10.1055/s-0034-1377005. Epub 2014 Jul 23. |
||||
| , Article | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25054310 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Prospective study | |
| USAGE OF SELF-MONITORING OF BLOOD GLUCOSE (SMBG) BY DIABETES THERAPY TYPE IN INDIA. | ||||
| Mast O1, Tan A2, Punjabi K3 | ||||
| 1Roche Diagnostics, Diabetes Care, Mannheim, Germany, 2Cegedim Strategic Data, Singapore, Singapore, 3Cegedim Strategic Data, Mumbai, India | ||||
| ISPOR 17th Annual European Congress Amsterdam, The Netherlands November, 2014 |
||||
| , Poster | ||||
| , India | ||||
| Abstract: http://www.ispor.org/ScientificPresentationsDatabase/Presentation/51144 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | ||
| Obesity independently predicts responders to biphasic insulin 50/50 (Humalog Mix50 and Insuman Comb 50) following conversion from other insulin regimens: a retrospective cohort study | ||||
| Mamza J, Mehta R, Idris I | ||||
| University of Nottingham Division of Medical Sciences & Graduate Entry Medicine | ||||
| BMJ Open Diab Res Care2014;2:e000021 doi:10.1136/bmjdrc-2014-000021 |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://drc.bmj.com/content/2/1/e000021.abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Retrospective database analysis | |
| Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study | ||||
| Dubreuil M, Rho YH, Man A, Zhu Y, Zhang Y, Love TJ, Ogdie A, Gelfand JM & Choi HK | ||||
| Boston University School of Medicine Section of Rheumatology and the Clinical Epidemiology Unit | ||||
| Rheumatology (Oxford). 2014 Feb;53(2):346-52. doi: 10.1093/rheumatology/ket343. Epub 2013 Oct 31. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894671/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Rheumatology | 2014 | English | , Retrospective database analysis | |
| Treatment maintenance duration of dual therapy with Metformin and Sitagliptin in type 2 Diabetes - Real-World data From ODYSEE Study | ||||
| Leproust S1, Dallongeville J2, Valensi P3, Boutmy E4, Moisan C1, Chanut-Vogel C5, de Pouvourville G6 | ||||
| 1Merck (MSD France), Paris, France, 2INSERM U744, Lille, France, 3Service d’Endocrinologie-Diabétologie-Nutrition, Bondy, France, 4Cegedim Strategic Data, Boulogne-Billancourt, France, 5Laboratoires MSD France, Courbevoie, France, 6ESSEC, Cergy-Pontoise, France | ||||
| Ispor 17th Annual European Congress, 8-12 November 2014, Amsterdam RAI, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Prospective study, Retrospective database analysis | |
| Diabète de type 2 : quels objectifs thérapeutiques selon les nouvelles recommandations de l’HAS ? Analyse de 6 680 patients suivis par des médecins [Type 2 diabetes: which therapeutic objectives according to the new recommendations of the HAS? Analysis of 6,680 patients followed by doctors]. | ||||
| Larger E1, Ansolabehere X2, Grandfils N2, Le Jeunne P2 | ||||
| 1 GH Cochin Hôtel-Dieu, Paris 2 IMS Health HEOR, La Défense | ||||
| Congrès annuel de la Société Francophone du Diabète (SFD). 11-14 mars 2014 Paris |
||||
| , Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Endocrinology, Metabolic Disorders | 2014 | French | , Retrospective database analysis | |
| Regional variation in fasting and hypoglycemia experiences in MOSAIc study patients with T2DM taking insulin. | ||||
| Seeger JD, Patrick AR, Shrank WH, Avorn J, Choudhry NK, Polinski JM | ||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| Diabetes knowledge, distress, and glycemic control: global insights from the MOSAIc study | ||||
| Rogers JR, Curtis BH, Polonsky WH, Cos X, Newton T, Rodriguez-Vigil E, Zagar A, Polinski JM | ||||
| Poster presentation. American Diabetes Association Scientific Sessions. San Francisco, CA, June 13 – 17, 2014 |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| Geographic patterns of patient demographics and insulin usage: a global perspective from the MOSAIc study | ||||
| Polinski JM, Zagar A, Funnell MM, Hassoun A, Shrank WH, Curtis BH | ||||
| Poster presentation. American Diabetes Association Scientific Sessions. San Francisco, CA, June 13 – 17, 2014 |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| Cross-national variation in physicians’ characteristics and their goals for patients taking insulin: evidence from the MOSAIc study | ||||
| Xie J, Suzuki S, Cos X, Hassoun A, Matsuba I, Polinski JM | ||||
| Poster presentation. American Diabetes Association Scientific Sessions. San Francisco, CA, June 13 – 17, 2014. |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| Diabetes-related resource use, provider communication, and perceived support: cross-national comparisons from MOSAIc | ||||
| Shrank WH, Seeger JD, Avorn J, Newton T, Funnell MM, Choudhry NK, Polinski JM | ||||
| Poster presentation. American Diabetes Association Scientific Sessions. San Francisco, CA, June 13 – 17, 2014 |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| Depression, type 2 diabetes, and glycemic control: global patterns in the MOSAIc study | ||||
| Fischer MA, Rogers JR, Seeger JD, Choudhry NK, Avorn J, Shrank WH, Brill G, Polinski JM | ||||
| Abstract publication. American Diabetes Association Scientific Sessions. San Francisco, CA, June 13 – 17, 2014 |
||||
| , Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| Cross-national variation in insulin use among patients with diabetes taking Insulin: the MOSAIc study | ||||
| Patrick AR, Seeger JD, Shrank WH, Matsuba I, Polinski JM | ||||
| Abstract publication. American Diabetes Association Scientific Sessions. San Francisco, CA, June 13 – 17, 2014 |
||||
| , Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012 | ||||
| Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. | ||||
| Bloomberg School of Public Health, Baltimore | ||||
| Diabetes Care 2014;37(4):985-992. |
||||
| , Article | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24198301 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | French | , Real World Evidence | |
| Association of Changes In Body Weight With Health Care Costs Among Patients With Newly-Diagnosed Type-2 Diabetes In Sweden | ||||
| U. Sabale1, J. Bodegård1, J. Sundström2, B. Svennblad3, C.J. Östgren4, P. Nilsson5, G. Johansson3, M. Henriksson1 | ||||
| 1 AstraZeneca Nordic-Baltic, Södertälje, Sweden, 2 Uppsala University, Uppsala, Australia, 3 Uppsala University, Uppsala, Sweden, 4 Linköping University, Linköping, Sweden, 5 Lund University, Malmö, Sweden | ||||
| Value in Health |
||||
| , Abstract | ||||
| , Nordic, Sweden | ||||
| Abstract: http://www.sciencedirect.com/science/article/pii/S109830151402590X | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Real World Evidence | |
| Using Electronic Medical Records as Real World Evidence to Understand the Impact of Flu Vaccinations on Patient Health | ||||
| Gillman A1 | ||||
| 1 IMS Brogan, Toronto, Canada | ||||
| CAPT 2014 |
||||
| , Poster | ||||
| , Canada | ||||
| Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/capt2014-conference-poster-final-corrected.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Infectious disease | 2014 | English | , Longitudinal study | |
| Diabetes complexities drive resource consumption in Canada | ||||
| Borrelli R, Mokin S, Sung M | ||||
| IMS Brogan | ||||
| Accesspoint, 2014, 5(9): 15-19 |
||||
| , Article | ||||
| , Canada | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Retrospective database analysis | |
| Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries. | ||||
| Divino V., DeKoven M., Hallinan S., Varol N., Wirta SB., Lee WC., Reaney M. | ||||
| Lilly. IMS authors: Divino V, DeKoven M | ||||
| Diabetes Ther. |
||||
| , Article | ||||
| , Belgium, France, Germany, Netherlands, Sweden, UK | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/25366334 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Retrospective database analysis | |
| Regional Assessment of Severe Hypoglycemic Coma Events in Finland | ||||
| Hoti F, Vattulainen P, Mushnikov V, Saukkonen T, Korhonen P | ||||
| EPID Research, Espoo, Finland | ||||
| Value in Health (2014);17(7):A332 |
||||
| , Poster | ||||
| , Finland, Nordic | ||||
| Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(14)02557-1/fulltext | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Epidemiological study, Observational study, Population Based Study | |
| Lower Risk of Mortality in Patients with Type 2 Diabetes Using Insulins Detemir or Glargine Compared to NPH: A Propensity Score Matched Nationwide Register Study in Finland | ||||
| Mäkimattila S, Hoti F, Christopher S, Haukka J, Korhonen P, Saukkonen T | ||||
| EPID Research Ltd, Espoo, Finland | ||||
| Diabetes (2014);63 (Suppl 1):A343-A425 |
||||
| , Poster | ||||
| , Finland, Nordic | ||||
| Abstract: http://diabetes.diabetesjournals.org/mwg-internal/de5fs23hu73ds/progress?id=tLDZcQ3XmqwM1R5WmUnmnK6ZYf5Vk0j-7PYr0VdNiOQ,&dl | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Retrospective database analysis | |
| Lower Risk of Mortality in Patients with Type 2 Diabetes Using Insulins Detemir or Glargine Compared to NPH: A Propensity Score Matched Nationwide Register Study in Finland | ||||
| Mäkimattila S, Hoti F, Christopher S, Haukka J, Korhonen P, Saukkonen T | ||||
| EPID Research Ltd, Espoo, Finland | ||||
| American Diabetes Association 74th Scientific Session, San Francisco, USA, 13-17 June, 2014 |
||||
| , Poster | ||||
| , Finland | ||||
| Abstract: https://ada.scientificposters.com/epsAbstractADA.cfm?id=1 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Retrospective database analysis | |
| Uses of Electronic Patient Information Systems and National Registers ? Implementation of the Clinical Practice Guideline and Evaluation of Costs and Use of Resources in Patients with Incident Type 2 Diabetes in Finland | ||||
| Prami T, Sulamaa A, Sipilä R, Linna M, Hahl J, Miettinen T, Leppä E, Haukka J, Tuomilehto J, Enlund H, Niskanen L, Korhonen P | ||||
| EPID Research, Espoo, Finland | ||||
| Value in Health. (2014);17(7): A336 |
||||
| , Abstract | ||||
| , Finland, Nordic | ||||
| Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(14)02579-0/fulltext | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Population Based Study | |
| ASSOCIATION OF CHANGES IN BODY WEIGHT WITH HEALTH CARE COSTS AMONG PATIENTS WITH NEWLY-DIAGNOSED TYPE-2 DIABETES IN SWEDEN | ||||
| Sabale U, Bodegård J, Sundström J, Svennblad B, Östgren CJ, Nilsson P, Johansson G, Henriksson M | ||||
| AstraZeneca Nordic-Baltic, Södertälje, Sweden | ||||
| Value in Health (2014);17(7): A338 |
||||
| , Abstract | ||||
| , Nordic, Sweden | ||||
| Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(14)02590-X/fulltext | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Cost analysis, Population Based Study, Retrospective database analysis | |
| Regional assessment of severe hypoglycemic coma events in Finland | ||||
| Vattulainen P, Mushnikov V, Hoti F, Saukkonen T, Korhonen P. | ||||
| EPID Research, Espoo, Finland | ||||
| Value Health. (2014) 17(7): A332 |
||||
| , Poster | ||||
| , Finland, Nordic | ||||
| Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(14)02557-1/fulltext | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Epidemiological study, Observational study, Population Based Study | |
| Evaluation of the pharmacy budget impact of alogliptin plus pioglitazone fixed dose combination in the treatment of Type-2 diabetes mellitus. | ||||
| Bron M1, Ferrufino CP2, Samyshkin Y3, Munakata J4 | ||||
| 1Takeda Pharmaceuticals, Deerfield, IL, USA, 2IMS Health, Alexandria, VA, USA, 3IMS Health, London, UK, 4IMS Health, Redwood City, CA, USA | ||||
| ISPOR 18th Annual International Meeting to be held May 18-22, 2013 New Orleans, LA, USA. Abstract ID# 42951 |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Budget impact, Economic evaluation | |
| Cardiovascular Event Rates in a Type 2 Diabetes Population in a Real-World UK Setting: A Large Database Study Using the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) | ||||
| McDonell A1, DeVore S2, Muthutantri A1, Demuth D1, Richards C1, Wu Y2, Kim J2 | ||||
| 1 IMS Health, London, UK 2 AstraZeneca, Wilmington, DE, USA | ||||
| American Diabetes Association Scientific Sessions, June 21 - 25, Chicago, US |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Drivers of cost-effectiveness in type-2 diabetes mellitus | ||||
| McEwan P1, Foos V2, Grant D3, Lamotte M4, Palmer JL5, Lloyd A3 | ||||
| 1Swansea University, Cardiff, United Kingdom, 2IMS Health, Basel, Switzerland, 3IMS Health, London, United Kingdom, 4IMS Health, Vilvoorde, Belgium, 5IMS Health, Allschwil, Basel-Landschaft, Switzerland | ||||
| ISPOR 18th Annual International Meeting, May 18-22, 2013 New Orleans, LA, USA. Abstract ID# 42422 |
||||
| , Podium presentation, Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Cost analysis, Cost effectiveness, Cost utility | |
| Do existing risk equations fail to adequately account for the relationship between body mass index and mortality in subjects with type-2 diabetes? | ||||
| McEwan P1, Foos V2, Grant D3, Palmer JL4, Lamotte M5, Lloyd A3 | ||||
| 1Swansea University, Cardiff, United Kingdom, 2IMS Health, Basel, Switzerland, 3IMS Health, London, United Kingdom, 4IMS Health, Allschwil, Basel-Landschaft, Switzerland, 5IMS Health, Vilvoorde, Belgium | ||||
| ISPOR 18th Annual International Meeting, May 18-22, 2013 New Orleans, LA, USA. |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Methodology | |
| Assessing the consistency of absolute cardiovascular risk prediction and relative risk reduction in type-2 diabetes mellitus | ||||
| McEwan P1;Lamotte M2;Grant D3;Palmer JL4;Lloyd A3, Foos V5 | ||||
| 1Swansea University, Cardiff, United Kingdom, 2IMS Health, Vilvoorde, Belgium, 3IMS Health, London, United Kingdom, 4IMS Health, Allschwil, Basel-Landschaft, Switzerland, 5IMS Health, Basel, Switzerland | ||||
| ISPOR 18th Annual International Meeting, May 18-22, 2013 New Orleans, LA, USA. |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2013 | English | , Quality of life | |
| The cost and productivity consequences of non-severe hypoglycaemic episodes (nshe) in patients treated with sulfonylurea or dpp4 dual combination oral therapy | ||||
| Foos V1, McEwan P2, Grant D3, Palmer JL4, Lamotte M5, Lloyd A3 | ||||
| 1IMS Health, Basel, Switzerland, 2Swansea University, Cardiff, United Kingdom, 3IMS Health, London, United Kingdom, 4IMS Health, Allschwil, Basel-Landschaft, Switzerland, 5IMS Health, Vilvoorde, Belgium | ||||
| ISPOR 18th Annual International Meeting, May 18-22, 2013 New Orleans, LA, USA. |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Cost consequence | |
| The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥ 30 kg/m2 in Spain | ||||
| Fonseca T1, Clegg J2, Caputo G3, Norrbacka K4, Dilla T5, Alvarez M5 | ||||
| 1IMS Health, London,UK, 2IMS Health, Basel, Switzerland, 3IMS Health, Keppel Towers, Singapore, 4dEli Lilly Finland Ab, , Helsinki, Finland, 5eLilly SA, Spain | ||||
| J Med Econ. 2013 Jul;16(7):926-38 |
||||
| , Abstract | ||||
| , Spain | ||||
| Abstract: http://informahealthcare.com/doi/abs/10.3111/13696998.2013.803110 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Cost effectiveness | |
| The CANARD Project (project CANARD) – Cost-effectiveness ANAlysis of Real-world outcomes in a Diabetic population | ||||
| Sutherland CS 1,2, Gillet M2, Brennan A2, Duran A1 , Ansolabehere, X3 | ||||
| 1IMS Health, London, United Kingdom, 2University of Sheffield, Sheffield, United Kingdom, 3IMS Health, Paris, France | ||||
| ISPOR 18th Annual International Meeting , New Orleans, 18th – 22nd May, 2013. Poster ID: PCV74 |
||||
| , Poster | ||||
| , France, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Cost effectiveness | |
| Direct Medical Costs of Treating Diabetes-Related Complications In Argentina | ||||
| Elgart J, De la Llave G, Camillucci C, Vega-Hernandez G, Watkins M, Hammerby E, Nikolajsen A, Gagliardino JJ | ||||
| IMS Health, London, UK | ||||
| ISPOR 4th Latin America Conference Value in Health 2013 |
||||
| , Abstract | ||||
| , Argentina | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Cost analysis, Cost of illness, Pricing & Reimbursement | |
| Direct Costs of Type 2 Diabetes from fhe Brazilian Public Healthcare Sector Perspective | ||||
| Hnoosh A1, Babineaux SM2, Piras de Oliveira C3, McDonell A1, Vega-Hernandez G1 | ||||
| 1IMS, London, England, 2Eli Lilly & Company, Indianapolis, IN, USA, 3Eli Lilly do Brasil, Sao Paulo, Brazil | ||||
| ISPOR 4th Latin America Conference. Value in Health 2013 |
||||
| , Poster | ||||
| , Brazil | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Burden of illness, Cost analysis, Cost of illness | |
| Direct Costs of Type 2 Diabetes in Mexico from the Public Healthcare Sector Perspective | ||||
| Chatzitheofilou I1, Babineaux SM2, Ramírez-Gámez J3, McDonell A1, Vega-Hernandez G1 | ||||
| 1IMS, London, England, 2Eli Lilly & Company, Indianapolis, IN, USA, 3Eli Lilly and Company, México, Mexico | ||||
| ISPOR 4th Latin America Conference. Value in Health 2013 |
||||
| , Poster | ||||
| , Mexico | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Burden of illness, Cost analysis, Cost of illness | |
| Direct medical costs for complications among adults with type 2 diabetes in a US commercial payer setting | ||||
| Yeaw J1, Halinan S1, Hines D1, DeLozier A2, Perez M2, Boye M2, Boye KS2, Blanchette CM1 | ||||
| 1 IMS Health, Alexandria, USA 2 Eli Lilly and Company, Indianapolis, USA | ||||
| Society for Pharmacoeconomics and Outcomes Research 18th Annual International Meeting, May 18-22, 2013 in New Orleans, LA |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Cost of illness | |
| Review of cost of diabetes complications in four European countries | ||||
| Beaudet A1, Grabbi E2, Maurel F3, Ramos M4, Lebioda A2 | ||||
| 1 IMS Health, Basel, Switzerland, 2 IMS Health, London, UK, 3 IMS Health, Paris, France, 4 IMS Health, Barcelona, Spain | ||||
| ISPOR 16th annual European congress, 2013, November 2-6, Dublin, Ireland |
||||
| , Poster | ||||
| , Europe | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Cost of illness, Review | |
| The burden of hospitalizations due to hypoglycemia in Belgium. | ||||
| Lamotte M1, Chevalier P1, Vandebrouck T2 | ||||
| 1 IMS Health, Vilvoorde, Belgium 2 NovoNordisk, Brussels, Belgium | ||||
| American Diabetes Association (ADA) 73rd Scientific Sessions, 2013, June 21-25, Chicago, IL, USA |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Burden of illness | |
| Estimating the cost of hospitalization for hypoglycemia in Belgium. | ||||
| Lamotte M1, Chevalier P1, Vandebrouck T2 | ||||
| 1 IMS Health, Vilvoorde, Belgium 2 NovoNordisk, Brussels, Belgium | ||||
| ISPOR 18th Annual International Meeting, 2013, May 18-22, New Orleans, LA, USA |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Cost analysis | |
| Screening characteristics and diabetes biomarkers in French and UK patient-level databases | ||||
| Cabrera C1, Le Jeunne P2, Lee A3, Thomas F4, Mian N3, McDonell A5 | ||||
| 1AstraZeneca, Mölndal, Sweden, 2IMS Health, Paris, France, 3AstraZeneca GMD UK, Cheshire, England, 4AstraZeneca France, GMD, Paris, France, 5IMS Health, London, England | ||||
| ISPOR 16th Annual European Congress, 2-6 November 2013, Abstract #45156 |
||||
| , Poster | ||||
| , France, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Real World Data | |
| The CANARD Project (project CANARD) – Cost-effectiveness ANAlysis of Real-world outcomes in a Diabetic population The impact of baseline characteristics in France | ||||
| Sutherland CS 1,2, Gillet M2, Brennan A2, Duran A1 , Ansolabehere, X3 | ||||
| 1- IMS Health, London, United Kingdom, 2 - University of Sheffield, Sheffield, United Kingdom, 3 - IMS Health, Paris, France | ||||
| ISPOR 18th annual international meeting, New Orleans - May 2013 |
||||
| , Poster | ||||
| , France, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Diabetes | 2013 | English | , Cost effectiveness | |
| Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients. | ||||
| Sundström J, Sheikhi R, Ostgren CJ, Svennblad B, Bodegård J, Nilsson PM, Johansson G. | ||||
| IMS Health (Formally Pygargus) | ||||
| J Hypertens. 2013 Aug;31(8):1603-10 |
||||
| , Abstract, Article | ||||
| , Sweden | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23625112 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2013 | English | , Retrospective cohort analysis | |
| Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care. | ||||
| Östgren CJ, Sundström J, Svennblad B, Lohm L, Nilsson PM, Johansson G. | ||||
| IMS Health, Stockholm, Sweden (Formally Pygargus) | ||||
| Diabet Med. 2013 May;30(5):e170-7 |
||||
| , Article | ||||
| , Sweden | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23350893 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2013 | English | , Retrospective cohort analysis | |
| Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8,486 primary care patients | ||||
| Bodegard J, Sundström J, Svennblad B, Östgren CJ, Nilsson PM, Johansson G | ||||
| IMS Health, Stockholm, Sweden (Formally Pygargus) | ||||
| Diabetes Metab. 2013 Sep;39(4):306-13 |
||||
| , Article | ||||
| , Sweden | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23871502 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2013 | English | , Retrospective cohort analysis | |
| Consistency of current type 2 diabetes (T2DM) treatmeent patterns in general practice versus the 2013 French HAS T2DM guidelines : a transversal study based on the French IMS LifelinkTM prospective diabetes cohort | ||||
| 1. Larger E, 2.Ansolabehere X, 2.Le Jeunne P, 2.Grandfils N, 3.Briand Y, 3.Gibelin B | ||||
| 1. Hotel Dieu Paris, Paris France 2. IMS Health, Paris La Défense France, 3. Boehringer Ingelheim France, Paris France. | ||||
| 16th annual European ISPOR |
||||
| , Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Real World Data, Retrospective cohort analysis | |
| Do fixed-dose combinations improve antidiabetic treatment compliance? A study based on French IMS Lifelink disease analyszer database | ||||
| 1. Grandfils N, 1. Le Jeunne P, 1. maillard C, 1. Solomiac A, 1. Besson A | ||||
| 1. IMS Health, Paris La Défense France | ||||
| 16th Annual European ISPOR |
||||
| , Abstract | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Compliance, Retrospective cohort analysis | |
| Lower incidence of recorded cardiovascular outcomes in patients with Type 2 Diabetes using Insulin Aspart versus those on human regular insulin: Observational evidence from General Practices. | ||||
| Rathmann W1, Kostev K2 | ||||
| 1 Institute of Biometrics and Epidemiology, German Diabetes Center, Dusseldorf, Germany 2 IMS Health, Frankfurt, Germany | ||||
| Diabetes Obes Metab., 2013, Apr;15(4):358-63 |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23137345 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Observational study | |
| Influence of macro- and microvascular comorbidity on time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany, France, and UK. | ||||
| Kostev K1, Rathmann W2 | ||||
| 1 IMS Health, Frankfurt, Germany 2 Institute of Biometrics and Epidemiology, German Diabetes Center, Dusseldorf, Germany | ||||
| Prim Care Diabetes., 2013, Jul;7(2):167-71 |
||||
| , Article | ||||
| , France, Germany, UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=influence%20of%20macro%20and%20microvascular%20comorbidity%20on%20time%20to%20insulin%20initiation%20in%20type%202%20diabetes%20patients%20a%20retrospective%20database%20analysis%20in%20germany,%20france,%20and%20uk&cmd=correctspelling | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Changes in time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany and UK (2005-2010). | ||||
| Kostev K1, Rathmann W2 | ||||
| 1 IMS Health, Frankfurt, Germany 2 Institute of Biometrics and Epidemiology, German Diabetes Center, Dusseldorf, Germany | ||||
| Prim Care Diabetes., 2013, Oct;7(3):229-33 |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23608219 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Different injection frequencies of basal insulins in type 2 diabetes patients under real-life conditions: a retrospective database analysis. | ||||
| Rathmann W1, Dippel FW2, Kostev K3 | ||||
| 1 Institute of Biometrics and Epidemiology, German Diabetes Center, Dusseldorf, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS Health, Frankfurt, Germany | ||||
| J Diabetes Sci Technol., 2013, September, 7(5): 1354–1358 |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/?term=Different+injection+frequencies+of+basal+insulins+in+type+2+diabetes+patients+under+real-life+conditions%3A+A+retrospective+database+analysis | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Predictors of hypoglycaemia in insulin-treated type 2 diabetes patients in primary care: a retrospective database analysis. | ||||
| Kostev K1, Dippel FW2, Rathmann W3 | ||||
| 1 IMS Health, Frankfurt, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 Institute of Biometrics and Epidemiology, German Diabetes Center, Dusseldorf, Germany | ||||
| Prim Care Diabetes., 2013, Oct 30. pii: S1751-9918(13)00117-4. doi: 10.1016/j.pcd.2013.10.001. [Epub ahead of print] |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/?term=Predictors+of+Hypoglycaemia+in+Insulin-treated+Type+2+Diabetes+Patients+in+Primary+Care%3A+A+Retrospective+Database+Analysis+Primary+Care+Diabetes | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. | ||||
| Rathmann W1, Kostev K2, Gruenberger JB3, Dworak M3, Bader G3, Giani G1 | ||||
| 1 Institute of Biometrics and Epidemiology, German Diabetes Center, Dusseldorf, Germany 2 IMS Health, Frankfurt, Germany 3 Novartis Pharma, Basel, Switzerland | ||||
| Diabetes Obes Metab., 2013, Jan;15(1):55-61 |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/?term=Treatment+Persistence%2C+Hypoglycemia%2C+and+Clinical+Outcomes+in+Type+2+Diabetes+Patients+with+DPP-4+Inhibitors+and+Sulfonylureas%3A+A+Primary+Care+Database+Analysis | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Resource consumption and costs of treatment in patients with type 1 diabetes under intensified conventional therapy under German real-life conditions. | ||||
| Kostev K1, Dippel FW2, Bierwirth R3 | ||||
| 1 IMS Health, Frankfurt, Germany 2 Sanofi Deutschland GmbH, Berlin, Germany 3 Ambulantes Diabeteszentrum am Elisabeth-Krankenhaus, Essen, Germany | ||||
| J Diabetes Sci Technol., 2013, May 1;7(3):736-42 |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: http://jdst.org/May2013/PDF/Abstracts/VOL-7-3-ORG12-KOSTEV-ABSTRACT.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Cost analysis | |
| Diabetic retinopathy at diagnosis of type 2 diabetes in the UK: a database analysis. | ||||
| Kostev K1, Rathmann W2 | ||||
| 1 Institute of Biometrics and Epidemiology, German Diabetes Center, Dusseldorf, Germany 2 IMS Health, Frankfurt, Germany | ||||
| Diabetologia, 2013, Jan;56(1):109-11 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=Diabetic+retinopathy+at+diagnosis+of+type+2+diabetes+in+UK&TransSchema=title&cmd=detailssearch | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Glucose lowering therapeutic strategies for type 2 diabetic patients with chronic kidney disease in primary care setting in France: a cross-sectional study. | ||||
| Grandfils N1, Detournay B2, Attali C3, Joly D4, Simon D5, Vergès B6, Toussi M1, Briand Y8, Delaitre O8 | ||||
| 1 IMS Health, Paris, France 2 Cemka-Eval, Bourg-la-Reine, France 3 Medical office, Epinay sous Senart, France 4 Hôpital Necker-Enfants Malades, Paris, France 5 Hôpital de la Pitié-Salpétrière, Paris, France 6 INSERM CESP, Villejuif, France 7 Hôpital du Bocage, Dijon, France 8 Boehringer-Ingelheim, Paris, France | ||||
| International Journal of Endocrinology, 2013, 640-632. |
||||
| , Article | ||||
| , France | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638677/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Hypoglycemic treatment in type 2 diabetes patients suffering from moderate to severe renal failure in France. Aim of the study. | ||||
| Bouée S1, Gaudin AF, Amelineau E, Bonnet F. | ||||
| 1Cemka-Eval, Bourg la Reine, France | ||||
| Therapie. 2013 Jan-Feb;68(1):19-26. doi: 10.2515/therapie/2013002. Epub 2013 Mar 14 |
||||
| , Article | ||||
| , France | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23484656 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Nephrology | 2013 | English | , Retrospective database analysis | |
| A new "Comparative Effectiveness" assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone. | ||||
| Tannen R, Xie D, Wang X, Yu M & Weiner MG | ||||
| University of Pennsylvania School of Medicine | ||||
| Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):86-97. doi: 10.1002/pds.3360. Epub 2012 Oct 16 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23070833 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study | ||||
| Lind M1, Garcia-Rodriguez LA, Booth GL, Cea-Soriano L, Shah BR, Ekeroth G & Lipscombe LL | ||||
| 1 Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg Institute of Medicine Department of Molecular and Clinical Medicine | ||||
| Diabetologia. 2013 Dec;56(12):2765. doi: 10.1007/s00125-013-2949-2. Epub 2013 Jun 22 |
||||
| , Article | ||||
| , Canada, UK | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/24114114 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. | ||||
| Hall GC, McMahon AD, Dain MP, Wang E, Home PD | ||||
| Grimsdyke House | ||||
| Diabet Med. 2013 Jun;30(6):681-6. doi: 10.1111/dme.12137. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23330649 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Type 2 diabetes mellitus and survival in pancreatic adenocarcinoma: a retrospective cohort study. | ||||
| Hwang A, Narayan V & Yang YX | ||||
| University of Pennsylvania Department of Gastroenterology | ||||
| Cancer. 2013 Jan 15;119(2):404-10. doi: 10.1002/cncr.27731. Epub 2012 Aug 1. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23292900 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Oncology | 2013 | English | , Retrospective database analysis | |
| Metformin and survival in pancreatic cancer: a retrospective cohort study | ||||
| Hwang AL, Haynes K, Hwang WT, Yang YX | ||||
| Pancreas. 2013 Oct;42(7):1054-9. doi: 10.1097/MPA.0b013e3182965a3c. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779343/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Oncology | 2013 | English | , Retrospective database analysis | |
| Distinguishing incident and prevalent diabetes in an electronic medical record database | ||||
| Mamtani R, Haynes K, Finkelman BS, Scott FI & Lewis JD | ||||
| University of Pennsylvania Abramson Cancer Center | ||||
| Pharmacoepidemiology and Drug Safety [ahead of print] |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24375925 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Motifs de non intensification thérapeutique chez des patients DT2 non contrôlés par une monothérapie en Médecine Générale en France – Phase prospective étude DIAttitude | ||||
| Halimi S, BlickleJF, Balkau B, Attali C, Avignon A, Tocque E, Geoffroy MA, Chartier I, Vergès B | ||||
| Department of Endocrinology,Department of Diabetology Pole DIGIDUNE, Grenoble University Hospital, Grenoble, France. | ||||
| Diabetes Metab. 2013 Mar;39 (S1):A32 |
||||
| , Article | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Anti-diabetic treatment compliance with regards to the fixed or free treatments combination | ||||
| Grandfils N, Le Jeunne P, Maillard C, Solomiac A, Besson A | ||||
| IMS Health, Paris La Défense France | ||||
| Ispor 16th Annual European Congrès 2-6 Novembre 2013 the convention centre Dublin |
||||
| , Poster | ||||
| , France | ||||
| Abstract: www.ispor.org | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | ||
| La diffusion des nouveaux antidiabétiques : une comparaison internationale | ||||
| Pichetti S1, Sermet C1, Saskia van der Erf2 | ||||
| 1IRDES, 2CNAMTS | ||||
| Points de repère n° 40 - mai 2013 |
||||
| , Article | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | French | ||
| Anti-diabetic treatment compliance with regards to the fixed or free treatments combination | ||||
| Grandfils N, Le Jeunne P, Maillard C, Solomiac A, Besson A | ||||
| IMS Health, Paris La Défense France | ||||
| ISPOR 16th Annual European Congress, 2-6 November 2013 |
||||
| , Poster | ||||
| , France | ||||
| Abstract: www.ispor.org | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Retrospective database analysis | |
| Perspectives on complementary data sources in diabetes health technology assessment: an enrolling practice-based research network and a large commercial health plan | ||||
| Dalal MR; Frimpter J; Pan C; Stewart J; Johnstone B; Gemmen E; Reed J, Vlajnic A | ||||
| Poster, ISPOR 18th Annual International Meeting, New Orleans, LA 2013 |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| A cross-national comparison of safety and efficacy information in insulin glargine drug labels | ||||
| Polinski JM, Kesselheim AS, Seeger JD, Connolly JG, Choudhry NK, Shrank WH | ||||
| American Diabetes Association, 73nd Scientific Session, Chicago, June 21-25, 2013 |
||||
| , Conference | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| A practice-based research network focused on comparative effectiveness research in type 2 diabetes management | ||||
| Anderson JE, Rhinehart AS, Reid TS, Cuddihy RM, Vlajnic A, Dalal MR, Gemmen E, Johnstone B, Abbaszadeh B, Reed J, Sheller J, Stewart J, Mozaffari E, Diabetes FORWARD Investigators | ||||
| Postgrad Med. 2013 May;125(3):172-80 |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| Using Anonymized Longitudinal Patient Data to Monitor the Impact of Reimbursement Policies on Patient Compliance | ||||
| Gillman, A | ||||
| IMS Brogan, Toronto, Canada | ||||
| CAPT 2013 |
||||
| , Poster | ||||
| , Canada | ||||
| Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/capt-agillman-final.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Longitudinal study | |
| Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study | ||||
| Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P | ||||
| EPID Research Ltd, Espoo, Finland | ||||
| Pharmacoepidemiology and drug safety (2013); 22: 1326-1335 |
||||
| , Article | ||||
| , Finland | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265848/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Clinical setting: hospital, clinical setting: Secondary care, Epidemiological study, Retrospective database analysis | |
| Assessing the relationship between the effect of glycemic control and avoided symptomatic Hypoglycemia on quality of life in the management of type 2 Diabetes | ||||
| Foos V1, McEwan P2, Lloyd A3, Palmer JL1, Lamotte M4, Grant D3 | ||||
| 1 IMS Health, Basel, Basel-Stadt, Switzerland 2 HEOR Consulting, Monmouth, Monmouthshire, UK 3 IMS Health, London, UK 5 IMS Health, Vilvoorde, Belgium | ||||
| ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany |
||||
| , Podium presentation | ||||
| Abstract: http://www.ispor.org/congresses/Berlin1112/Podiums.aspx#sessionI | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Quality of life | |
| Medication adherence and medical costs associated with exenatide BID versus liraglutide: A retrospective database analysis. | ||||
| Pelletier EM1, Pawaskar M2, Chapman R3 | ||||
| 1IMS Health, Watertown, MA, USA, 2Eli Lilly and Company and Lilly USA, LLC, Indianapolis, IN, USA, 3IMS Health, Alexandria, VA, USA | ||||
| International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting, 2012, June, Washington, DC, USA |
||||
| , Abstract, Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost analysis, Retrospective cohort analysis, Retrospective database analysis | |
| Long-term cost-consequence analysis of exenatide once weekly versus sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. | ||||
| Guillermin AL1, Lloyd A1, Best JH2, Beth Deyoung M2, Samyshkin Y1, Aledort Gaebler J2. | ||||
| 1 IMS Health, London, UK 2 1Amylin Pharmaceuticals, Inc., San Diego, CA, USA | ||||
| J Med Econ. 2012 Mar 12. [Epub ahead of print] |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=Guillermin+A%5Bfirst+author%5D+AND+exenatide&TransSchema=title&cmd=detailssearch | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost consequence | |
| Long-term clinical and economic benefit associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a Core Diabetes Model study. | ||||
| Lee WC1, Samyshkin Y2, Langer J3, Palmer J4 | ||||
| 1IMS Health, Alexandria, VA, USA, 2IMS Health, London, UK, 3Novo Nordisk, Inc., Princeton, NJ, USA, 4IMS Health, Allschwil, Basel, Switzerland | ||||
| ISPOR 17th Annual International Meeting. June 2-6, 2012 Washington, DC, USA. |
||||
| , Abstract, Poster | ||||
| , USA | ||||
| Abstract: http://www.ispor.org/meetings/washingtondc0512/Posters4.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost benefit | |
| Economic outcomes of exenatide versus liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis. | ||||
| Pelletier EM1, Pawaskar M2, Smith PJ1, Best JH3, Chapman RH4 | ||||
| 1IMS Health Inc., Watertown, MA, USA, 2Eli Lilly and Company and Lilly USA, LLC, Indianapolis, IN, USA, 3Amylin Pharmaceuticals Inc., San Diego, CA, USA, 4IMS Health Inc., Alexandria, VA, USA | ||||
| J Med Econ 2012 [in press]; 2012 Apr 26 [Epub ahead of print] |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost analysis, Retrospective cohort analysis, Retrospective database analysis | |
| Cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) in type 2 diabetes (T2DM) | ||||
| Fonda SJ, Graham C, Samyshkin Y, Munakata J, Powers J, Vigersky RA | ||||
| American Diabetes Association, 2012, June 8-12, Philadelphia, PA |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost effectiveness | |
| Direct Medical Costs of Treating Diabetes Related Complications in Mexico | ||||
| Vega-Hernandez G1, Jugrin A1, Radford M1, Bloomfield E1, Todorova L2, Hansen BB3 | ||||
| 1 IMS Health, HEOR London, UK 2 Novo Nordisk International Operations, Zurich, Switzerland 3 Novo Nordisk A/S, Søborg, Denmark | ||||
| ISPOR 17th Annual International Meeting, June 2-6 2012, Washington, USA |
||||
| , Poster | ||||
| , Mexico | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost of illness | |
| Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial | ||||
| Mitchell P1, Annemans L2, Gallagher M3, Hasan R3, Thomas S4, Gairy K5, Knudsen M6, Onwordi H6 | ||||
| 1 Centre for Vision Research,Westmead Millennium Institute,University of Sydney, NSW, Australia 2 Ghent University, Ghent,Belgium 3 Novartis Pharma AG, Basel, Switzerland 4 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA 5 Novartis Pharmaceuticals, Frimley, UK 6 IMS Health, London, UK | ||||
| Br J Ophthalmol 2012;96:688e693. (epub ahead of print) |
||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost effectiveness | |
| Direct Medical Costs of Diabetes-Related Complications in Saudi Arabia | ||||
| Hnoosh A1; Vega-Hernández G1; Jugrin A1; Todorova L2 | ||||
| 1 IMS Health, HEOR, London, UK; 2 Novo Nordisk International Operations, Zurich, Switzerland | ||||
| ISPOR 17th Annual International Meeting, June 2-6 2012, Washington, USA |
||||
| , Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost analysis | |
| Direct Medical Costs Of Diabetes-Related Complications In India | ||||
| Todorova L1, Hnoosh A2, Korde G3, Shiu ML4 | ||||
| 1 Novo Nordisk International Operations, Zurich, Switzerland, 2 IMS Health, London, UK, 3 IMS Health Consulting Group, Mumbai, India, 4 Novo Nordisk Pharma Operations (BAOS) Sdn. Bhd., Kuala Lumpur, Malaysia | ||||
| ISPOR 5th Asia-Pacific Conference, 2-4 September 2012, Taipei, Taiwan. |
||||
| , Abstract | ||||
| , India | ||||
| Abstract: http://www.ispor.org/conferences/Taipei0912/Posters2.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost analysis | |
| Estimating the Direct Medical Costs associated with Diabetes-Related Complications in Indonesia | ||||
| Todorova L1, Hnoosh A2, Bloomfield E2, Shiu ML3 | ||||
| 1 Novo Nordisk International Operations, Zurich, Switzerland, 2 IMS Health Consulting Group, London, United Kingdom, 3 Novo Nordisk Pharma Operations (BAOS) Sdn. Bhd., Kuala Lumpur, Malaysia | ||||
| ISPOR 5th Asia-Pacific Conference, 2-4 September 2012, Taipei, Taiwan. PDB20 |
||||
| , Abstract | ||||
| , Indonesia | ||||
| Abstract: http://www.ispor.org/conferences/Taipei0912/Posters2.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost analysis | |
| Estimating the Costs of Diabetes Mellitus: An Analysis in Malaysia | ||||
| Todorova L1, Hnoosh A2, Bloomfield E2, Shiu ML3 | ||||
| 1 Novo Nordisk International Operations, Zurich, Switzerland 2 IMS Health, London, UK 3 Novo Nordisk Pharma Operations (BAOS) Sdn. Bhd., Kuala Lumpur, Malaysia | ||||
| ISPOR 5th Asia-Pacific Conference, 2-4 September 2012, Taipei, Taiwan. |
||||
| , Abstract | ||||
| , Malaysia | ||||
| Abstract: http://www.ispor.org/conferences/Taipei0912/Posters2.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost analysis | |
| Direct Medical Management Costs of Diabetes-Related Complications in Algeria | ||||
| Hnoosh A1; Vega-Hernández G1; Jugrin A1; Todorova L2 | ||||
| 1 IMS Health, HEOR, London, UK; 2 Novo Nordisk International Operations, Zurich, Switzerland | ||||
| ISPOR 17th Annual International Meeting, June 2-6 2012, Washington, USA |
||||
| , Abstract | ||||
| , Algeria | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost analysis | |
| Direct Medical Management Costs of Diabetes-Related Complications in Brazil | ||||
| Vega-Hernández G1; Hnoosh A1; Jugrin A1; Todorova L2; Hansen BB3 | ||||
| 1 IMS Health, HEOR, London, UK; 2 Novo Nordisk International Operations, Zurich, Switzerland; 3 Novo Nordisk A/S, Soeborg, Denmark | ||||
| ISPOR 17th Annual International Meeting, June 2-6 2012, Washington, USA |
||||
| , Abstract | ||||
| , Brazil | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost analysis | |
| Validation and Evaluation of the Risk-To-Benefit Ratio of Glucose Lowering Therapies in High Cardiovascular Risk Type 2 Diabetes Patients; Projections using the IMS CORE Diabetes Model. | ||||
| Foos V1, Freemantle N2, Palmer J1, Grant D3, Lloyd A3, Evans M4, Mcewan P | ||||
| 1 IMS Health, Basel, Switzerland 2 UCL Medical School, London, UK 3 IMS Health, London, UK 4 University of Cambridge, UK, 5 Swansea Centre for Health Economics, Swansea University, UK | ||||
| 72nd Scientific Sessions, American Diabetes Association, Philadelphia, PA, June 8–12 2012 |
||||
| , Oral presentation | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Economic evaluation | |
| Long-Term Validation of the IMS CORE Diabetes Model in Type 1 and Type 2 Diabetes. | ||||
| Grant D1, Foos V2 , Palmer J2 , Lloyd A1, Evans M3, Mcewan P4 | ||||
| 1 IMS Health, London, UK 2 IMS Health, Basel, Switzerland 3 University of Cambridge, UK, 4 Swansea Centre for Health Economics, Swansea University, UK | ||||
| 72nd Scientific Sessions, American Diabetes Association, Philadelphia, PA, June 8–12 2012 |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Economic evaluation | |
| The Cost and Productivity Consequences of Non-Severe Hypoglycaemic Episodes (NSHE) in Patients Receiving Sulfonylurea or DPP4 Dual Combination Oral Therapy | ||||
| McEwan P1, Evans M2, Foos V3, Lloyd A4, Grant D4 | ||||
| 1 Swansea Centre for Health Economics, Swansea University, UK 2 University of Cambridge, UK 3 IMS Health, Basel, Switzerland 4 IMS Health, London, UK | ||||
| 72nd Scientific Sessions, American Diabetes Association, Philadelphia, PA, June 8–12 2012 |
||||
| , Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Burden of illness | |
| Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes (T2DM) | ||||
| Fonda SJ, Graham C, Samyshkin Y, Munakata О, MS, Powers J, Price D, Vigersky RA, | ||||
| ADA 72nd Scientific Sessions, June 8 - 12, 2012, Pennsylvania Convention Center, Philadelphia, PA |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost effectiveness | |
| Long-term clinical and economic benefit associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a Core Diabetes Model study. | ||||
| Lee WC1, Samyshkin Y2, Langer J3, Palmer J4 | ||||
| 1IMS Health Consulting Group, Alexandria, VA, USA, 2IMS Health Consulting Group, London, UK, 3Novo Nordisk, Inc., Princeton, NJ, USA, 4IMS Health Consulting Group, Allschwil, Basel-Land, Switzerland | ||||
| ISPOR 17th Annual International Meeting, Washington, DC, USA, June 2-6, 2012 |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost benefit | |
| Long-Term Cost-utility analysis of Exenatide once weekly versus insulin Glargine for the treatment of Type 2 diabetes patients in the United States. | ||||
| Samyshkin Y1, Guillermin A-L1, Best JH2, Brunell SC2, Lloyd A1 | ||||
| 1 IMS Health, London, UK 2 Amylin Pharmaceuticals, San Diego, CA, USA | ||||
| Journal of Medical Economics, 2012;15(6):1-8 |
||||
| , Article | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost utility | |
| Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes | ||||
| Yeaw J1, Lee WC1, Aagren M2, Christensen T2 | ||||
| 1 IMS Health, Redwood City, CA, US 2 Novo Nordisk, Copenhagen, Denmark | ||||
| J Manag Care Pharm. 2012 Jan-Feb;18(1):21-32. |
||||
| , Article | ||||
| , USA | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22235952 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Retrospective database analysis | |
| Cost of self-monitoring of blood glucose in Canada among patients on an insulin regimen for diabetes | ||||
| Yeaw J1, Lee WC1, Wolden ML2, Christensen T2, Groleau D2 | ||||
| 1 IMS Health, Redwood City, CA, US 2 Novo Nordisk, Copenhagen, Denmark | ||||
| Diabetes Ther. 2012 Nov;3(1):7. Epub 2012 Jun 27. |
||||
| , Article | ||||
| , Canada | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/22736405 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Retrospective cohort analysis | |
| Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis | ||||
| Lee WC1, Samyshkin Y2, Langer J3, Palmer JL4 | ||||
| 1IMS Health, Alexandria, VA, USA, 2IMS Health, London, UK, 3Novo Nordisk, Inc., Princeton, NJ, USA, 4IMS Health, Allschwil, Basel, Switzerland | ||||
| Journal of Medical Economics |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost effectiveness | |
| How hypoglycaemicn events can influence diabetic patients'weight and affect HBA1C control | ||||
| Ansolabehere X, Grandfils N, Le Jeunne P, Morlet-Vigier D | ||||
| IMS Health, Puteaux, France | ||||
| ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany |
||||
| , Abstract, Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Retrospective cohort analysis | |
| The burden of diabetes mellitus in Belgium: a retrospective database study. | ||||
| Lamotte M1, Chevalier P1, Gerlier L1 | ||||
| 1 IMS Health, Vilvoorde, Belgium | ||||
| 15th ISPOR Annual European Congress, 2012, November 3-7, Berlin, Germany |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Retrospective database analysis | |
| The cost of diabetes complications in Belgium. | ||||
| Lamotte M1, Chevalier P1 | ||||
| 1 IMS Health, Vilvoorde, Belgium | ||||
| 15th ISPOR Annual European Congress, 2012, November 3-7, Berlin, Germany |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2012 | English | , Cost consequence, Cost of illness | |
| Burden of Chronic Kidney Disease in German Diabetes Patients, a Systematic Literature Review and Data Gap Analysis. | ||||
| Korolewa V1, Hengst N1, Wolff M1, Berger K2, Ehlken B2, Greiner RA2, Eheberg D2, Pfiffner C2 | ||||
| 1 Abbott GmbH & Co.KG, Wiesbaden, Germany 2 IMS Health, Munich, Germany | ||||
| ISPOR 15th Annual European Congress |
||||
| , Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Literature Review | |
| Long-term validation of the IMS Core Diabetes Model in Type 1 and Type 2 Diabetes | ||||
| Foos V1, Palmer JL2, Grant D3, Lloyd A3, Lamotte M4, McEwan P5 | ||||
| IMS Health, Basel, Basel-Stadt, Switzerland, 2IMS Health, Allschwil, Basel-Landschaft, Switzerland, 3IMS Health, London, UK, 4IMS Health, Vilvoorde, Belgium, 5HEOR Consulting, Monmouth, Monmouthshire, UK | ||||
| ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany |
||||
| , Poster | ||||
| Abstract: http://www.ispor.org/congresses/Berlin1112/Posters4.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Methodology | |
| Systematic literature review of utility values associated with Type 2 Diabetes-related complications | ||||
| Beaudet A1, Clegg JP1, Lloyd A2 | ||||
| IMS Health, Basel, BS, Switzerland, 2IMS Health, London, UK | ||||
| ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany |
||||
| , Poster | ||||
| Abstract: http://www.ispor.org/congresses/Berlin1112/Posters4.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Literature Review | |
| HBA1C testing frequency in primary care Diabetes patients in Germany and in the United Kingdom | ||||
| Kostev K, Grunow S, Rockel T | ||||
| IMS Health, Frankfurt am Main, Germany | ||||
| ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany |
||||
| , Poster | ||||
| , Germany | ||||
| Abstract: http://www.ispor.org/congresses/Berlin1112/Posters5.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Retrospective database analysis | |
| Direct medical costs of Diabetes Mellitus in China: Annual cost of illness and long-term projections using a validated diabetes model | ||||
| Palmer JL1, Caputo J2, Foos V1, Grant D3, Lamotte M4, Lloyd A3, McEwan P5 | ||||
| 1 IMS Health, Basel, Switzerland, 2 IMS Health, Singapore, Singapore, 3 IMS Health, London, UK, 4 IMS Health Consulting Group, Vilvoorde, Belgium, 5 HEOR Consulting, Monmouth, Monmouthshire, UK | ||||
| ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan, September 2nd – 4th 2012 |
||||
| , Poster | ||||
| , China | ||||
| Abstract: http://www.ispor.org/conferences/Taipei0912/Posters2.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Cost of illness | |
| Understanding the importance of more insightful HTA submissions | ||||
| Grant D1, McEwan P1 | ||||
| 1IMS Health, London, UK | ||||
| AccessPoint, Nov 2012; Vol 3(5); 37-41 |
||||
| , Article | ||||
| Abstract: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Services/Pharma%20Commercial%20Effectiveness/Health%20Economics%20_%20Outcomes%20Research/AccessPoint-5-281012%20F.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | ||
| A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care. | ||||
| Blak BT1, Smith HT, Hards M, Maguire A & Gimeno V | ||||
| 1Cegedim Strategic Data Medical Research Ltd, London, UK. betina.blak@gmail.com | ||||
| Diabet Med. 2012 Aug;29(8):e191-8. doi: 10.1111/j.1464-5491.2012.03694.x. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22507537 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Retrospective database analysis | |
| Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study. | ||||
| Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K & Lewis JD. | ||||
| Sherwood Forest Hospitals Foundation Trust University of Pennsylvania Department of Medicine | ||||
| J Natl Cancer Inst. 2012 Sep 19;104(18):1411-21. Epub 2012 Aug 9. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529598/pdf/djs328.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Oncology | 2012 | English | , Retrospective database analysis | |
| Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. | ||||
| Idris I, Warren G, Donnelly R. | ||||
| Arch Intern Med. 2012 Jul 9;172(13):1005-11. doi: 10.1001/archinternmed.2012.1938. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22688528 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Ophthalmology | 2012 | English | , Retrospective database analysis | |
| Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study. | ||||
| Hall GC, McMahon AD, Carroll D, Home PD. | ||||
| Grimsdyke House | ||||
| Pharmacoepidemiol Drug Saf. 2012 Mar;21(3):305-13. doi: 10.1002/pds.2345. Epub 2012 Jan 23. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22271442 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Retrospective database analysis | |
| Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. | ||||
| Blak BT1, Smith HT, Hards M, Curtis BH & Ivanyi T | ||||
| 1Cegedim Strategic Data Medical Research Ltd, London, UK. betina.blak@cegedim.com | ||||
| Diabet Med. 2012 Jul;29(7):e13-20. doi: 10.1111/j.1464-5491.2012.03586.x. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22268988 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Retrospective database analysis | |
| Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. | ||||
| Lo Re V 3rd, Haynes K, Ming EE, Wood Ives J, Horne LN, Fortier K, Carbonari DM, Hennessy S, Cardillo S, Reese PP, Reddy KR, Margolis D, Apter A, Kimmel SE, Roy J, Freeman CP, Razzaghi H, Holick CN, Esposito DB, Van Staa TP, Bhullar H & Strom BL. | ||||
| Cegedim | ||||
| Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1202-15. doi: 10.1002/pds.3318. Epub 2012 Jul 5. |
||||
| , Article | ||||
| , UK, USA | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22763953 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2012 | English | , Retrospective database analysis | |
| The impact of treatment non-compliance on mortality in people with type 1 diabetes. | ||||
| Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, Burton CM & Evans M | ||||
| Cardiff University Department of medicine | ||||
| J Diabetes Complications. 2013 May-Jun;27(3):219-23. doi: 10.1016/j.jdiacomp.2012.10.006. Epub 2012 Nov 13. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22511257 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Retrospective database analysis | |
| Therapeutic management of orally treated type 2 diabetic patients, by French general practitioners in 2010: the DIAttitude Study. | ||||
| Halimi S1, Balkau B, Attali C, Detournay B, Amelineau E, Blickle JF. | ||||
| 1CHU Grenoble - Clinique Diabétologie Nutrition Pôle DigiDUNE University Hospital Grenoble University Joseph Fourier | ||||
| Diabetes Metab. 2012 Mar;38 Suppl 3:S36-46. doi: 10.1016/S1262-3636(12)71533-1. |
||||
| , Article | ||||
| , France | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22541601 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Prospective study, Retrospective database analysis | |
| Type 2 diabetes treatment intensification in general practice in France in 2008-2009: the DIAttitude Study. | ||||
| Balkau B1, Bouée S, Avignon A, Vergès B, Chartier I, Amelineau E, Halimi S. | ||||
| 1Inserm, CESP Centre for Research in Epidemiology and Population Health, U1018, Epidemiology of Diabetes, Obesity and Chronic Kidney Disease Over the Lifecourse and Determinants of Early Nutrition, Villejuif, France | ||||
| Diabetes Metab. 2012 Mar;38 Suppl 3:S29-35. doi: 10.1016/S1262-3636(12)71532-X. |
||||
| , Article | ||||
| , France | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22541600 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Prospective study, Retrospective database analysis | |
| Usage of Self-Monitoring of Blood Glucose (SMBG) by Diabetes Therapy Type in Larger Cities in China. | ||||
| Mast O1, Tan A2, Zweyer S2, Perridy D2. | ||||
| 1Roche, Mannheim, Germany 2Cegedim Strategic Data, Shanghai, China | ||||
| ISPOR 5TH ASIA-PACIFIC CONFERENCE , TAIPEI, TAIWAN |
||||
| , Poster | ||||
| , China | ||||
| Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(12)01865-7/abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Compliance, Retrospective database analysis | |
| UTILIZATION OF FPG, HBA1C AND SELF-MONITORING OF BLOOD GLUCOSE (SMBG) IN COMMUNITY HEALTH CENTERS IN THE SHANGHAI AREA. | ||||
| Mast O1, Tan A2 | ||||
| 1Roche, Mannheim, Germany 2Cegedim Strategic Data, Shanghai, China | ||||
| ISPOR 5TH ASIA-PACIFIC CONFERENCE, TAIPEI, TAIWAN |
||||
| , Poster | ||||
| , China | ||||
| Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(12)01866-9/abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Compliance, Survey research | |
| Validation of diabetic retinopathy and maculopathy diagnoses recorded in a U.K. primary care database. | ||||
| Martín-ME, Fortuny J, Rivero E & García LA | ||||
| Centro Español de Investigación Farmacoepidemiológica | ||||
| Diabetes Care. 2012 Apr;35(4):762-7. doi: 10.2337/dc11-2069. Epub 2012 Feb 22. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22357184 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Ophthalmology | 2012 | English | , Retrospective database analysis | |
| Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer | ||||
| Renehan AG, Yeh HC, Johsnon JA, Wild SH, Gale EA, Moller H, Diabetes and Cancer Research Consortium | ||||
| University of Manchester Department of Surgery, School of Cancer and Enabling Sciences | ||||
| Diabetologia. 2012 Jun;55(6):1619-32. doi: 10.1007/s00125-012-2526-0. Epub 2012 Apr 4. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://link.springer.com/article/10.1007/s00125-012-2526-0/fulltext.html | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Oncology | 2012 | English | , Retrospective database analysis | |
| Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. | ||||
| Johnson JA1, Carstensen B2 3, Witte D2, Bowker SL1, Lipscombe L4 & Renehan AG5 | ||||
| 1 School of Public Health, University of Alberta, 2 Steno Diabetes Center, 3 2 Department of Biostatistics, University of Copenhagen 4 Women’s College Hospital, University of Toronto, 5 School of Cancer and Enabling Sciences, University of Manchester | ||||
| Diabetologia. 2012 Jun;55(6):1607-18. doi: 10.1007/s00125-012-2525-1. Epub 2012 Apr 4. |
||||
| , Article | ||||
| , Canada, UK | ||||
| Abstract: http://link.springer.com/article/10.1007/s00125-012-2525-1/fulltext.html | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Oncology | 2012 | English | , Retrospective cohort analysis, Retrospective database analysis | |
| Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease | ||||
| Hall GC, McMahon AD, Carroll D & et al | ||||
| Grimsdyke House | ||||
| PLoS One. 2012;7(11):e49908. doi: 10.1371/journal.pone.0049908. Epub 2012 Nov 14. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0049908 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Vascular disease | 2012 | English | , Retrospective database analysis | |
| GLP-1 Receptor Agonist (GLP1ra) and Insulin Efficacy in Primary Health Care | ||||
| Hall GC, McMahon AD, Dain M-P & et al | ||||
| Sanofi | ||||
| Diabetes 61(S1):A276 |
||||
| , Article | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2012 | English | , Retrospective database analysis | |
| Evaluation of Methods to Estimate Days’ Supply of Oral Antidiabetic Drugs in The Health Improvement Network | ||||
| Haynes K, Fortier K, Newcomb C, Roy J, Ming E, Horne L, Wood-Ives J, Strom B &Lo Re V | ||||
| University of Nottingham | ||||
| 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Barcelona, Spain |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Retrospective database analysis | |
| A new "Comparative Effectiveness" assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone. | ||||
| Tannen R, Xie D, Wang X, Yu M & Weiner MG | ||||
| University of Pennsylvania School of Medicine | ||||
| Pharmacoepidemiology and Drug Safety 22(1):86-96 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23070833 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Retrospective database analysis | |
| Better analyze the determinants of therapeutic inertia to overcome it | ||||
| Halimia S, Balkaub B. | ||||
| Department of Diabetology,Grenoble University Hospital Center, Grenoble, France | ||||
| Diabetes Metab. 2012 Mar;38 Suppl 3:S27-8. doi: 10.1016/S1262-3636(12)71531-8. |
||||
| , Article | ||||
| , France | ||||
| Abstract: http://www.em-consulte.com/en/article/709573 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Prospective study, Retrospective database analysis, Survey research | |
| Direct medical costs of diabetes-related complications in Saudi Arabia | ||||
| 1. Hnoosh A IMS Health, HEOR, London, UK 2. Vega-Hernández G IMS Health, HEOR, London, UK 3. Jugrin A IMS Health, HEOR, London, UK 4. Todorova L Novo Nordisk International Operations, Zürich, Switzerland | ||||
| IMS Health HEOR and Novo Nordisk International Operations, Zurich | ||||
| ISPOR 17th Annual International Meeting, Washington, USA |
||||
| , Conference, Poster | ||||
| , Saudi Arabia | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Literature Review | |
| Ims LifeLinkTM cohorte diabète : validité et utilité | ||||
| Le Jeunne P1 | ||||
| 1IMS Health, Paris La Défense France | ||||
| Le revue du Praticien médecine générale 2012 Nov; 26: n° 889 |
||||
| , Article | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | French | ||
| Ims LifeLinkTM cohorte diabète : validité et utilité | ||||
| Le Jeunne P1 | ||||
| 1IMS Health, Paris La Défense France | ||||
| Le revue du Praticien médecine générale 2012 Nov; 26: n° 889 |
||||
| , Article | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Retrospective database analysis | |
| Optimisation of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin | ||||
| Blak B, Hards M, Smith HT, Curtis BH, Ivanyi T | ||||
| Diabetic Medicine 2012 Jul;29(7):e13-20 |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| Rationale and design of the Multinational Observational Study Assessing Insulin use: the MOSAIc study | ||||
| Polinski JM, Curtis BH, Seeger JD, Choudhry NK, Zagar A, Shrank WH | ||||
| BMC Endocr Dis 2012; 12: 20 |
||||
| , Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| Weight gain within the first year after new onset diabetes is associated with risk of cardiovascular mortality: a cohort of 8,326 primary care patients. | ||||
| Bodegard J1, Sundström J2, Svennblad B3, Östgren C4, Nilsson PM5, Johansson G2 | ||||
| 1 Medical Department, AstraZeneca, Oslo, Norway, 2 Uppsala University, Sweden, 3 Uppsala Clinical Research Center, Sweden, 4 Linköping University, Sweden, 5Lund University, Sweden | ||||
| 48th EASD Annual Meeting of the European Association for the Study of Diabetes; 2012; Berlin, Germany |
||||
| , Abstract | ||||
| , Sweden | ||||
| Abstract: http://www.easdvirtualmeeting.org/resources/weight-gain-within-the-first-year-after-new-onset-diabetes-is-associated-with-risk-of-cardiovascular-mortality-a-cohort-of-8-326-primary-care-patients | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Real World Evidence | |
| The risk of first severe hypoglycaemia depends on the type of basal insulin but does not differ between patients with type 1 and type 2 diabetes: The EpiHypo Study | ||||
| Korhonen P, Haukka J, Hoti F, Erästö P, Mäkimattila S, Saukkonen T | ||||
| EPID Research Ltd, Espoo, Finland | ||||
| Diabetologia (2012);55: (Suppl 1): S254 |
||||
| , Poster | ||||
| , Finland | ||||
| Abstract: https://www.easd.org/virtualmeeting/home.html#!resources/the-risk-of-first-severe-hypoglycaemia-depends-on-the-type-of-basal-insulin-but-does-not-differ-between-patients-with-type-1-and-type-2-diabetes-the-epihypo-study--2 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Clinical setting: hospital, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective database analysis | |
| Type of Insulin and Age are Predictors of Hospitalization due to Severe Hypoglycemia: The EpiHypo Study | ||||
| Mäkimattila S, Korhonen P, Haukka J, Hoti F, Pajunen P, Saukkonen T | ||||
| EPID Research Ltd, Espoo, Finland | ||||
| Diabetes (2012);61:A101-A102 |
||||
| , Poster | ||||
| , Finland | ||||
| Abstract: http://diabetes.diabetesjournals.org/content/diabetes/61/Supplement_1/A99.full.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Clinical setting: hospital, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective database analysis | |
| Automated data extraction—A feasible way to construct patient registers of primary care utilization | ||||
| Martinell M, Stalhammar J, Hallqvist J | ||||
| Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden | ||||
| Upsala Journal of Medical Sciences (2012);117(1):52-56 |
||||
| , Article | ||||
| , Sweden | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282243/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Clinical setting: Primary care, Real World Evidence | |
| Risk of First Severe Hypoglycaemic (SH) Coma Event among Patients with Diabetes Who Initiate the Use of Detemir (IDet), Glargine (IGla) and NPH Insulins: A Nationwide Register-Linkage Study in Finland | ||||
| Korhonen P, Hoti F, Erästö P, Mäkimattila S, Saukkonen T, Haukka J | ||||
| EPID Research Ltd, Espoo, Finland | ||||
| PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012) 21: (Suppl 3): 27-27 |
||||
| , Abstract | ||||
| , Finland | ||||
| Abstract: https://onlinelibrary.wiley.com/doi/epdf/10.1002/pds.3324 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Population Based Study, Retrospective database analysis | |
| Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. | ||||
| Valentine WJ1, Aagren M2, Haglund M3-4, Ericsson A3, Gschwend MH5 | ||||
| 1Ossian Health Economics and Communication, Basel, Switzerland, 2Novo Nordisk Inc., Princeton, NJ, USA, 3Novo Nordisk Scandinavia AB, Malmo, Sweden, 4NeuroSearch A/S, Ballerup, Denmark and 5IMS Health, Basel, Switzerland | ||||
| Scandinavian journal of public health |
||||
| , Manuscript in preparation | ||||
| , Nordic, Switzerland | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20688795 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost effectiveness | |
| Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis | ||||
| Guillermin A1, Samyshkin Y1, Wright D1, Nguyen T1, Villeneuve J2 | ||||
| 1 IMS Health, London, UK 2 Sanofi-Aventis, Laval, Canada | ||||
| Journal of Medical Economics 2011; 14(2):207-216 |
||||
| , Article | ||||
| , Canada | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/21361858 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost minimization, Meta analysis | |
| Cost of all-cause and cardiovascular disease-related hospitalization in patients with type 2 diabetes treated with exenatide BID, sulfonylureas, or insulin: a retrospective analysis of the LifeLink™ Database. | ||||
| Best JH1, Pelletier EM2, Smith DB2 | ||||
| 1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2IMS Health, Watertown, MA, USA | ||||
| International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting, 2011, May, Baltimore, MD, USA |
||||
| , Abstract, Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost analysis, Retrospective cohort analysis, Retrospective database analysis | |
| Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the GLP-1 receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink™ database. | ||||
| Best JH1, Hoogwerf BJ2, Herman WH3, Pelletier EM4, Smith DB4, Wenten M1, Hussein MA5 | ||||
| 1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3University of Michigan, Ann Arbor, MI, USA, 4IMS Health, Watertown, MA, USA, 5IMS Health, Falls Church, VA, USA | ||||
| Diabetes Care 2011;34(1):90-95; 2012 Oct 7 (Epub ahead of print) |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost analysis, Retrospective cohort analysis, Retrospective database analysis | |
| Insulin glargin reduziert das Risiko für ein diabetisches Fußsyndrom und makrovaskuläre Komplikationen [Insuline glargine reduces the risk of diabetic food syndorme and maro-vascular disease] | ||||
| Siegmund T1, Dippel,FW2, Kostev,K3, Lauterbach, S4, Fuchs, S5, Kotowa, W5 | ||||
| 1 Städtisches Klinikum München GmbH 2 Sanofi-Aventis Deutschland GmbH, Berlin 3 IMS Health GmbH & Co, OHG, Frankfurt/Main 4 Apotheke Rotes-Kreuz-Krankenhaus, Kassel 5 IMS Health GmbH & Co, OHG, Health Economics & Outcomes Research, Nürnberg | ||||
| Perfusion 2011; 24: 44–52 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | German | , Retrospective database analysis | |
| Exenatide (Bid) and Liraglutide (Qd) treatment patterns among type-2 diabetes patients in Germany. | ||||
| Miller L, Burudpakdee C, Zagar A, Bhosle M, Reaney M, Schabert V | ||||
| Eli Lilly and Company, Indianapolis, IN, USA; IMS Health Incorporated, Falls Church, VA, USA;Eli Lilly and Company, Windlesham, Surrey, UK | ||||
| ISPOR 16th Annual International Meeting, Baltimore, MD, USA |
||||
| , Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Retrospective database analysis | |
| Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. | ||||
| Lee WC1, Conner C2, Hammer M3. | ||||
| 1 Health Economics & Outcomes Research, IMS Health, Falls Church, VA, USA 2 Novo Nordisk Inc., Princeton, New Jersey, USA 3 Novo Nordisk A/S, Soborg, Denmark | ||||
| Curr Med Res Opin. 2011 Feb 25. |
||||
| , Article | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost effectiveness | |
| Ermittlung der tatsächlichen Tagesdosierung von Liraglutid (PDD) unter realen Versorgungsbedingungen im Hinblick auf die Berechnung von Tagestherapiekosten | ||||
| Fuchs S, Kostev K, Seitz L, Wohlleben M | ||||
| 46. Jahrestagung der Deutschen-Diabetes-Gesellschaft (Juni 2011) |
||||
| , Abstract, Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | German | ||
| Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. | ||||
| Beaudet A1, Palmer JL1, Timlin L2, Wilson B3, Bruhn D4, Boye KS4, Lloyd A5 | ||||
| 1 IMS Health, Basel, Switzerland, 2 Lilly UK, Windlesham, Surrey, UK, 3 Lilly UK, Basingstoke, UK, 4 Eli Lilly & Co, Indianapolis, IN, USA, 5 IMS Health, London, UK | ||||
| Journal of Medical Economics |
||||
| , Manuscript in preparation | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost effectiveness | |
| Basal Supported Oral Therapy with Insulin Glargine Results in Longer Persistence and Lower Costs Compared with Insulin Detemir in Type 2 Diabetics in Germany | ||||
| Pfohl M1, Dippel F-W2, Kostev K3, Fuchs S4, Kotowa W4 | ||||
| 1 Evangelisches Bethesda-Johanniter-Klinikum Duisburg GmbH, Duisburg, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS Health GmbH & Co, OHG, Frankfurt/Main, Germany 4 IMS Health GmbH & Co, OHG, Health Economics & Outcomes Research, Nürnberg, Germany | ||||
| Health Outcomes Research in Medicine; 2(1):e39-e50 |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: http://www.healthoutcomesresearch.org/article/S1877-1319(11)00002-4/abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost consequence | |
| Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK | ||||
| Beaudet A1, Palmer JL1, Timlin L2, Wilson B3, Bruhn D4, Boye KS4, Lloyd A5 | ||||
| 1 IMS Health, Basel, Switzerland 2 Lilly UK, Windlesham, Surrey, UK 3 Lilly UK, Basingstoke, UK 4 Eli Lilly & Co, Indianapolis, IN, USA 5 IMS Health, London, UK | ||||
| Journal of Medical Economics 2011; 14(3):357-366 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=Beaudet+A%5Bfirst+author%5D+AND+diabetes&TransSchema=title&cmd=detailssearch | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost utility | |
| Basal Supported Oral Therapy with Insulin Glargine Results in Longer Persistence and Lower Costs Compared with Insulin Detemir in Type 2 Diabetics in Germany | ||||
| Pfohl M1, Dippel F-W2, Kostev K3, Fuchs S4, Kotowa W4 | ||||
| 1 Evangelisches Bethesda-Johanniter-Klinikum Duisburg GmbH, Duisburg, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS Health GmbH & Co, OHG, Frankfurt/Main, Germany 4 IMS Health GmbH & Co, OHG, Health Economics & Outcomes Research, Nürnberg, Germany | ||||
| Health Outcomes Research in Medicine Volume 2, Issue 1, Pages e39-e50 |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: http://www.healthoutcomesresearch.org/article/S1877-1319(11)00002-4/abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | ||
| Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta-analysis studies. | ||||
| Foos V1, Lloyd A2, Freemantle N3, Grant D2, Herman W4. | ||||
| 1 IMS Health, Basel, Switzerland, 2 IMS Health, London, UK, 3 University College London, UK, 4 University of Michigan, Ann Arbor, MI, USA | ||||
| 47th EASD Annual Meeting, Lisbon, Portugal, 12 - 16 September 2011 |
||||
| , Oral presentation | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Meta analysis | |
| Estimating the impact of different methods of utility assessment on the value of interventions in Type 2 diabetes | ||||
| Lloyd A1, Foos V2, Donatti C1, Grant D1, Herman W3 | ||||
| 1 IMS London, UK 2 IMS Basel, Switzerland 3 University of Michigan, Ann Arbor, MI, USA | ||||
| 47th EASD Annual Meeting, Lisbon, Portugal, 12 - 16 September 2011 |
||||
| , Oral presentation | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Utility analysis | |
| Duration of time off paid employment associated with diabetes-related complications | ||||
| Beaudet A1, Myrén K-J2, Grant D3, Lloyd A3 | ||||
| 1 IMS Health, Basel, Switzerland, 2 IMS Health, Stockholm, Sweden, 3 IMS, Health, London, UK | ||||
| 47th EASD Annual Meeting, Lisbon, Portugal, 12 - 16 September 2011 |
||||
| , Poster | ||||
| , Sweden | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Observational study | |
| Projected cost-effectiveness of exenatide once weekly versus exenatide BID for the treatment of type 2 diabetes in the UK | ||||
| Wilson BP1,Beaudet A2,Caputo J3, Timlin L1 | ||||
| 1 Eli Lilly and Company Ltd, Erl Wood, UK 2 IMS Consulting Group, Basel, Switzerland 3 IMS Consulting Group, London, UK | ||||
| ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost effectiveness | |
| Projected long-term clinical and economic outcomes of exenatide once weekly versus sitagliptin for the treatment of type 2 diabetes in the UK | ||||
| Beaudet A1, Wilson BP2, Caputo J3, Timlin2 | ||||
| 1 IMS Consulting Group Basel, Switzerland 2 Eli Lilly and Company Ltd, Erl Wood, UK 3 IMS Consulting Group, London, UK | ||||
| ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost effectiveness | |
| Estimating the Real Life Daily Usage and Daily Cost of Glp-1 Receptor Agonists in the UK setting | ||||
| McDonell A1, Zammit DC2, Haslam T1, Gregor Z3, Wilson BP4 | ||||
| 1IMS Health, London, United Kingdom 2 IMS Health, Basel, Switzerland 3 Eli Lilly & Company, Prague, Czech Republic 4 LILLY UK, Hampshire, United Kingdom | ||||
| ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain |
||||
| , Oral presentation, Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost analysis | |
| Estimating the Direct Costs of Type 2 Diabetes in Saudi Arabia | ||||
| Babineaux S1, Fakhoury W2, McDonell A3, Kotchie R3, Ali M4. | ||||
| 1 Eli Lilly and Company, Indianapolis, USA 2 Eli Lilly and Company, Erl Wood, UK 3 IMS Health, London, UK 4 IMS Health, Riyadh, Saudi Arabia | ||||
| World Diabetes Congress, 4 - 8 December 2011, Dubai |
||||
| , Oral presentation | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Economic evaluation | |
| Anti-diabetic therapeutic strategies for type 2 diabetes patients with chronic kidney disease in France. | ||||
| Amalric F1, Attali C2, Joly D3, Simon D4, Vergès B5, Grandfils N1, Briand Y6 | ||||
| 1 IMS Health, Paris, France 2 Epinay-sous-Dénart, France 3 Hôpital Necker, Paris, France 4 Hôpital Robert Debré, Paris, France 5. Hôpital du Bocage, Dijon, France 6. Boehringer Ingelheim France, Paris, France | ||||
| Abstract - Presentation PDB63 for the 14th European congress of Ispor 2011 |
||||
| , Abstract | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Clinical practice, Diabetes | 2011 | English | , Retrospective database analysis | |
| Healthcare costs associated with treatment modification in type 2 diabetes mellitus patients taking oral anti-diabetic drugs. | ||||
| Krishnarajah G, Bhosle M, Chapman R. | ||||
| Bristol Myers Squibb, IMS Health | ||||
| Managed Care 2011; 20(6):42-48 |
||||
| , Article | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost analysis | |
| Economic evaluation of Ranibizumab in the treatment of visual impairment due to diabetic macular edema in Austria | ||||
| Brennig C1, Schöllbauer V1, Walter E1, Gallagher M2, Knudsen MS3 | ||||
| 1Institute for Pharmaeconomic Research, Vienna, Austria, 2Novartis Pharma AG, Basel, Switzerland, 3IMS Health, London, UK | ||||
| ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain |
||||
| , Poster | ||||
| , Austria | ||||
| Abstract: http://www.ispor.org/congresses/Spain1111/Posters3.aspx PDB38 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Economic evaluation | |
| Assessment of utility loss from diabetic macular edema based on RESTORE trial. | ||||
| Knudsen MS1, Thomas S2, Gallagher M3, Mitchell P4 | ||||
| 1IMS Health, London, UK, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Novartis Pharma AG, Basel, Switzerland, 4University of Sydney, Westmead, Australia | ||||
| ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain |
||||
| , Poster | ||||
| Abstract: http://www.ispor.org/congresses/Spain1111/Posters3.aspx PSS30 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost utility | |
| Cost-effectiveness of transferring Type-2 Diabetic patients from Neutral Protamine Hagedorn (NPH) To Detemir in Portugal settings | ||||
| Carvalho D1, Lindner L2, Kozarzewski M3 | ||||
| 1São João Hospital, Porto, Porto, Portugal, 2IMS Health, Barcelona, Cataluña, Spain, 3Novo Nordisk Portugal, Lisboa, Lisboa, Portugal | ||||
| ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain |
||||
| , Poster | ||||
| , Portugal | ||||
| Abstract: http://www.ispor.org/congresses/Spain1111/Posters3.aspx PDB45 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost effectiveness | |
| Development of a new measure for assessing Health Related Quality Of Life (HRQOL) in patients with Primary Hyperparathyroidism (PHPQOL) | ||||
| Farrerons J1, Muñoz M2, Puig M3, Villabona C4, Webb S5, Badia X6 | ||||
| 1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Hospital San Cecilio, Granada, Spain, 3Hospital Germans Trias i Pujol, Badalona, Spain, 4Hospital Universitari de Bellvitge, Hospitalet del Llobregat, Spain, 5Hospital de la Santa Creu i Sant Pau and CIBERER, Barcelona, Spain, 6IMS Health S.A, Barcelona, Spain | ||||
| ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain |
||||
| , Poster | ||||
| Abstract: http://www.ispor.org/congresses/Spain1111/Posters3.aspx PDB56 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Quality of life | |
| Exenatide (BID) and liraglutide (QD) treatment patterns among patients with Type 2 diabetes in Germany. | ||||
| Miller LA1, Burudpakdee C2, Zagar A1, Bhosle M3, Reaney M4, Schabert VF3. | ||||
| 1Eli Lilly and Company, Indianapolis, IN, USA, 2IMS Consulting, Falls Church, VA, USA, 3IMS Health, Falls Church, VA, USA, 4Eli Lilly and Company, Surrey, UK | ||||
| 16th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) |
||||
| , Poster | ||||
| , Germany | ||||
| Abstract: http://www.ispor.org/meetings/baltimore0511/Posters2.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | ||
| Relative Risk of Acute Pancreatitis in Initiators of Exenatide BID Compared to Other Antidiabetic Medication: A Follow-up Study. | ||||
| Wenten M1, Gaebler JA1, Hussein M2, Pelletier EM2, Smith DB2, Girase P2, Noel RA3, Braun DK3, Bloomgren GL1 | ||||
| 1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2IMS Health Incorporated, Watertown, MA, USA, 3Eli Lilly and Company, Indianapolis, IN, USA | ||||
| Diabet Med 2012 [in press]; 2012 Mar 12 [Epub ahead of print] |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Retrospective cohort analysis, Retrospective database analysis | |
| Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes (T2DM) | ||||
| Fonda J.S1, Graham C2, Samyshkin Y3, Munakata J3, Powers J3, Price D2, Vigersky R.A1 | ||||
| 1Diabetes Institute, Endocrinology Service, Walter Reed National Military Medical Center (Washington ,DC), 2Dexcom, Inc. (San Diego), 3IMS Health, (London, Redwood City, & Alexandria) | ||||
| , Poster | ||||
| Abstract: http://www.dexcom.com/research/create-clinical-research-2 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Cost effectiveness | |
| Systolic and diastolic blood pressure levels associated with lowest risk in type 2 diabetes: a cohort study of 37,798 primary care patients | ||||
| Sundström1 J2, Östgren CJ3, Svennblad B2, Sheikhi R1, Bodegård J4, Nilsson PM5, Johansson G6 | ||||
| 1Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden, 3Department of Medical and Health Sciences, Linköping University, Linköping, Sweden, 4AstraZeneca Nordic, Södertälje, Sweden, 5Department of Clinical Sciences, Lund University, Lund, Sweden, 6Department of Public Health & Caring Sciences, Uppsala University, Uppsala, Sweden | ||||
| 47th EASD Annual Meeting, Lisbon, Portugal. Presentation 53, Tuesday, Sep 13, 2011. |
||||
| , Presentation | ||||
| , Sweden | ||||
| Abstract: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=237d5d03-5ca2-4781-b2af-ae93644fb307&cKey=e87414dc-b005-45f9-a81e-84610372dcf1&mKey=%7bBAFB2746-B0DD-4110-8588-E385FAF957B7%7d | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2011 | English | , Retrospective cohort analysis | |
| Type II diabetes cost of illness study | ||||
| S. Babineaux1, W. Fakhoury2, A. McDonell3, R. Kotchie3, M. Ali4. | ||||
| 1Eli Lilly and Company, Global Health Outcomes, Indianapolis IN, USA. 2Eli Lilly and Company, Global Health Outcomes, Erl Wood, United Kingdom. 3IMS Health, UK, London, United Kingdom. 4IMS Health, Saudi Arabia, Riyadh, Saudi Arabia. | ||||
| World Diabetes Congress December 2011, Dubai, UAE |
||||
| , Conference, Poster | ||||
| , Saudi Arabia | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Literature Review | |
| External validation of QDSCORE(®) for predicting the 10-year risk of developing Type 2 diabetes. | ||||
| Collins GS & Altman DG | ||||
| Diabet Med. 2011 May;28(5):599-607. doi: 10.1111/j.1464-5491.2011.03237.x. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21480970 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | ||
| Les pratiques d’intensification thérapeutique dans le diabète de type 2, en France, en médecine générale. | ||||
| Balkaua Ba,b, Avignonc Ac, Vergèsd Bd, Bouéee Se, Chartierf If, Amelineaug Eg, Halimih Sh | ||||
| INSERM U1018, Center for Research in Epidemiology and Population Health, Villejuif, France Paris-South University, Villejuif, France University of Versailles Saint-Quentin-en-Yvelines, Versailles, France. | ||||
| Diabetes & Metabolism 03/2011; 59. DOI: 10.1016/j.respe.2011.08.050 |
||||
| , Oral communication | ||||
| , France | ||||
| Abstract: http://www.researchgate.net/publication/251590567_Les_pratiques_dintensification_thrapeutique_dans_le_diabte_de_type_2_en_France_en_mdecine_gnrale | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | French | , Prospective study, Retrospective database analysis | |
| The Use of Large GPs Longitudinal Database in the Reasearch of Causal Associations Among Pathologies: The Case of Diabetes and Cancer Incidence. | ||||
| Katz P, Ripellino C., Heiman F., Chatenoud F. | ||||
| Value in Health. 11/2011; 14(7). DOI: 10.1016/j.jval.2011.08.1293 |
||||
| , Article | ||||
| Abstract: http://www.researchgate.net/publication/238509387_PCN194_The_Use_of_Large_GPs_Longitudinal_Database_in_the_Reasearch_of_Causal_Associations_Among_Pathologies_The_Case_of_Diabetes_and_Cancer_Incidence | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Oncology | 2011 | English | ||
| A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes | ||||
| Hall GC, McMahon AD, Dain MP & Home PD | ||||
| Grimsdyke House, London | ||||
| Diabetes Res Clin Pract. 2011 Dec;94(3):442-8. doi: 10.1016/j.diabres.2011.09.003. Epub 2011 Oct 2. |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21963105 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Retrospective database analysis | |
| Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning | ||||
| Hall GC, Smith HT, Curtis B & McMahon AD | ||||
| Grimsdyke House, London | ||||
| Int J Clin Pract. 2011 May;65(5):586-91. doi: 10.1111/j.1742-1241.2011.02648.x. |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21489082 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , Retrospective database analysis | |
| The use of large GPs longitudinal database in the research of causal associations among pathologies : the case of diabetes and cancer incidence | ||||
| Katz P 1, Ripellino C 1, Heiman F 1, Chatenoud L. 2 | ||||
| 1 CSD Medical Research srl, Milan, Italy, 2 Istituto di Ricerche Farmacologiche, Milan, Italy | ||||
| ISPOR Annual European Congress, Madrid, 2011 |
||||
| , Poster | ||||
| , Italy | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Oncology | 2011 | English | , Retrospective database analysis | |
| A national survey on aspirin patterns of use and persistence in community outpatients in Italy. | ||||
| Filippi A1, Bianchi C, Parazzini F, Cricelli C, Sessa E, Mazzaglia G. | ||||
| 1Italian College of General Practitioners, Florence, Italy. | ||||
| Eur J Cardiovasc Prev Rehabil. 2011 Oct;18(5):695-703 |
||||
| , Abstract | ||||
| , Italy | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2011 | English | , Retrospective Field Study | |
| The European network of centres for pharmacoepidemiology and pharmacovigilance: Application to diabetes and vascular disease | ||||
| Blake KV, Smeraldi C, Kurz X, Arlett P, Blackburn S, Fitt H | ||||
| British Journal of Diabetes and Vascular Disease. 2011;11(6):304-7 |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2011 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| Association of HbA1c with the risk of cardiovascular events in patients with type 2 diabetes: a cohort study of 40, 204 patients in primary care. | ||||
| Östgren C1, Sundstrom C2, Svennblad B3, Lohm L4, Nilsson P5, Johansson G2 | ||||
| 1 Linköping University, Linköping, Sweden 2 Uppsala University, Uppsala, Sweden 3 Uppsala Clinical Research Center, Uppsala, Sweden 4 AstraZeneca Nordic, Södertälje, Sweden 5 Malmö University Hospital, Malmö, Sweden | ||||
| European Association for Study of Diabetes, Annual Meeting 2011, Lisbon, Portugal |
||||
| , Oral presentation | ||||
| , Sweden | ||||
| Abstract: http://www.easdvirtualmeeting.org/resources/association-of-hba1c-with-the-risk-of-cardiovascular-events-in-patients-with-type-2-diabetes-a-cohort-study-of-40-204-patients-in-primary-care | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2011 | English | , Real World Evidence | |
| Kosteneffektivität von Pioglitazon bei Patienten mit Typ-2-Diabetes und makrovaskulären Vorerkrankungen in Deutschland [Cost-Effectiveness of Pioglitazone in Patients with Type 2 Diabetes and a History of Macrovascular Disease in Germany] | ||||
| Bierwirth R1, Liebl A2, Gschwend MH3 | ||||
| 1 Diabetes-Praxis, Essen 2 Diabetes- und Stoffwechselzentrum, m & i-Fachklinik Bad Heilbrunn 3 IMS Health, Allschwil, Schweiz | ||||
| Diabetologie und Stoffwechsel 2010;5(1):32-39 |
||||
| , Manuscript in preparation | ||||
| , Germany | ||||
| Abstract: https://www.thieme-connect.de/DOI/DOI?10.1055/s-0029-1224723 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | German | , Cost effectiveness | |
| Glycaemic control and insulin utilization in UK patients with type 2 Diabetes initiated on either Biphasic Insulin Aspart 30 or Biphasic Human Insulin 30 | ||||
| Fakhoury W1, Richter H2, Christensen T3, Thomsen TL4, Irwin D5, Anderson P1 | ||||
| 1IMS Health, London, UK, 2IMS Health GmbH & Co. OHG, Frankfurt am Main, Germany, 3Novo Nordisk, Virum, Denmark, 4Novo Nordisk A/S, Virum, Denmark, 5University of North Carolina – Chapel Hill, Chapel Hill, NC, USA | ||||
| ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA |
||||
| , Poster | ||||
| , UK | ||||
| Abstract: http://www.ispor.org/meetings/atlanta0510/Posters1.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| Risk of cardiovascular events in patients with diabetes treated with exenatide or thiazolidinediones: a retrospective analysis of the pharmetrics database. | ||||
| Best JH1, Pelletier EM2, Hoogwerf BJ3, Herman WH4, DeYoung MB1, Smith DB2, Yushmanova I1, Hussein M5 | ||||
| 1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2IMS Health, Watertown, MA, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4University of Michigan, Ann Arbor, MI, USA, 5IMS Health, Falls Church, VA, USA | ||||
| ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA |
||||
| , Poster | ||||
| , USA | ||||
| Abstract: http://www.ispor.org/meetings/atlanta0510/Posters1.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective cohort analysis, Retrospective database analysis | |
| PDB78 Randomized clinical trial (RCT) design and analytic issues impacting assumed clinical effects and results of cost-effectiveness analyses: Illustration from a recent Canadian report on the cost-effectiveness of blood glucose test strips for type 2 diabetes. | ||||
| Tunis S | ||||
| IMS Health Inc., Falls Church, VA, USA | ||||
| ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA Value in Health, 2010, 13(3): A68 |
||||
| , Poster | ||||
| , Canada | ||||
| Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(10)72320-2/abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Cost effectiveness | |
| Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. | ||||
| Palmer JL1, Knudsen MS2, Aagren M3, Thomsen TL4. | ||||
| 1 IMS Health, Basel, Switzerland 2 IMS Health, London, UK 3 Novo Nordisk Inc., Princeton, NJ, USA 4 Novo Nordisk A/S, Virum, Denmark | ||||
| J Med Econ. 2010;13(2):212-20. |
||||
| , Article | ||||
| , USA | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/sites/entrez | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , , Cost effectiveness | |
| Risk of cardiovascular events in patients with diabetes treated with exenatide or other glucose-lowering therapies: a retrospective analysis of the PharMetrics database. | ||||
| Best JH1, Pelletier EM2, Herman WH3, Hoogwerf BJ4, Smith DB2, Wenten M1, Hussein MA2 | ||||
| 1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2IMS Health, Watertown, MA, USA, 3University of Michigan, Ann Arbor, MI, USA, 4Eli Lilly and Company, Indianapolis, IN, USA, 5IMS Health, Falls Church, VA, USA | ||||
| American Diabetes Association (ADA) 70th Scientific Sessions, June 25-29, 2010, Orlando, FL, USA |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective cohort analysis, Retrospective database analysis | |
| Krebsinzidenz bei insulinpflichtigen Diabetikern in Deutschland – eine Analyse der Publikation von Hemkens et al. anhand der STROBE-Qualitätskriterien [Cancer incidence for insulin-dependent diabetics in Germany - an analysis of the publication of Hemkens et al. based on the STROBE criteria] | ||||
| Fuchs S1, Fricke F-U1,2, Pirk O1 | ||||
| 1 IMS Health GmbH & Co. OHG, Nuremberg, Germany 2 Georg Simon Ohm University, Nuremberg, Germany | ||||
| Perfusion 2010; 23: 4-10 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Oncology | 2010 | German | , Literature Review | |
| Starting an insulin therapy with glargine leads to lower long-term treatment costs compared to detemir in German type-2-diabetics: Results of a model approach | ||||
| Pfohl M1, Dippel F-W2, Reichelt A3, Kostev K4, Fuchs S3, Kotowa W3 | ||||
| 1 Evangelisches Bethesda-Johanniter-Klinikum GmbH, Duisburg, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS HEALTH GmbH & Co. OHG, Nuremberg, Germany 4 IMS HEALTH GmbH & Co. OHG, Frankfurt, Germany | ||||
| American Diabetes Association, 70th Scientific Sessions Abstract Book, 2010 |
||||
| , Abstract | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Cost effectiveness | |
| Prädiktoren für die Initiierung einer basalunterstützten oralen Therapie (BOT) bei Patienten mit Diabetes mellitus Typ 2 unter realen Versorgungsbedingungen [Predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions] | ||||
| Hammer H1, Dippel F-W2, Kostev K3, Fuchs S4, Kotowa W4 | ||||
| 1 Facharzt für Innere Medizin und Diabetologie, Bremen, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS HEALTH GmbH & Co. OHG, Frankfurt/Main, Germany 4 IMS HEALTH GmbH & Co. OHG, Nuremberg, Germany | ||||
| 45th annual conference of the DDG, Stuttgart, Germany, 12. – 15. May, 2010 |
||||
| , Abstract, Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | German | , Retrospective cohort analysis | |
| Insulin Glargin reduziert das Risiko eines diabetischen Fußsyndroms sowie makrovaskulärer Komplikationen bei Typ-2-Diabetikern [Insulin glargine reduces the risk of a diabetic foot syndrome and macrovascular complications of type 2 diabetes] | ||||
| Martin S1, Dippel FW2, Kostev K3, Lauterbach S4, Fuchs S5, Kotowa W5 | ||||
| 1 Sana Kliniken Düsseldorf GmbH, Düsseldorf, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS HEALTH GmbH & Co. OHG, Frankfurt/Main, Germany 4 Apotheke Rotes-Kreuz-Krankenhaus, Kassel, Germany 5 IMS HEALTH GmbH & Co. OHG, Nuremberg, Germany | ||||
| 45th annual congress of the DDG, Stuttgart, Germany, 12. -15. May, 2010 |
||||
| , Abstract, Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | German | , Retrospective cohort analysis | |
| Längere Verweildauer auf einer basalunterstützten oralen Therapie mit Insulin glargin (BOT) im Vergleich zu einer Kombinationstherapie aus Insulindetemir und oralen Antidiabetika [Longer length of stay for a basal supporting oral therapy with insulin glargine compared to a combination therapy of insulin detemir and oral antidiabetics] | ||||
| Pfohl M1, Dippel F-W2, Kostev K³, Pirk O4, Reichelt A4, Kotowa W4 | ||||
| 1Evangelisches Bethesda-Johanniter-Klinikum Duisburg GmbH, Duisburg, Germany 2Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3IMS Health GmbH & Co. OHG, Frankfurt, Germany 4 IMS Health GmbH & Co. OHG, Nürnberg, Germany | ||||
| 2nd annual conference of the Deutschen Gesellschaft für Gesundheitsökonomie (dggö) [German Association for Health Economics], Berlin, Germany, 1.-2.- March, 2010 |
||||
| , Abstract | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | German | , Retrospective database analysis | |
| A retrospective cohort study to assess the relative risk of acute pancreatitis among initiators of exenatide compared to initiators of other anti-diabetic medication: a follow-up study. | ||||
| Wenten M1, Gaebler JA1, Pelletier EM2, Smith DB2, Girase P2, Noel R3, Braun D3, Bloomgren G1, Hussein MA4 | ||||
| 1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2IMS Health, Watertown, MA, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4IMS Health, Falls Church, VA, USA | ||||
| ISPE 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 19-22, 2010, Brighton, England, UK |
||||
| , Podium presentation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective cohort analysis, Retrospective database analysis | |
| German real-life data indicate lower costs for basal supported oral therapy (BOT) with insulin glargine compared to combination therapy with exenatide and oral antidiabetic drugs | ||||
| Fuchs S1, Dippel FW2, Kostev K3, Kotowa W1 | ||||
| 1 IMS HEALTH GmbH & Co. OHG, Nuremberg, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS Health GmbH & Co. OHG, Frankfurt/Main, Germany | ||||
| 46th EASD Annual Meeting, Stockholm, Sweden, 20.-24. September, 2010 |
||||
| , Abstract, Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective cohort analysis | |
| Resource utilization and diabetes-related treatment costs of type-1-diabetics treated with ICT based on insulin glargine, insulindetemir or NPH insulin in Germany | ||||
| Bierwirth R1, Dippel FW2, Kostev K3, Fuchs S4, Kotowa W4 | ||||
| 1 Ambulantes Diabeteszentrum am Elisabth-Krankenhaus, Essen, Germany, 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS Health GmbH & Co. OHG, Frankfurt, Germany 4 IMS Health GmbH & Co. OHG, Nuremberg, Germany | ||||
| 46th EASD Annual Meeting, Stockholm, Sweden, September 20-24, 2010 |
||||
| , Abstract, Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Cost analysis | |
| Ressourcenverbrauch und Behandlungskosten unter einer intensivierten konventionellen Therapie (ICT) mit Insulin glargin, Insulindetemir oder NPH-Insulin bei Patienten mit Typ-1-Diabetes [Resource utilization and diabetes-related treatment costs of type-1-diabetics treated with ICT based on insulin glargine, insulin detemir or NPH insulin in Germany] | ||||
| Bierwirth R1, Dippel FW2, Kostev K3, Fuchs S4, Kotowa W4 | ||||
| 1 Ambulantes Diabeteszentrum am Elisabeth-Krankenhaus, Essen, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS Health GmbH & Co. OHG, Frankfurt, Germany 4 IMS Health GmbH & Co. OHG, Nuremberg, Germany | ||||
| Perfusion, 2010, 23: pp. 96-103 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | German | , Cost analysis | |
| Retrospective cohort studies of the risk of acute pancreatitis: initiators of exenatide compared to other antidiabetic drugs in two commercial US health insurance databases. | ||||
| Bloomgren G1, Wenten M1, Dore D2, Hussein M3, Pelletier E4, Smith D4, Noel R5, Braun D5, Seeger J2 | ||||
| 1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2i3 Drug Safety, Waltham, MA, USA, 3IMS Health, Falls Church, VA, USA, 4IMS Health, Watertown, MA, USA, 5Eli Lilly and Company, Indianapolis, IN, USA | ||||
| EASD 46th Annual Meeting, September 20-24, 2010, Stockholm, Sweden. |
||||
| , Podium presentation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| Risk of cardiovascular events in patients with type 2 diabetes treated with exenatide or other glucose-lowering therapies: a retrospective analysis of the LifeLinkTM database. | ||||
| Best JH1, Hoogwerf BJ2, Pelletier EM3, Smith DM3, Wenten M1, Hussein MA3 | ||||
| 1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3IMS Health, Watertown, MA, USA, 4IMS Health, Falls Church, VA, USA | ||||
| EASD 46th Annual Meeting, September 20-24, 2010, Stockholm, Sweden. |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| A retrospective cohort study to assess the relative risk of acute pancreatitis among initiators of exenatide compared to initiators of other anti-diabetic medication: a follow-up study. | ||||
| Wenten M1, Gaebler J1, Hussein M2, Pelletier E3, Smith D3, Girase P3, Noel R4, Braun D4, Bloomgren G1 | ||||
| 1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2IMS Health, Falls Church, VA, USA, 3IMS Health, Watertown, MA, USA, 4Eli Lilly and Company, Indianapolis, IN, USA | ||||
| American Diabetes Association (ADA) 70th Scientific Sessions, June 25-29, 2010, Orlando, FL, USA |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes | ||||
| Fakhoury WKH1, LeReun C1, Wright D1 | ||||
| 1 IMS Health, London, UK | ||||
| Pharmacology 2010 Jul 12;86(1):44-57 |
||||
| , Article | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20616619 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Literature Review, Meta analysis | |
| A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes | ||||
| Fakhoury WKH1, LeReun C1, Wright D1 | ||||
| 1 IMS Health, London, UK | ||||
| Pharmacology 2010 Jul 12;86(1):44-57 |
||||
| , Article | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20616619 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Meta analysis | |
| Risk of cardiovascular events in patients with type 2 diabetes treated with exenatide BID or other glucose-lowering therapies: a retrospective analysis of the LifeLinkTM Database. | ||||
| Pelletier EM1, Hoogwerf BJ2, Smith DB1, Best JH3 | ||||
| 1IMS Health, Watertown, MA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Amylin Pharmaceuticals, Inc., San Diego, CA, USA | ||||
| American Heart Association (AHA) Scientific Sessions, November 13-17, 2010, Chicago, IL, USA |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective cohort analysis, Retrospective database analysis | |
| Long-term clinical outcomes of Exenatide once-weekly versus Insulin Glargine for the treatment of Type 2 Diabetes projected using the Core Diabetes Model | ||||
| Timlin L1, Beaudet A2, Wilson B3, Bruhn D4, Boye KS5, Palmer JL2, Lloyd A6 | ||||
| 1Lilly, Windlesham, Surrey, UK, 2IMS Health, Allschwil, Basel-Landschaft, Switzerland, 3Lilly, Basingstoke, Hampshire, UK, 4Eli Lilly & Company, Indianapolis, IN, USA, 5Lilly, Indianapolis, IN, USA, 6IMS Health, London, UK | ||||
| ISPOR 13th Annual European Congress, 6-9 November 2010, Prague, Czech Republic |
||||
| , Poster | ||||
| Abstract: http://www.ispor.org/congresses/Prague1110/posters1.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Prospective study | |
| Long-Term cost-consequence analysis of Exenatide once weekly versus Sitagliptin or Pioglitazone in Type 2 Diabetes patients in the United States | ||||
| Aledort Gaebler J1, Samyshkin Y2, Guillermin ALG2, Lloyd A2 | ||||
| 1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2IMS Health, London, UK | ||||
| ISPOR 13th Annual European Congress, 6-9 November 2010, Prague, Czech Republic |
||||
| , Poster | ||||
| , USA | ||||
| Abstract: http://www.ispor.org/congresses/Prague1110/posters1.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Cost consequence | |
| Predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions in Germany | ||||
| Hammer H1, Dippel F-W2, Kostev K3, Fuchs S4, Kotowa W4 | ||||
| 1 Facharzt für Innere Medizin und Diabetologie, Bremen, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS HEALTH GmbH & Co. OHG, Frankfurt/Main, Germany 4 IMS HEALTH GmbH & Co. OHG, Nuremberg, Germany | ||||
| Perfusion 2010; 23: 132-140 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective cohort analysis | |
| Clinical and cost effectiveness of biphasic insulin aspart 30 once or twice daily versus insulin glargine in type 2 diabetes mellitus: a modeling analysis in the Chinese setting | ||||
| Palmer JL1, Beaudet A1, White,J2, Plun-Favreau J3,Smith-Palmer J1 | ||||
| 1 IMS Health, Basel, Switzerland; 2 Novo Nordisk I/O, Zurich, Switzerland; 3 Novo Nordisk A/S, Copenhagen, Denmark | ||||
| ISPOR 4th Asia-Pacific Conference, 5-7 September 2010, Hilton Phuket, Phuket, Thailand |
||||
| , Poster | ||||
| , China | ||||
| Abstract: http://www.ispor.org/conferences/Phuket0910/posters.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Cost effectiveness | |
| Insulin glargine is associated with a lower incidence of diabetic foot syndrome and macrovascular complications compared to NPH insulin in type 2 diabetics under German real-life conditions | ||||
| Siegmund T1, Dippel FW2, Kostev K3, Lauterbach S4, Fuchs S3, Kotowa W3 | ||||
| 1 Städt. Klinikum München GmbH, Klinikum Bogenhausen, 81925 München, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS Health GmbH & Co. OHG. Frankfurt/Main & Nürnberg, Germany 4 Apotheke Rotes-Kreuz-Krankenhaus, Hansteinstraße 29, 34121 Kassel, Germany | ||||
| ISPOR 13th Annual European Congress, 6-9 Nov., 2010, Prague, Czech Republic |
||||
| , Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective cohort analysis | |
| Predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions | ||||
| Hammer H1, Dippel FW2, Kostev K3, Fuchs S3, Kotowa W3 | ||||
| 1 Practice for internal medicine and diabetology, Bremen, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS Health GmbH & Co. OHG, Frankfurt/Main & Nürnberg, Germany | ||||
| ISPOR 13th Annual European Congress, 6-9 Nov., 2010, Prague, Czech Republic |
||||
| , Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective cohort analysis | |
| Insulin glargin und Exenatide bei Typ-2-Diabetes: Ein Kostenvergleich in Kombination mit oralen Antidiabetika [Cost comparison between insulin glargine and exenatide in type-2-diabetes both in combination with oral antidiabetics] | ||||
| Fuchs S1, Kostev K2, W. Kotowa W1, Dippel F-W3 | ||||
| 1 IMS Health, Nuremberg, Germany 2 IMS Health, Frankfurt/Main, Germany 3 Sanofi-Aventis Deutschland GmbH, Berlin, Germany | ||||
| Monitor Versorgungsforschung 2010: 3. Jahrgang 11.10.2010 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | German | , Retrospective cohort analysis | |
| Different persistence on initial basal supported oral therapy in type-2-diabetics results in unequal distributions of insulin treatment regimens under real-life conditions in Germany | ||||
| Pfohl M1, Dippel F-W2, Kostev K3, Fuchs S3, Kotowa W3 | ||||
| 1 Evangelisches Bethesda-Johanniter-Klinikum GmbH, Duisburg, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS HEALTH GmbH & Co. OHG, Frankfurt/Nuremberg, Germany | ||||
| International Journal of Clinical Pharmacology and Therapeutics, Vol. 48 – No. 11/2010 (761-766) |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective cohort analysis | |
| Modellierung der Langzeit-Behandlungskosten insulinpflichtiger Typ-2-Diabetiker in Abhängigkeit von der Art des Insulineinstiegs: Vergleich zwischen Insulin glargin und NPH-Insulin [Modelling of long-term treatment costs of type-2-diabetes patients depending on the initial insulin therapy: A comparison of insulin glargine vs. NPH-insulin.] | ||||
| Pfohl M1, Dippel FW2, Kostev K3, Kotowa W3 | ||||
| 1 Evangelisches Bethesda-Johanniter-Klinikum GmbH, Duisburg, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS Health, Frankfurt/Nürnberg, Germany | ||||
| Gesundh ökon Qual manag 2010; 15: 1–7 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | German | , Retrospective cohort analysis | |
| Cost-Effectiveness of Biphasic Insulin Aspart versus Insulin Glargine in Patients with Type 2 Diabetes in China | ||||
| Palmer JL1, Beaudet A1, White J2, Plun-Favreau J3, Smith‑Palmer J1 | ||||
| 1 IMS Health, Theaterstrasse 4, 4051, Basel, Switzerland 2 Novo Nordisk I/O, Zurich, Switzerland 3 Novo Nordisk A/S, Copenhagen, Denmark | ||||
| Adv Ther. 2010 Nov;27(11):814-27 |
||||
| , Manuscript in preparation | ||||
| , China | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21061114 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Cost effectiveness | |
| Clinical and cost effectiveness of testosterone replacement in patients with type 2 diabetes mellitus and hypogonadism | ||||
| Beaudet A1, Gilmour L2, Church N2, Lloyd A3, McLeod E3, Jones TH4,5 | ||||
| 1IMS Health, Basel, Switzerland, 2Bayer Schering Pharma, Newbury, UK, 3IMS Health, London, UK 4Barnsley NHS Foundation Trust Hospital, Barnsley, UK, 5University of Sheffield, UK | ||||
| Journal of Men's Health 2010; 7(3):289 |
||||
| , Poster | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21061114 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Cost effectiveness | |
| Cost-effectiveness of Exenatide Versus Insulin Glargine and Versus Biphasic Insulin Aspart for the Treatment of Type 2 Diabetes in Portugal: A Long-term Health Economic Analysis | ||||
| Palmer JL1, Pinto CG2, Duarte R3, Miguel LS2, Gregor Z4 | ||||
| 1 IMS Health, Basel, Switzerland 2 Centro de Investigação sobre Economia Portuguesa, Lisbon, Portugal 3 Associação Protectora dos Diabéticos, Lisbon, Portugal 4 Eli Lilly and Company, European Health Outcomes Research, Prague, Czech Republic | ||||
| ISPOR 13thAnnual European Congress; Prague, Czech Republic; November 6–9, 2010 |
||||
| , Manuscript in preparation | ||||
| , Portugal | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Cost effectiveness | |
| Utility values for Diabetes complications | ||||
| Donatti C1, Lloyd A1, Henry N1, Grant D1 | ||||
| 1 IMS Health, London, UK | ||||
| ISPOR 13th Annual European Congress, 6-9 November 2010, Prague, Czech Republic |
||||
| , Poster | ||||
| Abstract: http://www.ispor.org/congresses/Prague1110/posters1.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Utility analysis | |
| Cost-effectiveness of liraglutide versus exenatide added to metformin, sulfonylurea or both for the treatment of type 2 diabetes in the U.S. | ||||
| Lee WC1, Conner C2, Hammer M. | ||||
| 1 Health Economics & Outcomes Research, IMS Health, Falls Church, Virginia, USA 2 Novo Nordisk Inc., Princeton, New Jersey, USA 3 Novo Nordisk A/S, Soborg, Denmark | ||||
| Clinical Therapeutics. 2010 Sep;32(10):1756-67. |
||||
| , Article | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Cost effectiveness | |
| Real-life dosage and clinical efficacy of biphasic insulin preparations in patients with type 2 diabetes. | ||||
| Fakhoury WK1, Richter H2, Christensen TE3. | ||||
| 1 IMS Health, London, UK. 2 IMS Health, Frankfurt, Germany 3 Novo Nordisk A/S, Virum, Denmark | ||||
| Adv Ther. 2010 Nov;27(11):859-69. Epub 2010 Oct 14. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20949340 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes | ||||
| Ringborg A, Lindgren P, Yin DD, Martinell M, Stålhammar J. | ||||
| IMS Health, Stockholm (Formally Pygargus) | ||||
| Diabetes Metab. 2010 Jun;36(3):198-203. doi: 10.1016/j.diabet.2009.11.006. Epub 2010 Mar 28 |
||||
| , Article | ||||
| , Sweden | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20347376 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| Costs of glaucoma in Sweden– a pilot study | ||||
| Svensson J, Berdeaux G, Bergström A, Forsby M, Ghatnekar O | ||||
| IMS Health, Stockholm (Formally Pygargus) | ||||
| Poster PSS9. ISPOR 13th Annual European Congress, 6-9 November 2010, Prague, Czech Republic. Value in Health Volume 13, Issue 7, November 2010, Pages: A250–A480. |
||||
| , Poster | ||||
| , Sweden | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Cost consequence, Pricing & Reimbursement | |
| Resource consumption and costs of care the year before and after initiation of insulin therapy in Swedish patients with type 2 diabetes | ||||
| Pettersson B, Lindgren P, Ringborg A, Martinell M, Stålhammar J | ||||
| IMS Health, Stockholm. (Formally Pygargus) | ||||
| Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 13, no 3, p. A58-A58 |
||||
| , Article | ||||
| , Sweden | ||||
| Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(10)72270-1/abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Burden of illness, Cost analysis | |
| Cardiovascular and metabolic risk profiles in young and old patients with type 2 diabetes | ||||
| Gunathilake W, Song S, Sridharan S, Fernando DJ & Idris I | ||||
| Sherwood Forest Hospitals Foundation Trust, Nottinghamshire | ||||
| QJM. 2010 Nov;103(11):881-4. doi: 10.1093/qjmed/hcq135. Epub 2010 Jul 30 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://qjmed.oxfordjournals.org/content/103/11/881.long | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2010 | English | , Retrospective database analysis | |
| A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study | ||||
| Gordon J, Pockett RD, Tetlow AP, McEwan P & Home PD | ||||
| School of Population Health and Clinical Practice, University of Adelaide | ||||
| Int J Clin Pract. 2010 Nov;64(12):1609-18. doi: 10.1111/j.1742-1241.2010.02520.x. Epub 2010 Oct 4. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036815/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| Impact of diabetes against the future risk of developing gout | ||||
| Rodríguez LA, Soriano LC & Choi HK | ||||
| Spanish Centre for Pharmacoepidemiological Research (CEIFE), Madrid, Spain | ||||
| Ann Rheum Dis. 2010 Dec;69(12):2090-4. doi: 10.1136/ard.2010.130013. Epub 2010 Jun 22. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136217/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Rheumatology | 2010 | English | , Retrospective database analysis | |
| Predictors of responders to insulin therapy at 1 year among adults with type 2 diabetes | ||||
| Owen V, Seetho I & Idris I | ||||
| East Midlands Research Support Unit, University of Nottingham | ||||
| Diabetes Obes Metab. 2010 Oct;12(10):865-70. doi: 10.1111/j.1463-1326.2010.01239.x. |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20920038 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study | ||||
| Gonzalez-Perez A, Schlienger RG & García Rodríguez LA. | ||||
| Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain | ||||
| Diabetes Care. 2010 Dec;33(12):2580-5. doi: 10.2337/dc10-0842. Epub 2010 Sep 10. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992194/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| Incidence of Diabetic Retinopathy and Diabetic Macular Edema in Newly Diagnosed Type 1 and Type 2 Diabetic Patients | ||||
| Martin-Merino E, Fortuny J, Plana E, Rivero E & Garcia-Rodriguez L | ||||
| CEIFE | ||||
| ICPE 2010 Pharmacoepidemiology and Drug Safety (19): S1-S347 |
||||
| , Abstract, Poster | ||||
| , UK | ||||
| Abstract: https://www.yumpu.com/en/document/view/5337032/poster-session-international-society-for-pharmacoepidemiology/19 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2010 | English | , Retrospective database analysis | |
| Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007 | ||||
| Currie CJ, Gale EA & Poole CD | ||||
| Department of Medicine, School of Medicine, Cardiff University | ||||
| Diabet Med. 2010 Aug;27(8):938-48. doi: 10.1111/j.1464-5491.2010.03040.x. |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20653753 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| DURATION OF FIRST INSULIN THERAPY IN PREVIOUSLY UNCONTROLLED TYPE 2 DIABETES: COMPARISON OF INSULINS GLARGINE, DETEMIR AND NPH AND ASSOCIATION WITH GLYCEMIC CONTROL | ||||
| Hall G, McMahon A, Dain M & Home PD | ||||
| Grimsdyke House, London, | ||||
| Value in Health 13(7):A298 |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(11)72137-4/abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: a retrospective cohort-based analysis using the THIN database | ||||
| Evans ML, Sharplin P, Owens DR, Chamberlain GH, Longman AJ & McEwan P | ||||
| University Hospital Llandough, Cardiff | ||||
| British Journal of Diabetes & Vascular Disease 2010 10: 178: DOI: 10.1177/1474651410370659 |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://dvd.sagepub.com/content/10/4/178.refs.html | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| Explorative analysis about the potential of a large GPs longitudinal database on searching causal associations among pathologies | ||||
| Katz P, Heiman F. | ||||
| CSD Medical Research srl | ||||
| ISPOR Annual European Congress, Prague, 2010 |
||||
| , Poster | ||||
| , Italy | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Oncology | 2010 | English | , Retrospective database analysis | |
| Risk of acute pancreatitis in association with type 2 diabetes mellitus | ||||
| Gonzalez-Perez A, Schlienger RG & Garcia Rodriguez A | ||||
| Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain | ||||
| Pharmacoepidemiology and Drug Safety (19): S1-S347 |
||||
| , Abstract | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| Les pratiques d’intensification thérapeutique dans le diabète de type 2 en France en Médecine Générale | ||||
| Halimi S, Balkau B, Blickle JF, Attali C, Vergès B, Avignon A, Andre l, Amelineau E, Detournay B | ||||
| Inserm, CESP Centre for Research in Epidemiology and Population Health, U1018, Epidemiology of Diabetes, Obesity and Chronic Kidney Disease Over the Lifecourse and Determinants of Early Nutrition, Villejuif, France | ||||
| Bull Epidemiol Hebd (Paris). 2010 Nov;n° 42-43:436-40. [French |
||||
| , Article | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| Type 2 diabetes treatment intensification in general practice in France in 2008-2009 | ||||
| Balkau B1, Bouée S, Avignon A, Vergès B, Chartier I, Amelineau E, Halimi S. | ||||
| 1Inserm, CESP Centre for Research in Epidemiology and Population Health, U1018, Epidemiology of Diabetes, Obesity and Chronic Kidney Disease Over the Lifecourse and Determinants of Early Nutrition, Villejuif, France. | ||||
| Diabetes Metab. 2012 Mar;38 Suppl 3:S29-35. doi: 10.1016/S1262-3636(12)71532-X. |
||||
| , Article | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2010 | English | , Retrospective database analysis | |
| Cost effectiveness of Roux-En-Y gastric bypass for the treatment of type 2 diabetes mellitus. | ||||
| Ikramuddin S, Klingman D1, Swan T, Gill M, Geraci D, Minshall ME2 | ||||
| 1 IMS Health, Falls Church, VA, USA 2 Covidien, North Haven, CT, USA | ||||
| American Journal of Managed Care, 2009, 15(9): 607-615 |
||||
| , Manuscript in preparation | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Cost effectiveness | |
| A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US. | ||||
| St. Charles M, Minshall M, Pandya B, Baran R, Tunis S | ||||
| Current Medical Research and Opinion, 2009, 25(6): 1343-53 |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Cost effectiveness | |
| Cost-effectiveness of insulin aspart compared to human insulin in pregnant women with type 1 diabetes in the UK | ||||
| Lloyd,A1; Townsend,C2; Munro,V3; Twena,N3; Nielsen,S2; Holman,A1 | ||||
| 1 IMS Health, London, UK 2 Novo Nordisk A/S, Bagsvaerd, Denmark 3 Novo Nordisk Limited, Crawley, UK | ||||
| Current Medical Research and Opinion 2009; Vol 25 No 3: 599-605 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19232034?dopt=Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Cost effectiveness | |
| Cost-effectiveness of insulin analogues for diabetes mellitus | ||||
| Cameron C1, Bennett H1 | ||||
| 1 Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada | ||||
| Canadian Medical Association Journal, 2009, 180(4): 400-407 |
||||
| , Article | ||||
| , Canada | ||||
| Abstract: http://www.cmaj.ca/cgi/content/full/180/4/400 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Cost effectiveness | |
| Health economic comparison between continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) of insulin for the treatment of adult type 1 diabetes in Canada. | ||||
| St. Charles M1, Sadri H2, Minshall M1, Tunis S3 | ||||
| 1 Formerly of IMS Health, Indianapolis, IN, US 2 Medtronic Canada Ontario 3 IMS Health, Indianapolis, IN, US | ||||
| Clinical Therapeutics, 2009, 31(3): 657-67 |
||||
| , Manuscript in preparation | ||||
| , Canada | ||||
| Abstract: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VRS-4W4CMKG-N&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=bbc2be5b77a418d332505b1ea4e93261 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Cost effectiveness | |
| Economic outcomes associated with microvascular complications of diabetes mellitus: results from a US claims data analysis. | ||||
| Pelletier EM1, Shim B1, Ben-Joseph R2, Caro JJ3 | ||||
| 1IMS Health, Watertown, MA, USA, 2sanofi-aventis, Bridgewater, NJ, USA, 3United BioSource Corp, Concord, MA, USA | ||||
| Pharmacoeconomics, 2009, 27(6): 479-490 |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Abstract: http://ideas.repec.org/a/wkh/phecon/v27y2009i6p479-490.html | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Retrospective database analysis | |
| Kosten für antihyperglykämische Arznei- und Verbrauchsmittel und Therapiezufriedenheit bei Typ-2-Diabetes: Ergebnisse der Versorgungsforschungsstudie LIVE-DE [Costs of antihyperglycemic treatment and consumables and treatment satisfaction in patients with type 2 diabetes: results of a cross-sectional cost-evaluation study of long-acting insulin glargine compared with NPH insulin in Germany (LIVE-DE)] | ||||
| Hauner H1, Kohlmann T2, Landgraf W3, Holle R4, Pirk O5, Scholten T6 | ||||
| 1 ElseKröner-Fresenius-Zentrum für Ernährungswissenschaft, TU München, Germany 2 Institut für Cummunity Medicine, Universität Greifswald, Germany 3 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 4 Institut für Gesundheitsökonomie und Management, Helmholtz-Zentrum München, Germany 5 IMS HEOR Nürnberg, Germany 6 Lehrstuhl für Innere Medizin, Universität Witten/Herdecke, Germany | ||||
| Dsch Med Wochenschr., 2009, 134: pp.1207-1213 |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: http://www.find-health-articles.com/rec_pub_19472091-costs-antihyperglycemic-drugs-consumables-treatment-satisfaction.htm | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | German | , Cost analysis | |
| Längere Verweildauer unter einer basalunterstützten oralen Thearpie mit Insulin Glargin (BOT) im Vergleich zu einer Kombinationstherapie aus NPH-Insulin und oralen Antidiabetika [Higher Persistence with basal supported oral therapy (BOT) with insulin glargine compared to NPH insulin therapy combined with oral antidiabetics] | ||||
| Pfohl M1, Dippel FW2, Kostev K3, Maltz A4, Kotowa W4 | ||||
| 1 Evangelisches Bethesda-Johanniter-Klinikum Duisburg GmbH, Duisburg, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin 3 IMS Health GmbH&Co. OHG, Frankfurt, Germany 4 IMS GmbH&Co. OHG, Nürnberg, Germany | ||||
| Diabetologie, 2009; 4: pp.1-6 |
||||
| , Article | ||||
| , Germany | ||||
| Abstract: http://www.thieme-connect.com/ejournals/abstract/ds/doi/10.1055/s-0028-1098896 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | German | , Retrospective cohort analysis | |
| Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. | ||||
| Gschwend MH1, Aagren M2, Valentine WJ1 | ||||
| 1 IMS Health, Basel, Switzerland, 2 Novo Nordisk Inc., New Jersey, United States | ||||
| Journal of Medical Economics, 2009; 12(2): 114–123 |
||||
| , Manuscript in preparation | ||||
| , Belgium, France, Germany, Italy, Spain | ||||
| Abstract: http://informahealthcare.com/doi/abs/10.3111/13696990903080344 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Cost effectiveness | |
| Literature review of the impact of obesity on adverse cardiovascular outcomes in the general population and in patients with type 2 diabetes. | ||||
| Smith-Palmer J1, Kalsekar A2, Boye KS2, Goodall G1 | ||||
| 1IMS Health, Basel, Switzerland, 2Eli Lilly and Company, Indianapolis, USA | ||||
| ISPOR 2009 14th Annual International Meeting |
||||
| , Poster | ||||
| Abstract: http://www.la-press.com/the-impact-of-obesity-on-adverse-cardiovascular-outcomes-in-the-genera-a1719 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Literature Review | |
| Evaluation of exenatide versus insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. | ||||
| Mittendorf T1, Happich M2, Smith-Palmer J3, Timlin L4, Goodall G3 | ||||
| 1Gottfried Wilhelm Leibniz University, Hannover, Germany, 2Lilly Deutschland GmbH, Bad Homburg, Germany, 3IMS Health, Basel, Switzerland, 4Lilly UK, Surrey, United Kingdom | ||||
| Diabetes, Obesity and Metabolism (In press) |
||||
| , Manuscript in preparation | ||||
| , Germany | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19732121 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Cost effectiveness | |
| Estimating the long-term clinical and economic benefits of insulin lispro in type 1 diabetes in Germany: a cost-effectiveness analysis based on the results of a recent meta-analysis | ||||
| Pratoomsoot C1, Smith HT2, Arellano J2, Goodall G1 | ||||
| 1IMS Health, Basel, Switzerland, 2Eli Lilly, Surrey, UK | ||||
| Deutsche Diabetes-Gesellschaft, 20-23 Mai 2009, Leipzig, Germany |
||||
| , Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | German | , Cost effectiveness | |
| An estimation of the long-term clinical and economic benefits of insulin lispro in type 1 diabetes in the UK. | ||||
| 1. C. Pratoomsoot, H. 2. T. Smith, 3. A. Kalsekar, 3. K. S. Boye, 2. J. Arellano and 1. W. J. Valentine | ||||
| 1. IMS Health, Allschwil, Switzerland, 2. Eli Lilly and Company, Surrey, UK, 3. †Eli Lilly and Company, Indianapolis, IN, USA. | ||||
| Diabetic Medicine 2009 (in press) Diabetic Medicine, 26; 803-814 (2009) |
||||
| , Manuscript in preparation | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19709151 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Cost effectiveness | |
| Insulin glargin mit oralen Antidiabetika: Vorteilhafter Einstieg in die Insulintherapie [Insulin glargine with oral antidiabetic agents: Advantageous access to the insulin therapy] | ||||
| Kress S1, Dippel FW2, Kostev K3, Pirk O3, Reichelt A3, Kotowa W3 | ||||
| 1 Vinzentius-Krankenhaus, Landau, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS Health, Frankfurt/Nürnberg, Germany | ||||
| Diabetes Stoffw Herz 2009; 18: pp.377-385 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | German | , Retrospective database analysis | |
| Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. | ||||
| Robert J Straka1, Larry Z Liu2, Prafulla S Girase3, Allyson DeLorenzo4 and Richard H Chapman5 | ||||
| 1 University of Minnesota College of Pharmacy, Minneapolis, MN, USA, 2 Pfizer Inc, New York, NY, USA, 3 IMS Health, Watertown, MA, USA, 4 Columbia University, New York, NY, USA and 5 IMS Health, Falls Church, VA, USA | ||||
| Cardiovascular Diabetology 2009; 8:53-63 |
||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2009 | English | , Cost analysis, Retrospective cohort analysis | |
| Drug titration patterns and HbA1c levels in type 2 diabetes. | ||||
| Maclean JR1, Chapman RH2, Ferrufino CP2, Krishnarajah S1 | ||||
| 1 IMS Health, Falls Church, VA, USA | ||||
| International Journal of Clinical Practice |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2984545/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Retrospective cohort analysis | |
| Patterns of up-titration in type 2 diabetes (T2DM) patients taking oral anti-diabetic drugs (OADs). | ||||
| Krishnarajah G1, Bhosle M2, Chapman RH2 | ||||
| 1 Bristol-Myers Squibb, Princeton, NJ, USA 2 IMS Health, Inc., Falls Church, VA, USA | ||||
| American Diabetes Association's 69th Scientific Sessions, 2009, June 5-9, New Orleans, LA, USA |
||||
| , Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Retrospective cohort analysis | |
| Total health care expenditures associated with treatment modification in type 2 diabetes mellitus (T2DM) patients taking oral anti-diabetic drugs (OADs). | ||||
| Krishnarajah G1, Bhosle M2, Chapman RH2 | ||||
| 1 Bristol-Myers Squibb, Princeton, NJ, USA 2 IMS Health, Inc., Falls Church, VA, USA | ||||
| 20th World Diabetes Congress, 2009, October 18-22, Montreal, Quebec, Canada |
||||
| , Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Retrospective cohort analysis | |
| A standardized evidence based approach to assess non-traditional outcome measures for use in health-care decision making: the diabetes example. | ||||
| Badia X1, Vieta A1, Sacristán JA2 | ||||
| 1HEOR IMS Health, Spain 2Clinical Research Department, Lilly Spain | ||||
| ISPOR 12th Annual European Congress 2009, 24 to 27 October, Paris, France |
||||
| , Oral presentation | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Methodology | |
| Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective | ||||
| Werner A Scherbaum1, Gordon Goodall2, Katrina M Erny-Albrecht2, Massimo Massi-Benedetti3, Erland Erdmann4, William J Valentine2 | ||||
| 1Universität Düsseldorf, Klinik für Endokrinologie, Diabetologie und Rheumatologie, 2IMS Health, Basel, Switzerland, 3University of Perugia, Medicine and Metabolic Diseases, Perugia, Italy and 4Medizinische Klinik III der Universität zu Köln, Köln, Germany | ||||
| Cost Effectiveness and Resource Allocation |
||||
| , Manuscript in preparation | ||||
| , Germany | ||||
| Abstract: http://www.resource-allocation.com/content/pdf/1478-7547-7-9.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Cost effectiveness | |
| Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. | ||||
| Straka RJ1, Liu LZ2, Girase PS3, DeLorenzo A4, Chapman RH5. | ||||
| 1Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA 2Global Outcomes Research, Pfizer Inc, New York, NY and Weill Cornell Medical College, New York, NY, USA 3IMS Health, Watertown, MA, USA 4 Columbia University, New York, NY, USA 5 IMS Health, Falls Church, VA, USA | ||||
| Cardiovasc Diabetol. 2009 Sep 26;8:53 |
||||
| , Article | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=Straka+R%5Bfirst+author%5D+AND+incremental&TransSchema=title&cmd=detailssearch | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Cost of illness | |
| The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden. | ||||
| Ringborg A, Yin DD, Martinell M, Stålhammar J, Lindgren P. | ||||
| IMS Health, Stockholm. (Formally Pygargus) | ||||
| Eur J Cardiovasc Prev Rehabil. 2009 Oct;16(5):576-82. doi: 10.1097/HJR.0b013e32832d193b. |
||||
| , Article | ||||
| , Nordic, Sweden | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=The+impact+of+acute+myocardial+infarction+and+stroke+on+health+care+costs+in+patients+with+type+2+diabetes+in+Sweden&TransSchema=title&cmd=detailssearch | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Burden of illness, Cost of illness | |
| The influence of glucose-lowering therapies on cancer risk in type 2 diabetes | ||||
| Currie CJ, Poole CD & Gale EA | ||||
| Diabetologia. 2009 Sep;52(9):1766-77. doi: 10.1007/s00125-009-1440-6. Epub 2009 Jul 2. |
||||
| , Abstract | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19572116 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | ||
| The influence of glucose-lowering therapies on cancer risk in type 2 diabetes | ||||
| Currie CJ, Poole CD & Gale EA | ||||
| School of Medicine, Cardiff University, The Pharma Research Centre, Cardiff MediCentre | ||||
| Diabetologia. 2009 Sep;52(9):1766-77. doi: 10.1007/s00125-009-1440-6. Epub 2009 Jul 2. |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19572116 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Retrospective database analysis | |
| Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. | ||||
| Gribbin J, Hubbard R & Smith C | ||||
| Division of Epidemiology and Public Health, University of Nottingham | ||||
| Respir Med. 2009 Jun;103(6):927-31. doi: 10.1016/j.rmed.2008.11.001. Epub 2008 Dec 6. |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19058956 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Respiratory disease | 2009 | English | , Retrospective database analysis | |
| Trends in the prevalence and incidence of diabetes in the UK: 1996-2005 | ||||
| González EL, Johansson S, Wallander MA & Rodríguez LA. | ||||
| Spanish Centre for Pharmacoepidemiological Research, Almirante 28, Madrid, Spain | ||||
| J Epidemiol Community Health2009;63:332-336 doi:10.1136/jech.2008.080382 |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://jech.bmj.com/content/63/4/332 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Retrospective database analysis | |
| Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis | ||||
| Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ & McEwan P | ||||
| CHKS Health Economics Unit, Health Park, Cardiff | ||||
| Cardiovasc Diabetol. 2009 Feb 16;8:9. doi: 10.1186/1475-2840-8-9. |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19220880 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Retrospective database analysis | |
| “The “who, how and then what…” of insulin initiation in UK primary care” | ||||
| Smith HT, Blak BT, Hards M & Arrelano J | ||||
| Cegedim | ||||
| Value in Health 12(7):A412 |
||||
| , Abstract | ||||
| , UK | ||||
| Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(10)75036-1/abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Miscellaneous | 2009 | English | , Retrospective database analysis | |
| Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study | ||||
| Sharplin P, Gordon J, Peters J R, Tetlow A P, Longman A J & McEwan P | ||||
| CHKS Health Economics Unit, Health Park | ||||
| Cardiovascular Diabetology 2009, 8:3 |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://www.cardiab.com/content/8/1/3 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Retrospective database analysis | |
| The clinical impact of identifying metabolic syndrome in patients with diabetes: a cross-sectional study. | ||||
| Bulugahapitiya U, Siyambalapitiya S, Sithole J, Fernando DJ & Idris I | ||||
| Sherwood Forest Hospitals Foundation Trust, Nottinghamshire | ||||
| Diab Vasc Dis Res. 2009 Jan;6(1):21-4. doi: 10.3132/dvdr.2009.004. |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19156624 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Retrospective database analysis | |
| The impact of insulin detemir compared to Neutral Protamine Hagedorn insulin on long-term diabetes-related complications: a modeling analysis in type 1 diabetes patients in Belgium, France, Germany, Italy and Spain | ||||
| Gschwend M1, Aagren M2, Valentine WJ1 | ||||
| 1 IMS Health, Basel, Switzerland, 2 Novo Nordisk A/S, Bagsværd, Denmark | ||||
| ISPOR 2008 13th Annual International Congress |
||||
| , Poster | ||||
| , Belgium, France, Germany, Italy, Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Economic evaluation | |
| Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and achieving glycemic control, when administered in addition to conventional oral antidiabetic therapy in the treatment of type 2 diabetes patients; a meta-analysis | ||||
| Fakhoury W1, Lockhart I1, Kotchie RW1, Aagren M2, LeReun C3 | ||||
| 1 IMS Health, London, UK 2 Novo Nordisk A/S, Bagsvaerd, Denmark 3 MTAG, Sydney, N.S.W., Australia | ||||
| Pharmacology 2008;82(2):156-163 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.karger.com/doi/10.1159/000149569 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Meta analysis | |
| Canadian cost utility analysis comparing exenatide versus insulin glargine in patients with type two diabetes | ||||
| Coyle D, Coyle K, Valentine WJ, Lee JB, Kisswani R, Boye KS | ||||
| ISPOR 2008 13th Annual International Congress |
||||
| , Poster | ||||
| , Canada | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost utility | |
| Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. | ||||
| Palmer JL1, Goodall G1, Nielsen S3, Kotchie RW,2 Valentine WJ1, Palmer AJ1, Roze S1. | ||||
| 1IMS Health, Basel, Switzerland, 2Novo Nordisk, Bagsværd, Denmark, 3IMS Health, London, UK | ||||
| Curr Med Res Opin. 2008; 24(5):1417-1428 |
||||
| , Manuscript in preparation | ||||
| , Italy, Poland, Spain, Sweden | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Cost-effectiveness of Insulin Detemir Compared to NPH Insulin for Type 1 Diabetes mellitus (T1DM) in the Canadian Payer Setting: Modeling Analysis using a Randomized Controlled Trial. | ||||
| Minshall ME1, Tunis SL2, Conner C, McCormick JI, Kapor J, Groleau D | ||||
| 1 Formerly of IMS Health, Falls Church, VA, USA IMS Health, Falls Church, VA, USA | ||||
| ISPOR 2008 13th Annual International Congress Value in Health, 2008; 11(3):A223-A224. |
||||
| , Manuscript in preparation, Poster | ||||
| , Canada | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Long-term clinical and cost outcomes of treatment with insulin detemir plus insulin aspart in type 1 diabetes patients in the Czech setting; data from the predictive study | ||||
| 1Clegg JP, 1Valentine WJ, 2Rychna K, 3Honka M, 4Doležal T | ||||
| 1IMS, Allschwil, Switzerland, 2Novo Nordisk s.r.o, Praha 6, Czech Republic, 3Faculty Hospital Ostrava, Ostrava, Czech Republic, 4Charles University in Prague, Prague 10, Czech Republic | ||||
| ISPOR 2008 13th Annual International Congress |
||||
| , Poster | ||||
| , Czech | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on proactive | ||||
| 1Valentine WJ, 1Tucker D, 1Palmer AJ, 2Minshall ME, 1Foos V, 3Silberman C | ||||
| 1IMS-Health, Allschwil, Switzerland; 2IMSHealth, Noblesville, IN, USA; 3Takeda Global Research and Development, Ltd., Deerfield, IL, USA | ||||
| Value in Health - Published Online: 24 Jul 2008 |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Prevalence and antihyperglycemic prescribing trends for patients with type 2 diabetes in Italy: a four year descriptive study from national primary care data. | ||||
| Mazzaglia G1, Yurgin N2, Boye KS2, Trifirò G34, Cottrell S5, Allen E5, Filippi A1, Medea G1, Cricelli C1 | ||||
| 1 Italian College of General Practitioners, Florence, Italy 2 Eli Lilly & Co, Indianapolis, IN, USA 3 IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy 4 Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Italy 5 IMS Health, London, UK | ||||
| Pharmacol Res. 2008 May;57(5):358-63. Epub 2008 Mar 29 |
||||
| , Manuscript in preparation | ||||
| , Italy | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Epidemiological study | |
| Self-monitoring of Blood Glucose in Type 2 Diabetes: Cost-effectiveness in the United States | ||||
| Tunis SL1, Minshall ME1 | ||||
| 1 IMS Health, Falls Church, VA, US | ||||
| Am J Manag Care. 2008;14(3):131-140 |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| The cost-effectiveness of aliskiren as add on to losartan and optimal antihypertensive therapy in patients with type 2 diabetes, hypertension and nephropathy in the United Kingdom setting. | ||||
| Palmer JL1, Munk VC2, Kotchie R3, Vincze G2, Charney A4, Tucker D1, Annemans L5 | ||||
| 1 IMS Health, Basel, Switzerland 2 Novartis Pharma AG, Basel, Switzerland 3 IMS Health, London, UK 4 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA 5 Ghent University, Ghent, Belgium | ||||
| ISPOR 13th Annual International Meeting, 2008, May 3-7, Toronto, Canada |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| The Impact of Clinical Trial Design on Cost-Effectiveness Analyses: Illustration from a Published Study of the One-Touch® Ultrasmart® Blood Glucose Meter for Insulin-Using Diabetes Patients. | ||||
| Tunis SL1, Minshall ME1 | ||||
| 1 IMS Health, Falls Church, VA, USA | ||||
| Diabetes Technology & Therapeutics, 2008;10(3): 227-31 |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Abstract: http://www.liebertonline.com/doi/abs/10.1089/dia.2007.0270 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Cost-Effectiveness of Switching to Biphasic Insulin Aspart in Poorly-Controlled Type 2 Diabetes Patients in China | ||||
| Palmer JL1, Gibbs M2, Scheijbeler H3, Kotchie R3, Nielsen S4, White J5, Valentine WJ1 | ||||
| 1IMS Health, Basel, Switzerland, 2IMS Health, Shanghai, China, 3IMS Health, London, UK, 4Novo Nordisk A/S, Bagsværd, Denmark, 5Novo Nordisk International Operations A/S, Zurich, Switzerland | ||||
| Adv Ther. 2008 Aug;25(8):752-74. |
||||
| , Article | ||||
| , China | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Quality of life and depression of people living with type 2 diabetes mellitus and those at low and high risk for type 2 diabetes: findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD) | ||||
| Grandy S1, Chapman RH2, Fox KM3, for the SHIELD Study Group | ||||
| (1) AstraZeneca LP, Wilmington, DE, USA (2) IMS Health -US HEOR, Falls Church, VA, USA (3) Strategic Healthcare Solutions, LLC, Monkton, MD, USA | ||||
| International Journal of Clinical Practice 2008; 62(4):562-568 |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Survey research | |
| Testing and control among type 2 diabetes mellitus patients on oral anti-diabetes drugs. | ||||
| Chapman RH1, Ferrufino CP1, Maclean JR, Krishnarajah S | ||||
| 1 IMS Health, Falls Church, VA, US | ||||
| American Diabetes Association’s 68th Scientific Sessions, San Francisco, CA, June 6-10, 2008 |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Retrospective cohort analysis | |
| Modelling the cost-effectiveness of acarbose in preventing type 2 diabetes in a South Korean setting | ||||
| JongMann K1, Clegg JP2, Chang K1, JuYeol P1, Wittrup-Jensen KU3, Palmer AJ2, Roze S2, Valentine WJ2 | ||||
| 1Bayer, Seoul, South Korea, 2IMS Health, Allschwil, Switzerland, 3Bayer Schering Pharma AG, Berlin, Germany, | ||||
| ISPOR 3rd Asia-Pacific Conference |
||||
| , Oral presentation | ||||
| , South Korea | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Physician and patient management of type 2 diabetes and factors related to glycemic control in Spain. | ||||
| Yurgin NR1, Boye KS1, Dilla T2, Lara N3, Badia X3 | ||||
| 1Eli Lilly and Company, Indianapolis, IN, USA; 2Eli Lilly and Company, Spain; 3HEOR, IMS Health, Spain | ||||
| Patient Preference and Adherence 2008:2 87–95. |
||||
| , Article | ||||
| , Spain | ||||
| Abstract: http://www.dovepress.com/physician-and-patient-management-of-type-2-diabetes-and-factors-relate-peer-reviewed-article-PPA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | ||
| Standardized type 2 diabetes complication costs from US commercial payers to be used in modeling the long-term economic outcomes of diabetes complications. | ||||
| Minshall ME1, Pelletier EM2, Smith PJ2, Forma FM3 | ||||
| 1IMS Health, Noblesville, IN, USA, 2IMS Health, Watertown, MA, USA 3Novo Nordisk, Princeton, NJ, USA | ||||
| International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual European Meeting, 2008, November 8-11, Athens, Greece |
||||
| , Oral presentation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Retrospective database analysis | |
| Cost-Effectiveness of Insulin Detemir Compared to NPH Insulin for Type 1 (T1DM) and Type 2 Diabetes Mellitus (T2DM) in the Canadian Payer Setting: modeling analysis | ||||
| Tunis S1, Minshall M2, Conner C, McCormick J, Kapor J, Yale J, Groleau D | ||||
| 1 IMS Health, Falls Church, VA, US 2 Formerly of IMS Health, Falls Church, VA, US | ||||
| Current Medical Research and Opinion, 2009, 25(5): 1273-84 |
||||
| , Manuscript in preparation, Poster | ||||
| , Canada | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/19366302 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Cost-Effectiveness Analysis of Continuous Subcutaneous Insulin Injection vs. Multiple Daily Injections in Type 1 Diabetes Patients: an International Comparison. | ||||
| Graham C, Lynch P, St. Charles M, Minshall M | ||||
| Value in Health, 2008; 11(3):A224. Value in Health, 2008; 11(3):A224. |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Long-Term Economic Value of a Hypothetical DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus: The Potential Impact of the Preservation of Beta-Cell Function. | ||||
| Tunis S1, Minshall M2, Bron M, Baran R, Pandya B | ||||
| 1 IMS Health, Falls Church, VA, US 2 Formerly of IMS Health, Falls Church, VA, US | ||||
| American Diabetes Association, 2008, June 6 - 10, San Francisco, USA |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost utility | |
| Direct medical costs for type 2 diabetes mellitus complications in the U.S. commercial payer setting: a resource for economic research. | ||||
| Pelletier EM1, Smith P1, Boye KS2, Misurski DA2, Tunis SL3, Minshall ME3 | ||||
| 1IMS Health, Watertown, MA, USA, 2Eli Lilly & Company, Indianapolis, IN, USA, 3IMS Health, Noblesville, IN, USA | ||||
| Diabetologia, 2008, 51(Suppl 1): S538 European Association for the Study of Diabetes (EASD) 44th Annual Meeting, 2008, September, Rome, Italy |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Retrospective database analysis | |
| Long-term cost-effectiveness of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with type 1 diabetes using a basal–bolus regimen in Belgium, France, Germany, Italy and Spain. | ||||
| Gschwend M, Aagren M, Valentine WJ | ||||
| ISPOR 2008 13th Annual International Congress |
||||
| , Poster | ||||
| , Belgium, France, Germany, Italy, Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Long-term cost-effectiveness of insulin detemir compared to neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal?bolus regimen in Sweden. | ||||
| Valentine WJ1, Lammert M2, Aagren M3, Gschwend M1. | ||||
| 1 IMS Health, Basel, Switzerland; 2 Novo Nordisk Scandinavia AB, Copenhagen, Denmark; 3 Novo Nordisk, Bagsværd, Denmark | ||||
| ISPOR 2008 13th Annual International Congress |
||||
| , Poster | ||||
| , Nordic, Sweden | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. | ||||
| Goodall G1, Jendle JH2, Valentine WJ1, Munro V3, Brandt AB4, Ray JA1, Roze S1, Foos V1, Palmer AJ1 | ||||
| 1 IMS Health, Basel, Switzerland, 2 Department of Clinical Medicine, Örebro University Hospital, Örebro, Sweden, 3 Novo Nordisk Ltd, Crawley, West Sussex, UK, 4 Novo Nordisk Scandinavia AB, Malmö, Sweden | ||||
| Int J Clin Pract. 2008 Jun;62(6):869-76. |
||||
| , Manuscript in preparation | ||||
| , Sweden | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18479280?dopt=Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. | ||||
| Valentine WJ1, Goodall G1, Aagren M2, Nielsen S2, Palmer AJ1, Erny-Albrecht K1 | ||||
| 1 IMS Health, Allschwil, Switzerland, 2 Novo Nordisk A/S, Bagsværd, Denmark | ||||
| Adv Ther. 2008 Jun;25(6):567-84. |
||||
| , Manuscript in preparation | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Evaluation of long-term clinical benefits associated with early versus late initiation of insulin in type 2 diabetes patients in the UK. | ||||
| E. Sarpong1, C. Pratoomsoot2, G. Goodall2, R. Hayes1, W.J. Valentine2 | ||||
| 1Gho-hta/policy, Eli Lilly and Company, Indianapolis, IN, United States, 2Health Economics and Outcomes Research, IMS Health, Basel, Switzerland | ||||
| 44th EASD Annual Meeting, Rome, 7-11 September 2008 EASD 2008 Annual Meeting, Rome |
||||
| , Oral presentation | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analyses in a Chinese setting. | ||||
| Chen X1, Clegg JP2, Chen L1, Yu H3, Wittrup-Jensen KU4, Valentine WJ1 | ||||
| 1Fu Dan University, Shanghai, China, 2IMS Health, Basel, Switzerland, 3Bayer Healthcare Co. Ltd, Shanghai, China, 4Bayer Schering Pharma AG, Berlin, Germany | ||||
| 3rd Asia-Pacific Conference, 7-9 September 2008 |
||||
| , Oral presentation | ||||
| , China | ||||
| Abstract: http://www.ingentaconnect.com/content/apl/cmro/2006/00000022/00000007/art00019?token=006718db3e1a03ae72752d455e4e2663433b393f6a3340257d7241255e437a63736a425b6b674c58662a702c2e6e49625371e31 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| El impacto de la obesidad en el manejo y evolución de la diabetes mellitus [The impact of obesity in the management and evolution of diabetes mellitus.] | ||||
| Dilla T1, Costi M1, Boye KS2, Reviriego J1, Yurgin N2, Badia X3, Lara-Suriñach N3 | ||||
| 1Clinical Research Department. Eli Lilly and Company. Madrid. España. 2Global Health Outcomes. Eli Lilly and Company. Corporate Center. Indianápolis. Estados Unidos. 3Health Economics and Outcomes Research (IMS Health). Barcelona. España. | ||||
| Revista Clínica Española 2008; 208(9):437-43 |
||||
| , Article | ||||
| , Spain | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19000471 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | Spanish | , Epidemiological study | |
| Adding Insulin Glargine to oral Therapy in patients with type 2 diabetes results in longer persistence with treatment compared to NPH insulin | ||||
| Pfohl M4, Dippel FW3, Kostev K2, Kotowa W1 | ||||
| 1 Evangelisches Bethesda-Johanniter-Klinikum Duisburg GmbH, Duisburg, Germany 2 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 3 IMS HEALTH GmbH & Co. OHG, Frankfurt, Germany 4 IMS Health HEOR, Nuremberg, Germany | ||||
| ISPOR 11th Annual European Congress, 8-11. November 2008, Athen, Greece |
||||
| , Abstract, Oral presentation | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Retrospective database analysis | |
| Cost advantages and improved patient treatment satisfaction with insulin glargine in type 2 diabetes patients. The long-acting insulin glergine vs NPH insulin cost evaluation study in germany (LIVE-DE) | ||||
| Scholten T1, Kohlmann T2, Moock J2, Holle R3, Landgraf W4, Pirk O5, Hauner H6 | ||||
| 1 Internal Medicine, Univ. of Witten/Herdecke, Germany; 2 Institute of Community Medicine, Univ. of Greifswald, Germany; 3 Institute of Health Economics & Health Care Management, Helmholtz Centre Munich, Germany; 4 sanofi-aventis, Berlin, Germany; 5 IMS Health HEOR, Nuremberg, Germany; 6 Else Kröner-Fresenius-Centre for Nutritional Medicine, TU Munich, Germany | ||||
| EASD 44th Annual Meeting, 7-11. September 2008, Rome, Italy |
||||
| , Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Insulin Glargine and NPH Insulin based regimens reveal comparable total direct treatment costs in type 2 diabetes patients. The long-acting insulin Glargine vs. NPH insulin cost evaluaton study in germany (LIVE-DE) | ||||
| Scholten T1, Holle R2, Dippel FW3, Spiesecke A4, Hauner H5 | ||||
| 1 University of Witten-Herdecke, Hagen, Germany 2 Institute of Health Economics & Health Care Management, Helmholtz Center Munich, Germany 3 sanofi-aventis, Berlin, Germany 4 IMS Health HEOR, Nuremberg, Germany 5 Else Kröner-Fresenius-Center for Nutritional Medicine, Technical University Munich, Munich, Germany | ||||
| ISPOR 11th Annual European Congress, 8-11. November 2008, Athen, Greece |
||||
| , Abstract, Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness, Retrospective database analysis | |
| Basal insulins (e. g. glargine) combined with oral antidiabetics are most commonly used to initiate insulin therapy in type-2-diabetes patients in Germany | ||||
| Kress S4, Dippel FW3, Kostev K2, Kogler C1, Kotowa W1 | ||||
| 1 IMS Health, Nuremberg, Germany 2 IMS Health GmbH, Frankfurt, Germany 3 Sanofi-Aventis, Berlin, Germany 4 Vinzentius-Krankenhaus Landau | ||||
| 15. Annual Meeting GAA e.V., 20-21. November 2008, Bonn, Germany |
||||
| , Abstract | ||||
| , Germany | ||||
| Abstract: http://www.egms.de/en/meetings/gaa2008/08gaa22.shtml | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Retrospective database analysis | |
| Basalinsuline in Kombination mit oralen Antidiabetika stellen den häufigsten Einstieg in die Insulintherapie bei Patienten mit Typ-2-Diabetes dar [Basal insulins (e. g. glargine) combined with oral antidiabetics are most commonly used to initiate insulin therapy in type-2-diabetes patients in Germany]. | ||||
| Kress S1, Dippel FW2, Kostev K3, Kogler C4, Kotowa W4 | ||||
| 1 Vinzentius-Krankenhaus Landau, Germany 2 Sanofi-Aventis Deutschland GmbH, Germany 3 IMS Health GmbH, Frankfurt, Germany 4 IMS Health, Nuremberg, Germany | ||||
| 15. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie 20.11. - 21.11.2008, Bonn |
||||
| , Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | German | , Retrospective database analysis | |
| Estimating the long-term clinical and economic benefits of insulin lispro in type 1 diabetes in the UK: a cost-effectiveness analysis based on the results of a recent meta-analysis | ||||
| Smith HT1, Valentine WJ2, Boye KS3, Kalsekar A3, Pratoomsoot C2 | ||||
| 1Eli Lilly and Company, Surrey, UK, 2IMS Health, Basel, Switzerland, 3Eli Lilly and Company, Indianapolis, IN, USA | ||||
| ISPOR 2008 11th Annual European Congress, Athens |
||||
| , Oral presentation | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Insulin glargine- and NPH insulin-based regimens reveal comparable total direct treatment costs in patients with type 2 diabetes. Results of the long-acting insulin glargine vs. NPH insulin cost evaluation study in Germany (LIVE-DE) | ||||
| Scholten T1, Holle R2, Dippel FW3, Spiesecke A4, Hauner H5 | ||||
| 1 University of Witten-Herdecke, Hagen, Germany 2 Institute of Health Economics & Health Care Management, Helmholtz Center Munich, Germany 3 sanofi-aventis, Berlin, Germany 4 IMS Health HEOR, Nuremberg, Germany 5 Else Kröner-Fresenius-Center for Nutritional Medicine, Technical University Munich, Munich, Germany | ||||
| ISPOR 11th Annual European Congress, 8-11. November 2008, Athen, Greece |
||||
| , Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Quality of life and depression of people living with type 2 diabetes mellitus and those at low and high risk for type 2 diabetes: findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD). | ||||
| Grandy S, Chapman RH, Fox KM, for the SHIELD Study Group. | ||||
| 2 IMS Health, Falls Church, VA, USA | ||||
| International Journal of Clinical Practice 2008; 62(4):562-568. |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Survey research | |
| Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. | ||||
| Tunis SL, Minshall ME, St. Charles M, Pandya BJ, Baran RW | ||||
| 1 IMS Health, Falls Church, VA, US 2 Formerly of IMS Health, Falls Church, VA, US 3 Formerly of IMS Health, Falls Church, VA, US 4 Takeda, Deerfield, IL, USA 5 Takeda, Deerfield, IL, US | ||||
| Current Medical Research and Opinion 2008;24(11):3085-3096. |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Treatment failures in type 2 diabetes patients taking oral anti-diabetes drugs | ||||
| Chapman R, Ferrufino C, Maclean JR, Krishnarajah G | ||||
| 1 IMS Health, Falls Church, VA, US 2 IMS Health, Falls Church, VA, US 3 Bristol-Myers Squibb, Princeton, NJ, US 4 Bristol-Myers Squibb, Princeton, NJ, US 4 | ||||
| American Diabetes Association’s 68th Scientific Sessions, 2008, June San Francisco, CA, US |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Retrospective cohort analysis | |
| Cost-effectiveness of blood glucose monitoring is controversial. Reply to Aspinall SL and Glassman PA | ||||
| Tunis SL, Minshall ME | ||||
| 1 IMS Health, Falls Church, VA, US 2 Formerly of IMS Health, Falls Church, VA, US | ||||
| American Journal of Managed Care, 2008;14(6):399-400. |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia | ||||
| Mohammed Ali1, Jeremy White2, Chen-Hui Lee2, James L Palmer3, Jayne Smith-Palmer3, Walid Fakhoury4, William J Valentine3 | ||||
| 1 IMS Health, Riyadh, Saudi Arabia 2 Novo Nordisk International Operations A/S, Zurich, Switzerland 3 IMS Health, Basel, Switzerland 4 IMS Health, London, UK | ||||
| , Manuscript in preparation | ||||
| Abstract: http://informahealthcare.com/doi/abs/10.3111/13696990802589122 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Direct medical costs for type 2 diabetes mellitus complications in the U.S. commercial payer setting. | ||||
| Pelletier EM1, Smith PJ1, Boye KS2, Misurski DA2, Tunis SL3, Minshall ME3 | ||||
| 1IMS Health, Watertown, MA, USA, 2Eli Lilly & Company, Indianapolis, IN, USA, 3IMS Health, Noblesville, IN, USA | ||||
| Applied Health Economics and Health Policy, 2008, 6(2-3): 103-112 |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost analysis | |
| Cost-Effectiveness of Aliskiren in Addition to Losartan and Optimal Antihypertensive Therapy in Patients with Hypertension and Diabetic Nephropathy: A US Healthcare System Perspective | ||||
| Thomas E Delea1; James L Palmer2; Lieven Annemans3; Helen Lau4; Veronica C Munk5; Jennifer Sung4; Alan Charney4; Sean D Sullivan6 | ||||
| 1 Policy Analysis Inc., Brookline, MA, USA; 2 IMS Health, Basel, Switzerland; 3 Ghent University, Ghent, Belgium; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 5 Novartis Pharma AG, Basel, Switzerland; 6 University of Washington, Seattle, WA, USA | ||||
| , Poster | ||||
| , USA | ||||
| Abstract: N/A | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Cost-effectiveness of aliskiren as add-on to losartan and optimal antihypertensive therapy in patients with type 2 diabetes, hypertension and nephropathy in the UK setting | ||||
| James L. Palmer1, Veronica C. Munk2, Robert W. Kotchie3, Gabor Vincze2, Alan Charney4, Daniel M.D. Tucker1, Lieven Annemans5 | ||||
| 1IMS Health, Basel, Switzerland; 2Novartis Pharma AG Basel, Switzerland; 3IMS Health, London, UK; 4Novartis Pharmaceuticals Corporation, New Jersey, USA; 5Ghent University, Ghent, Belgium | ||||
| , Poster | ||||
| , UK | ||||
| Abstract: N/A | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Standardized type 2 diabetes complication costs from U.S. commercial payers to be used in modeling the long-term economic outcomes of diabetes complications. | ||||
| Minshall ME1, Pelletier EM1, Smith PJ1, Forma FM2 | ||||
| 1IMS Health, Inc., Watertown, MA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA | ||||
| International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual European Meeting. Athens, Greece, November 2008. |
||||
| , Abstract, Podium presentation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Retrospective cohort analysis, Retrospective database analysis | |
| Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data. | ||||
| Ringborg A, Martinell M, Stålhammar J, Yin DD, Lindgren P. | ||||
| IMS Health, Stockholm. (Formally Pygargus) | ||||
| Int J Clin Pract. 2008 May;62(5):708-16. doi: 10.1111/j.1742-1241.2008.01716.x. Epub 2008 Mar 17. |
||||
| , Article | ||||
| , Nordic, Sweden | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=Resource+use+and+costs+of+type+2+diabetes+in+Sweden+%E2%80%93+estimates+from+population-based+register+data&TransSchema=title&cmd=detailssearch | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost consequence, Cost of illness | |
| Prevalence and incidence of Type 2 diabetes and its complications 1996-2003--estimates from a Swedish population-based study. | ||||
| Ringborg A, Lindgren P, Martinell M, Yin DD, Schön S, Stålhammar J. | ||||
| IMS Health, Stockholm. (Formally Pygargus) | ||||
| Diabet Med. 2008 Oct;25(10):1178-86. doi: 10.1111/j.1464-5491.2008.02541.x. |
||||
| , Article | ||||
| , Sweden | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=Prevalence+and+incidence+of+Type+2+diabetes+and+its+complications+1996%E2%80%932003+%E2%80%93+estimates+from+a+Swedish+population-based+study.&TransSchema=title&cmd=detailssearch | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Burden of illness | |
| Association between serious ischemic cardiac outcomes and medications used to treat diabetes. | ||||
| Margolis D J, Hoffstad O & Strom BL | ||||
| Department of Dermatology, University of Pennsylvania School of Medicine | ||||
| Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):753-9. doi: 10.1002/pds.1630. |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18613215 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2008 | English | , Retrospective database analysis | |
| Diabetes diagnosis, resource utilization, and health outcomes. | ||||
| Gulliford MC, Latinovic R & Charlton J | ||||
| King's College London, Public Health Sciences | ||||
| Am J Manag Care. 2008 Jan;14(1):32-8. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18197743 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Retrospective database analysis | |
| Risk of chronic end stage renal disease after use of ACE inhibitors compared to other antihypertensives or no-antihypertensive use in a cohort of diabetic patients in the United Kingdom | ||||
| Laudati J, Motsko S & Jones J | ||||
| Pharmacoepidemiology and Drug Safety 17(S233) |
||||
| , Abstract | ||||
| , UK | ||||
| Abstract: http://www.deggegroup.com/2008-ISPE%20-%20Diabetes-THIN.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2008 | English | , Retrospective database analysis | |
| Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia | ||||
| Mohammed Ali 1 , Jeremy White 2 , Chen-Hui Lee 2 , James L Palmer 3 , Jayne Smith-Palmer 3 , Walid Fakhoury 4 , William J Valentine 3 | ||||
| 1 IMS Health, Riyadh, Saudi Arabia 2 Novo Nordisk International Operations A/S, Zurich, Switzerland 3 IMS Health, Basel, Switzerland 4 IMS Health, London, UK | ||||
| Journal of Medical Economics 2008; 11: 651–670 |
||||
| , Abstract | ||||
| , Saudi Arabia | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost analysis | |
| The IMPROVE study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts | ||||
| Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y | ||||
| Int J Clin Pract 2008;62(11):1809–1819 |
||||
| , Article | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
| Cost-Effectiveness of Insulin Detemir Compared to NPH Insulin for Type 2 Diabetes Mellitus (T2DM) in the Canadian Payer Setting: Modeling Analysis using an Observational Study | ||||
| Minshall ME1, Tunis SL2, Conner C, McCormick JI, Kapor J, Groleau D | ||||
| 1 Formerly of IMS Health, Falls Church, VA, USA IMS Health, Falls Church, VA, USA | ||||
| ISPOR 2008 13th Annual International Congress |
||||
| , Poster | ||||
| , Canada | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Observational study | |
| Frequency of Self-Monitoring of Blood Glucose in Type 2 Diabetes: A Cost-Effectiveness Modeling Study in the U.S. Setting. | ||||
| Erny-Albrecht KM, Tunis SL1, Minshall ME2, Valentine W, Foos V, Palmer AJ. | ||||
| 1 IMS Health, Falls Church, VA, US 2 Formerly of IMS Health, Falls Church, VA, US | ||||
| American Diabetes Association 2007 Chicago, IL Diabetes, 2007; 56 (Suppl. 1):A308-A309. |
||||
| , Abstract, Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| The Cost-Effectiveness of Pioglitazone Plus Metformin Compared with Rosiglitazone Plus Metformin: an Economic Evaluation Using a Previously Validated Economic Model from a Third Party Payer Perspective in the USA | ||||
| Minshall ME, Donovan ME, Pandya BJ, Baran RW | ||||
| Diabetes Technology Society. October, 2007 USA |
||||
| , Abstract | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| The Cost-Effectiveness of Pioglitazone Compared with Sitagliptin: an Economic Evaluation Using a Validated Economic Model from a Third Party Payer Perspective in the USA | ||||
| Minshall ME, Donovan ME, Pandya BJ, Baran RW, Bron MS | ||||
| ISPOR 2007 10th Annual European Congress |
||||
| , Abstract | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Long-Term CEA on Actos™ for the USA from PROactive | ||||
| Palmer A, Minshall M, Valentine W, Foos V, Baran R, and Silberman C | ||||
| American Diabetes Association 2007 Chicago, IL |
||||
| , Abstract | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Long-Term Cost-Effectiveness Analysis on Actos™ for the USA from PROactive. | ||||
| Palmer AJ, Minshall ME, Valentine WJ, Foos V, Baran RW, Silberman C. | ||||
| Diabetes, 2007; 56 (Suppl. 1):A314. |
||||
| , Abstract | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Application of Cost-Effectiveness Analysis to Evaluate the Proposed Formulary Status of a Novel Antidiabetic Drug in a U.S. Commercial Health Plan. | ||||
| Watkins J, Minshall M, Sullivan SD. | ||||
| Value in Health, 2007; 10(3):A198. |
||||
| , Abstract | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Cost-effectiveness of diabetes case management for low-income populations | ||||
| Gilmer TP, Roze S, Valentine WJ, Emy-Albrecht K, Ray JA, Cobden D, Nicklasson L, Philis-Tsimikas A, Palmer AJ. | ||||
| Health Serv Res. 2007 Oct;42(5):1943-59. |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Abstract: http://findarticles.com/p/articles/mi_m4149/is_5_42/ai_n21041659 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Estimating the Long-Term Cost-Effectiveness of Exenatide in the United States: an Adjunctive Treatment for Type 2 Diabetes mellitus. | ||||
| Minshall ME, Oglesby AK, Wintle ME, Valentine WJ, Roze S, Palmer AJ. | ||||
| Volume 11, Issue 1, Date: January/February 2008, Pages: 22-33 |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Abstract: http://www.druglib.com/abstract/mi/minshall-me_value-health_20080100.html | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. | ||||
| Palmer AJ, Valentine WJ, Ray JA, Foos V, Lurati F, Smith I, Lammert M, Roze S. | ||||
| Curr Med Res Opin. 2007 Apr;23(4):895-901. |
||||
| , Manuscript in preparation | ||||
| , UK | ||||
| Abstract: http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?View=Full&ID=22007008078 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis. | ||||
| Palmer AJ, Valentine WJ, Ray JA, Roze S, Muszbek N. | ||||
| Eur J Health Econ. 2007 Jun;8(2):161-8. Epub 2007 Jan 20 |
||||
| , Manuscript in preparation | ||||
| , Hungary | ||||
| Abstract: http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007008181 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain | ||||
| Piñola C, Roze S, Valentine W, Evers T. | ||||
| Gaceta Sanitaria 2007;21(2):97-104 |
||||
| , Manuscript in preparation | ||||
| , Spain | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17419924 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. | ||||
| Joshua A. Ray1, Kristina S. Boye2, Nicole Yurgin2, William J. Valentine1, Stéphane Roze1, Jan McKendrick3, Daniel M. D. Tucker1, Volker Foos1 and Andrew J. Palmer1 | ||||
| 1IMS Health, Allschwil, Switzerland, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Eli Lilly and Company, Basingstoke, UK | ||||
| Curr Med Res Opin. 2007 Mar;23(3):609-22. |
||||
| , Manuscript in preparation | ||||
| , UK | ||||
| Abstract: http://pharmacy.researchtoday.net/archive/3/3/935.htm | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. | ||||
| Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ. | ||||
| Diabetes Obes Metab. 2007 Jan;9(1):103-13. |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Abstract: http://www.druglib.com/abstract/ra/ray-ja_diabetes-obes-metab_20070100.html | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. | ||||
| Valentine WJ, Bottomley JM, Palmer AJ, Brandle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; on behalf of the PROactive Study Group. | ||||
| Diabet Med. 2007 Sep;24(9):982-1002. |
||||
| , Manuscript in preparation | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. | ||||
| Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer AJ. | ||||
| Adv Ther. 2007 Mar-Apr;24(2):273-90. |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/17565917/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Cost-effectiveness of insulin detemir versus NPH for type 1 diabetes patients in an Italian setting. A meta-analysis. | ||||
| Aristides M1, Kotchie R1, Nielsen S2, Aagren M2, Valentine WJ3, Goodall G3 | ||||
| 1 IMS Health, London, UK; 2 Novo Nordisk A/S, Bagsværd, Denmark; 3 IMS Health, Basel, Switzerland. | ||||
| ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007 |
||||
| , Poster | ||||
| , Italy | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Cost-Effectiveness Of Biphasic Insulin Aspart 30 Versus Human Premix Insulin For Type 2 Diabetes Patients In A Polish Setting | ||||
| Aristides M1, Kotchie RW1, Nielsen S2, Townsend C2, Valentine WJ3, Scheijbeler HW1 | ||||
| 1 IMS Health, London, UK; 2 Novo Nordisk A/S, Bagsværd, Denmark; 3 IMS Health, Basel, Switzerland | ||||
| ISPOR 2007 10th Annual European Congress ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20 - 23 October 2007 |
||||
| , Poster | ||||
| , Poland | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Mealtime insulin aspart reduces the long-term cost of complications compared to human insulin as part of basal-bolus therapy in Polish type 2 diabetes patients | ||||
| Goodall G1, Nielsen S2, Townsend C2, Kotchie R3, Erny-Albrecht K1, Valentine WJ1 | ||||
| 1 IMS Health, Basel, Switzerland; 2 NovoNordisk, Bagsværd, Denmark; 3 IMS Health, London, UK. | ||||
| ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007 |
||||
| , Poster | ||||
| , Poland | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Long-term cost-utility analysis of insulin aspart (Novorapid®) versus human soluble insulin in type 2 diabetes patients in the German setting | ||||
| Erny-Albrecht K1, Valentine WJ1, Townsend C2, Kotchie RW3, Nielsen S2, Goodall G1 | ||||
| 1 IMS Health, Basel, Switzerland; 2 NovoNordisk, Bagsværd, Denmark; 3 IMS Health, London, UK. | ||||
| ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007 |
||||
| , Oral presentation, Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness, Cost utility | |
| Long-term clinical outcomes Of Insulin Detemir Versus NPH for Type I Diabetes Patients in Spain | ||||
| Kotchie R1, Aagren M2, Nielsen S2, Valentine WJ3, Goodall G3 | ||||
| 1 IMS Health, London, UK; 2 Novo Nordisk A/S, Bagværd, Denmark; 3 IMS Health, Basel, Switzerland. | ||||
| |
||||
| , Poster | ||||
| , Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Cost-effectiveness of insulin detemir versus NPH for type 1 diabetes patients in a German setting. A modeling evaluation based upon results from a meta-analysis. | ||||
| Kotchie RW1, Scheijbeler HW1, Aagren M2, Nielsen S3, Valentine WJ3 , Goodall G3 | ||||
| 1 IMS Health, London, UK; 2 Novo Nordisk A/S, Bagsværd, Denmark; 3 IMS Health, Basel, Switzerland. | ||||
| ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007 |
||||
| , Oral presentation, Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Long-term cost-effectiveness analysis of a modern insulin in patients with poorly controlled type 2 diabetes in the German setting; data from the PREDICTIVE study | ||||
| Palmer JL1, Goodall G1, Aagren M2, Nielsen S2, Kotchie RW3, Valentine WJ1 | ||||
| 1 IMS Health, Basel, Switzerland; 2 Novo Nordisk A/S, Bagsværd, Denmark; 3 IMS Health, London, UK. | ||||
| ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007 |
||||
| , Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Cost-effectiveness of detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in a Belgium setting. A modeling evaluation based on results from a meta-analysis of three clinical trials. | ||||
| Scheijbeler HW1, Aagren M2, Nielsen S2, Valentine WJ3, Goodall G3, Kotchie RW1 | ||||
| 1 IMS Health, London, UK; 2 Novo Nordisk A/S, Bagsværd, Denmark; 3 IMS Health, Basel, Switzerland. | ||||
| ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007 |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Evaluating the cost-effectiveness of Biphasic Insulin Aspart 30 Versus Human Premix Insulin for the Treatment of Type 2 Diabetes in a Spanish Setting | ||||
| Tucker D1, Valentine WJ1, Nielsen S2, Townsend C2, Kotchie R3, Scheijbeler H3 | ||||
| 1 IMS Health, Basel, Switzerland; 2 Novo Nordisk, Bagsværd, Denmark; 3 IMS Health, London, UK. | ||||
| ISPOR 2007 10th Annual European Congress, 2007 October 20-23, Dublin, Ireland |
||||
| , Poster | ||||
| , Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Evaluating the long-term clinical and economic implications of converting type 2 diabetes patients to insulin detemir (± oral hypoglycemic agents) from insulin glargine based regimens in Germany; data from the PREDICTIVE study | ||||
| Valentine WJ1, Goodall G1, Aagren M2, Nielsen S2, Kotchie RW3 | ||||
| 1 IMS Health, Basel, Switzerland; 2 Novo Nordisk A/S, Bagsværd, Denmark; 3 IMS Health, London, UK. | ||||
| ISPOR 2007 10th Annual European Congress ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007 |
||||
| , Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Evaluating the long-term cost-effectiveness of insulin aspart (Novorapid®) versus human soluble insulin in patients with type 2 diabetes in Spain and Italy | ||||
| Erny-Albrecht K1, Goodall G1, Townsend C2, Kotchie RW3, Nielsen S2, Valentine WJ1 | ||||
| 1 IMS Health, Basel, Switzerland; 2 Novo Nordisk, Bagsværd, Denmark; 3 IMS Health, London, UK | ||||
| ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007 |
||||
| , Poster | ||||
| , Italy, Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in China | ||||
| Lynch M1, Scheijbeler HW2, Kotchie R2, Valentine WJ3, Nielsen S4, White J5 | ||||
| 1IMS Health, Shanghai, China; 2IMS Health, London, UK; 3 IMS Health, Basel, Switzerland; 4Novo Nordisk, Bagsværd, Denmark; 5Novo Nordisk, Zürich, Switzerland | ||||
| ISPOR 2007 10th Annual European Congress, Athens, Greece, 8 – 11 November 2008 |
||||
| , Poster | ||||
| , China | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Cost-effectiveness of insulin detemir versus NPH for type 1 diabetes patients in an Italian setting. Long-term simulations based on a meta-analysis | ||||
| Aristides M1, Kotchie RW1, Nielsen S2, Aagren M2, Valentine WJ3, Goodall G3 | ||||
| 1 IMS Health, London, UK; 2 Novo Nordisk A/S, Bagsværd, Denmark; 3 IMS Health, Basel, Switzerland | ||||
| ISPOR 2007 10th Annual European Congress, Athens, Greece, 8 – 11 November 2008 |
||||
| , Poster | ||||
| , Italy | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Long-term economic outcomes associated with insulin aspart versus human bolus insulin in type 2 diabetes patients in the Swedish setting | ||||
| Valentine WJ1, Goodall G1, Townsend C2, Kotchie RW3, Nielsen S2, Erny-Albrecht K1 | ||||
| 1 IMS Health, Basel, Switzerland 2 Novo Nordisk, Bagsværd, Denmark 3 IMS Health, London, UK | ||||
| ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007 |
||||
| , Poster | ||||
| , Sweden | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Cost-utility of insulin detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in a French setting. A modeling evaluation based on results from a meta-analysis of three clinical trials | ||||
| Scheijbeler H1, Aagren M2, Nielsen S2, Valentine WJ3, Goodall G3, Kotchie R1 | ||||
| 1 IMS Health, London, UK; 2 Novo Nordisk A/S, Bagsværd, Denmark; 3 IMS Health, Basel, Switzerland | ||||
| ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007 |
||||
| , Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost utility | |
| SMBG Cost-Effectiveness in Canada | ||||
| Minshall M1, Tunis SL2, Tuttle, J, Ur E | ||||
| 1 Formerly of IMS Health, Falls Church, VA, US 2 IMS Health, Falls Church, VA, US | ||||
| Canadian Diabetes Association Professional Conference, Vancouver, October 24-27, 2007 |
||||
| , Abstract | ||||
| , Canada | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Health Related Quality of Life of Patients with Type 2 Diabetes in Primary Care in Spain: Self-reported and Proxy Assessment using the EQ-5D. | ||||
| Boye K S, Yurgin N, Dilla T, Cordero LA, Badia X, Lara Suriñach L, Perez P | ||||
| J Med Econ 2007;10:41-58 |
||||
| , Manuscript in preparation | ||||
| , Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Quality of life | |
| The relationship of body mass index to diabetes, hypertension, and dyslipidemia: Comparison of data from two national surveys | ||||
| Bays HE, Chapman RH, Grandy S for the SHIELD Investigators’ Group | ||||
| International Journal of Clinical Practice 2007; 61(5):737-747 |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Survey research | |
| Health-related quality of life and utilities of respondents with type 2 diabetes compared with those with differing levels of cardiometabolic risk | ||||
| Chapman RH, Fox KM, Grandy S | ||||
| Value in Health 2007; 10(3):A69 ISPOR 12th Annual International Meeting, Arlington, VA, May 19-23, 2007 |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Survey research | |
| Impact of obesity on work productivity among individuals with type 2 diabetes mellitus and varied levels of cardiometabolic risk | ||||
| Stewart WF, Chapman RH, Gavin JR, Fox KM, Grandy S | ||||
| Accepted at 67th Scientific Sessions of American Diabetes Association, Chicago, IL, June 22-26, 2007 |
||||
| , Poster | ||||
| , USA | ||||
| Abstract: http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=54373 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Survey research | |
| Self-Monitoring of Blood Glucose in Type 2 Diabetes: Frequency of Testing and Diabetes-Related Complications in a Simulated Cohort. | ||||
| Tunis SL, Erny-Albrecht KM, Minshall ME, Valentine W, Foos V, Palmer AJ. | ||||
| American Diabetes Association 2007 Chicago, IL Diabetes, 2007; 56 (Suppl. 1):A309. |
||||
| , Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | ||
| Health Related Quality of Life of Patients with Type 2 Diabetes in Primary Care in Spain: Self-reported and Proxy Assessment using the EQ-5D. | ||||
| Boye K S, Yurgin N, Dilla T, Cordero LA, Badia X, Lara Suriñach L, Perez P. | ||||
| J Med Econ 2007;10:41-58 |
||||
| , Article | ||||
| , Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Quality of life | |
| Health Economic Comparison between Continuous Subcutaneous Insulin Infusion (CSII) and Multiple Daily Injections (MDI) of Insulin for the Treatment of Adult and Adolescent Type 1 Diabetes in Australia. | ||||
| Cohen N, Minshall ME, Nash L, Zakrzewska, K, Valentine WJ, Palmer AJ. | ||||
| In press, PharmacoEconomics, 2008. |
||||
| , Manuscript in preparation | ||||
| , Australia | ||||
| Abstract: http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007002138 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | ||
| Proposed Formulary Status of a Novel Antidiabetic Drug in a U.S. Commercial Health Plan. | ||||
| Watkins J, Minshall M, Sullivan SD. Application of Cost-Effectiveness Analysis to Evaluate the | ||||
| Value in Health, 2007; 10(3):A198. |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | ||
| Comparative study of annual treatment cost of glargine insulin and detemir insulin in patients with type 2 diabetes mellitus in Spain | ||||
| Alvarez de Guisasola F, Casal Llorente C, Rubio C , Betegón L | ||||
| |
||||
| , Poster | ||||
| , Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost analysis | |
| Estimating the long-term clinical outcomes associated with switching to insulin aspart (novorapid®) from human soluble insulin in type 2 diabetes patients in the Polish setting | ||||
| Goodall G1, Valentine WJ1, Townsend C2, Kotchie RW3, Nielsen S2, Erny-Albrecht K1 | ||||
| 1 IMS Health, Basel, Switzerland; 2 NovoNordisk, Bagsværd, Denmark; 3 IMS Health, London, UK. | ||||
| ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007 |
||||
| , Poster | ||||
| , Poland | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost utility | |
| Costs And Neonatal Outcomes After Insulin Aspart Compared With Human Insulin In Pregnant Women With Type 1 Diabetes. | ||||
| Lloyd A1, Twena N2, Townsend C3, Holman AJ1. | ||||
| 1 IMS Health incorporating Fourth Hurdle Consulting Ltd, London, UK 2 Novo Nordisk Ltd, UK 3 Novo Nordisk A/S, Denmark | ||||
| International Society for Pharmacoeconomics and Outcomes Research, Dublin. 23-27 October 2007 |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost of illness | |
| Inpatient Costs and Health Outcomes for Pregnant Women with Type 1 Diabetes. | ||||
| Holman AJ1, Munro V2, Nielsen S3, Lloyd AC1 | ||||
| 1 IMS Health incorporating Fourth Hurdle Consulting Ltd, London, UK 2 Novo Nordisk Ltd, UK 3 Novo Nordisk A/S, Denmark | ||||
| International Society for Pharmacoeconomics and Outcomes Research, Dublin, 23-27 October 2007 |
||||
| , Poster | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost of illness | |
| Treatment failures in type 2 diabetes patients taking oral anti-diabetes drugs | ||||
| Chapman R, Ferrufino C, Maclean JR, Krishnarajah G | ||||
| American Diabetes Association’s 68th Scientific Sessions, San Francisco, CA, June 6-10, 2008 |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Retrospective cohort analysis | |
| Insulin Glargine and NPH Insulin based regimens reveal comparable total direct treatment costs in type 2 diabetes patients. The lon-acting insulin Glargine vs. NPH insulin cost evaluaton study in germany (LIVE-DE) | ||||
| Scholten T2, Holle R3, Landgraf W5, Spiesecke A1, Hauner H4 | ||||
| 1 IMS Health, Nuremberg, Germany 2 University of Witten-Herdecke, Hagen, Germany 3 Institute of Health Economics & Health Care Management, Helmholtz Center Munich, Germany 4 Else Kröner-Fresenius-Center for Nutritional Medicine, Technical University Munich, Munich, Germany 5 sanofi-aventis, Berlin, Germany | ||||
| ISPOR 11th Annual European Congress, 8-11. November 2008, Athen, Greece |
||||
| , Oral presentation | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. | ||||
| Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P. | ||||
| RTI Heath Solutions, Manchester | ||||
| Diabet Med. 2007 Dec;24(12):1412-8. |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18042083 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Retrospective database analysis | |
| The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis | ||||
| Currie CJ, Poole CD, Tetlow T, Holmes P & McEwan P | ||||
| Department of Medicine, School of Medicine, Cardiff University | ||||
| Current Medical Research & Opinion 23(1):33-9 |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://informahealthcare.com/doi/abs/10.1185/030079907X167534 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Retrospective database analysis | |
| The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis | ||||
| Poole C, Tetlow D, McEwan T, Holmes P, Currie P & Craig J | ||||
| threesixtydegree Research Ltd, Penarth | ||||
| Current Medical Research & Opinion (8):41-48 |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://informahealthcare.com/doi/abs/10.1185/030079907X167589 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Retrospective database analysis | |
| Combining Population Health and Baseline Risk Strategy by Determining an Age Cutoff for Initiating Statins in Patients With Diabetes A population-based study | ||||
| Siyambalapitiya S, Bulugahapitiya U, Sithole J, Song S, Fernando D J S & Idris I | ||||
| Department of Diabetes and Endocrinology, Sherwood Forest Hospitals Foundation Trust | ||||
| Diabetes Care 30:2025-2029 |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://care.diabetesjournals.org/content/30/8/2025.fulld | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Retrospective database analysis | |
| Medical management and costs associated with staphylococcus aureus (SA) bacteraemia in haemodialysis patients: A cost-of-illness study. | ||||
| Strens D, Moeremans K, Annemans L, Jadoul M, Cambier P, Billiouw JM | ||||
| ISPOR 9th Annual European Congress, 2006, October 29-31, Copenhagen, Denmark |
||||
| , Oral presentation | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Cost of illness | |
| Kosten-Effektivität der Acarbosetherapie bei Patienten mit gestörter Glukosetoleranz [Cost-effectiveness for acarbose therapy of patients with impaired glucose intolerance] | ||||
| Liebl A, Lueddeke HJ, Kotowa W et al | ||||
| IMS Health, Nuremberg, Germany | ||||
| Gesundh ökon Qual manag 2006; 11:105-111 |
||||
| , Article | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | German | , Cost effectiveness | |
| Cost-effectiveness of Acarbose in patients with type-2 diabetes in three countries | ||||
| Evers T, Roze S, Palmer AJ, Valentine WJ, Tucker D, Hanefeld M | ||||
| |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Cost effectiveness | |
| Long-term cost-effectiveness analysis or repaglinide versus nateglinine in combination with metformin in type 2 diabetes patients failing monotherapy in the Swedish setting | ||||
| Ray J1, Brandt AS2, Foos V1, Munro V3,Valentine WJ1, Roze S1,Palmer AJ1 | ||||
| 1 CORE—Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, 2 Novo Nordisk Scandinavia AB, Malmo, Sweden, 3 Novo Nordisk Ltd, Crawley, West Sussex, UK | ||||
| Value in Health, Vol. 9, Issue 6, A227 |
||||
| , Poster | ||||
| , Sweden | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Cost effectiveness | |
| Cost-effectiveness analysis of acarbose in the prevention of type 2 diabetes in South Korea | ||||
| JongMann Kim, Clegg John P, KyeungHee Chang, JuYeol Park, Wittrup-Jensen Kim, Valentine William J | ||||
| ISPOR 2007 10th Annual European Congress |
||||
| , Abstract | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Cost effectiveness | |
| Self monitoring of blood glucose in patients with type 2 diabetes: cost utility analysis in a United States third-party payer setting | ||||
| Palmer AJ, Minshall ME, Valentine WJ, Foos V, Tunis SL | ||||
| |
||||
| , Oral presentation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Cost utility | |
| Self monitoring of blood glucose in patients with type 2 diabetes: cost utility analysis in an Italian setting | ||||
| Palmer AJ, Minshall ME, Valentine WJ, Foos V, Tunis SL | ||||
| |
||||
| , Poster | ||||
| , Italy | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Cost utility | |
| Self monitoring of blood glucose in patients with type 2 diabetes: cost utility analysis in a German government payer setting | ||||
| Palmer AJ, Minshall ME, Valentine WJ, Foos V, Tunis SL | ||||
| |
||||
| , Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Cost utility | |
| Self monitoring of blood glucose in patients with type 2 diabetes: cost utility analysis in a French government payer setting | ||||
| Palmer AJ, Minshall ME, Valentine WJ, Foos V, Tunis SL | ||||
| |
||||
| , Poster | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Cost utility | |
| Prevalence of metabolic síndrome in patients with Diabetes Mellitus 2 in Spain. | ||||
| Rodríguez A, Polavieja P, García R, Cobo A, Reviriego J, Carreño A. | ||||
| XXVI Congreso de la Sociedad Española de Medicina Familiar y Comunitaria (SEMFYC), Valencia (Spain) 15-18 November |
||||
| , Poster | ||||
| , Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Epidemiological study | |
| The efficacy of insulin glargine compared to other injectable therapies - A meta-analysis of clinical outcomes in insulin naïve type 2 diabetes patients | ||||
| Pascoe K, McDonald-Everett CM, FitzGerland P, Yurgin NR, | ||||
| |
||||
| , Poster | ||||
| , Australia | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Meta analysis | |
| Overlapping cardiovascular risk factors in the United States adult diabetes population: Data from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes. | ||||
| Stewart W, Clark N, Ansell B, Reed ML, Chapman R, Grandy S, for the SHIELD Study Group. | ||||
| Circulation 2006; 113(21):44. |
||||
| , Manuscript in preparation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| High prevalence of misdiagnosis of the metabolic syndrome in a self-reported survey: Possible confusion with having “a metabolism problem”. | ||||
| Bays H, Chapman R, Klingman D, Fanning K, Grandy S. | ||||
| 2006 Annual Scientific Meeting of NAASO, the Obesity Society, Boston, MA, October 20-24, 2006. |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| Diabetes symptoms reported in SHIELD by people with or at high risk for type 2 diabetes. | ||||
| Clark N, Chapman R, Grandy S, for the SHIELD Study Group. | ||||
| American Diabetes Association’s 66th Scientific Sessions, Washington, DC, June 9-13, 2006. |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| Comparative health outcomes-based health economic evaluation of type 2 diabetes patients on basal insulin analogs | ||||
| Cobden D, Valentine WJ, Koenen C, Palmer AJ, Roze S | ||||
| |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| Continuous subcutaneous insulin infusions versus multiple daily injection of insulin in patients with type 1 diabetes: a long-term health economic analysis in the Norwegian and Swedish settings | ||||
| Goodall G1, Nicklasson L2, Zakrzewska K3, Foos V1,Valentine WJ1,Roze S1, Palmer AJ1 | ||||
| CORE—Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, 2 Medtronic AB, Järfälla, Sweden, 3 Medtronic AG, Tolochenaz, Switzerland | ||||
| Value in Health, 2006:9 (6) A227 |
||||
| , Poster | ||||
| , Norway, Sweden | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Economic evaluation | |
| Identifying high-risk populations in SHIELD with a 12-item screener questionnaire. | ||||
| Grandy S, Reed M, Chapman R, for the SHIELD Study Group. | ||||
| American Diabetes Association’s 66th Scientific Sessions, Washington, DC, June 9-13, 2006. |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| Agreement between patient and physician assessment of health-related quality life of patients with type 2 diabetes treated by primary care physicians in Spain. | ||||
| Lara N, Secnik K , Yurgin N, Pérez P, Dilla T, Cordero LA, Badia X. | ||||
| EuroQol Group Scientific Meeting 2006, Barcelona (Spain) 14-15 September |
||||
| , Poster | ||||
| , Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| The CORE diabetes model - simulating long-term effect of implementing health policies for management of diabetes. | ||||
| Palmer A, Valentine WJ, Ray JA, Lurati FM, Foos V, Minshall ME et al. | ||||
| ISPOR 2nd Asia-Pacific Congress,Shanghai, China |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| Economic evaluation of initiating insulin detemir among type 2 diabetes patients receiving oral medication | ||||
| Palmer AJ, Cobden D, Valentine WJ, Wagner S, Roze S | ||||
| |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| Management and treatment adherence in type 2 diabetic patients in Spain | ||||
| Secnik K, Yurgin NR, Lara N, Badia X, Dilla T, Cordero LA | ||||
| |
||||
| , Poster | ||||
| , Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| Long-term clinical and economic outcomes for patients with type 1 diabetes treated with insulin aspart versus human soluble insulin in Sweden | ||||
| Tucker D1, Brandt AS2, Foos V1, Munro V3, Goodall G1, Ray J1,Valentine WJ1, Roze S1, Palmer AJ1 | ||||
| 1 1 CORE?Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, 2 Novo Nordisk Scandinavia AB, Malmo, Sweden, 3 Novo Nordisk Ltd, Crawley, West Sussex, UK | ||||
| Value in Health, Vol. 9, Issue 6, A226–A227 |
||||
| , Poster | ||||
| , Nordic, Sweden | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Economic evaluation | |
| Therapy class conversion in patients with type 2 diabetes: economic evaluation of insulin detemir and NPH | ||||
| Valentine WJ, Cobden D, Palmer AJ, Wagner S, Roze S | ||||
| |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| Evaluating the long-term health outcomes and economics of initiating biphasic analog insulin compared to optimized oral therapy alone | ||||
| Valentine WJ, Cobden D, Wagner S, Palmer AJ, Braceras R, Roze S | ||||
| |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| Patient and physician drivers of health-related quality of life of patients with type 2 diabetes in primary care in Spain | ||||
| Yurgin NR, Secnik K, Lara N, Badia X, Dilla T, Cordero LA | ||||
| |
||||
| , Poster | ||||
| , Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| The CORE diabetes model - simulating long-term effects of implementing health policies for management of diabetes | ||||
| Palmer A, Valentine WJ, Ray JA, Lurati FM, Foos V, Minshall ME, Roze S. | ||||
| ISPOR 2nd Asia-Pacific conference, Worldfield Convention Hotel, Shanghai, China |
||||
| , Poster | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| Quantifying the impact of fear of hypoglycaemia on quality of life | ||||
| Walters N, Gordois A, Brown A, Lindsay P, Gonzalo F, Comas S | ||||
| ISPOR 9th Annual European Congress |
||||
| , Poster | ||||
| , Australia | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2006 | English | , Burden of illness | |
| Quality of life in people with and at risk for type 2 diabetes: Findings from the Study to Help Improve early Evaluation and management of risk factors Leading to Diabetes (SHIELD). | ||||
| Chapman RH, Grandy S. | ||||
| ISPOR 11th Annual International Meeting, Philadelphia, PA, May 20-24, 2006. |
||||
| , Oral presentation | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | ||
| Modelling the effectiveness of oral agents in achieving HbAlc and lipid targets in patients with type 2 diabetes mellitus. | ||||
| Lloyd AC1, Smith TW2, Bergenheim K3. | ||||
| 1 Fourth Hurdle Consulting Ltd, London, UK 2ValueMedics Research LLC, Falls Church, VA, USA, 3AstraZeneca, Mölndal, Sweden | ||||
| ISPOR 11th Annual International Meeting, Philadelphia, May 20th - 24th, 2006 |
||||
| , Poster | ||||
| , USA | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Cost effectiveness | |
| The efficacy of insulin glargine compared to other injectable therapies—a meta-analysis of clinical outcomes in insulin naïve type 2 diabetes patients | ||||
| Pascoe K, McDonald-Everett CM, FitzGerald P, Yurgin NR, Secnik K | ||||
| ISPOR 9th Annual European Congress |
||||
| , Poster | ||||
| , Australia | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Meta analysis | |
| Increased incidence of carpal tunnel syndrome up to 10 years before diagnosis of diabetes | ||||
| Gulliford MC, Latinovic R, Charlton J, & Hughes RAC | ||||
| Division of Health and Social Care Research, King's College | ||||
| Diabetes Care 29(8): 1929-1930 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: http://care.diabetesjournals.org/content/29/8/1929.full.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Retrospective database analysis | |
| Population-based study of time to insulin after failure or oral antidiabetic (OA) therapy in type 2 diabetes (T2DM) in the UK | ||||
| Rubino A, McQuay L, Kvasz M & Tennis P | ||||
| RTI | ||||
| Annual meeting of the American Diabetes Association Washington, USA |
||||
| , Abstract, Poster | ||||
| , UK | ||||
| Abstract: https://www.rtihs.org/publications/population-based-study-time-insulin-after-failure-or-oral-antidiabetic-oa-therapy-type | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Retrospective database analysis | |
| Risk of Diabetes Associated With Prescribed Glucocorticoids in a Large Population | ||||
| Gulliford MC, Charlton J & Latinovic R | ||||
| Division of Health and Social Care Research, King's College London School of Medicine | ||||
| Diabetes Care 29 (12): 2728-29 |
||||
| , Abstract, Article | ||||
| , UK | ||||
| Abstract: http://care.diabetesjournals.org/content/29/12/2728.full | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Retrospective database analysis | |
| Time to insulin after failure of oral antidiabetic therapy in type 2 diabetes: A UK population-based analysis | ||||
| Rubino A, McQuay L, Kvasz M & Tennis P | ||||
| RTI | ||||
| Pharmacoepidemiology and Drug Safety 15: (S1):S51 |
||||
| , Abstract | ||||
| , UK | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Retrospective database analysis | |